A/RE

Attorney Docket No. PPL-1 - Reissue

Applicants : Ian Garner et al.

For : PRODUCTION OF FIBRINOGEN IN TRANSGENIC ANIMALS

EXPRESS MAIL CERTIFICATION

"Express Mail" mailing label number EI187448225US

Date of Deposit January 15, 1999

I hereby certify that this transmittal letter and the other papers and fees identified in this transmittal letter as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and are addressed to the Hon. Assistant Commissioner for Patents, Washington, D.C. 20231.

CLARO F. SAINTH

Hon. Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
REISSUE PATENT APPLICATION

Sir:

This is a request for filing a reissue application of United States Patent No. 5,639,940, issued June 17, 1997 entitled, PRODUCTION OF FIBRINOGEN IN TRANSGENIC ANIMALS.

Transmitted herewith for filing are the ☒ specification (18 pages); ☒ claims (34); ☒ abstract; ☒ sequence listings (27); ☒ executed Reissue Declaration and Power of Attorney; ☒ executed Parker Declaration in Support of Reissue; ☒ Order for Title Report; ☒ Offer to Surrender Original Letters Patent; and ☒ Consent of Assignees (2) for the above-identified Patent application.

Also transmitted herewith are:

☒ 5 sheets of:

☒ Formal drawings.

The filing fee has been calculated as shown below on the basis of the reissue claims filed herewith:

FOR	NUMBER EXTRA		RATE		FEE
BASIC FEE					$760.00
TOTAL INDEPENDENT CLAIMS IN EXCESS OF THE NUMBER OF INDEPENDENT CLAIMS IN ORIGINAL PATENT	1	x	$ 78	=	$78.00
REISSUE CLAIMS IN EXCESS OF 20 AND IN EXCESS OF ORIGINAL CLAIMS	1	x	$18	=	$ 18.00
				TOTAL	$ 856.00

☒ A check in the amount of $ 856.00 in payment of the filing fee is transmitted herewith.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16 in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

James F. Haley, Jr.
Registration No. 27,794
c/o FISH & NEAVE
1251 Avenue of the Americas
50th Floor
New York, New York 10020
Tel.: (212) 596-9000
Fax: (212) 596-9090

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Reissue Application	:	Not yet assigned
Serial No.	:	Not yet assigned
Filed	:	January 15, 1999
Patent	:	5,639,940
Patentee	:	Ian Garner, Michael A. Dalrymple,* Donna E. Prunkard and Donald C. Foster
Assignee	:	Pharmaceutical Proteins, Ltd., and ZymoGenetics, Inc.
Issued	:	June 17, 1997
Application	:	08/206,176
Filed	:	March 3, 1994
For	:	PRODUCTION OF FIBRINOGEN IN TRANSGENIC ANIMALS

Hon. Assistant Commissioner for Patents
Washington, D.C. 20231

CONSENT OF ASSIGNEE TO REISSUE APPLICATION

Sir:

ZymoGenetics, Inc., a co-assignee of the above-identified '940 patent, by virtue of an August 19, 1994 assignment of United States patent application 08/206,176, filed March 3, 1994, from Donna E. Prunkard and Donald C. Foster, recorded at Reel 7166, Frame 0921, hereby consents to the above-identified reissue of the '940 Patent.

---

* The '940 patent incorrectly printed the middle initial of Dr. Dalrymple as "L."

EXPRESS MAIL
EI187448225US

Pursuant to 37 C.F.R. §§ 1.172 and 3.73(b), the undersigned hereby states and certifies that:

1. I am an officer of assignee corporation and am authorized to act on behalf of assignee corporation with respect to the above identified '940 Patent and this reissue thereof; and

2. The relevant evidentiary documents have been reviewed and, to the best of my knowledge and belief, an undivided share of the title to the '940 Patent is in the assignee.

ZYMOGENETICS, INC.,

_____
Date

By: Shinko Campos

Name: Shinko Campos.

Title: Sr. V.P. Finance + Admin.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Reissue Application	:	Not yet assigned
Serial No.	:	Not yet assigned
Filed	:	January 15, 1999
Patent	:	5,639,940
Patentee	:	Ian Garner, Michael A., Dalrymple,* Donna E. Prunkard and Donald C. Foster
Assignee	:	Pharmaceutical Proteins, Ltd., and ZymoGenetics, Inc
Issued	:	June 17, 1997
Application	:	08/206,176
Filed	:	March 3, 1994
For	:	PRODUCTION OF FIBRINOGEN IN TRANSGENIC ANIMALS

Hon. Assistant Commissioner for Patents
Washington, D.C. 20231

CONSENT OF ASSIGNEE TO REISSUE APPLICATION

Sir:

Pharmaceutical Proteins, Ltd., a co-assignee of the above-identified '940 Patent, by virtue of an August 12, 1994 assignment of United States patent application 08/206,176, filed March 3, 1994, from Ian Garner and Michael A. Dalrymple, recorded at Reel 7166, Frame 0931, hereby consents to the above-identified reissue of the '940 Patent.

---

* The '940 patent incorrectly printed the middle initial of Dr. Dalrymple as "L".

EXPRESS MAIL
EI187448225US

Pursuant to 37 C.F.R. §§ 1.172 and 3.73(b), the undersigned hereby states and certifies that:

1. I am an officer of assignee corporation and am authorized to act on behalf of assignee corporation with respect to the above identified '940 Patent and this reissue thereof; and

2. The relevant evidentiary documents have been reviewed and, to the best of my knowledge and belief, an undivided share of the title to the '940 Patent is in the assignee.

PHARMACEUTICAL PROTEINS, LTD.

15/1/99
Date

By: Alan Colman

Name: ALAN COLMAN

Title: RESEARCH DIRECTOR

1

PRODUCTION OF FIBRINOGEN IN TRANSGENIC ANIMALS

BACKGROUND OF THE INVENTION

The final step in the blood coagulation cascade is the thrombin-catalyzed conversion of the soluble plasma protein fibrinogen to insoluble fibrin. Thrombin cleaves a small peptide (fibrinopeptide A) from one of the three component chains (the Aα-chain) of fibrinogen. Fibrin monomers subsequently polymerize and are cross-linked by activated factor XIII to form a stable clot.

Fibrinogen is a key component of biological tissue glues (see, e.g., U.S. Pat. Nos. 4,377,572 and 4,442,655), which mimic the formation of natural blood clots to promote hemostasis and repair damaged tissue. Tissue glues provide an adjunct or alternative to sutures, staples and other mechanical means for wound closure. However, the principal ingredients of these products (fibrinogen, factor XIII and thrombin) are prepared from pooled human plasma by cryoprecipitation (e.g. U.S. Pat. Nos. 4,377,572; 4,362,567; 4,909,251) or ethanol precipitation (e.g. U.S. Pat. No. 4,442,655) or from single donor plasma (e.g. U.S. Pat. No. 4,627,879; Spotnitz et al., *Am. Surg.* 55: 166–168, 1989). The resultant fibrinogen/factor XIII preparation is mixed with bovine thrombin immediately before use to convert the fibrinogen to fibrin and activate the factor XIII, thus initiating coagulation of the adhesive.

Commercially available adhesives are of pooled plasma origin. Because blood-derived products have been associated with the transmission of human immunodeficiency virus (HIV), hepatitis virus and other etiologic agents, the acceptance and availability of such adhesives is limited. At present they are not approved for use in the United States.

While the use of autologous plasma reduces the risk of disease transmission, autologous adhesives can only be used in elective surgery when the patient is able to donate the necessary blood in advance.

As noted above, fibrinogen consists of three polypeptide chains, each of which is present in two copies in the assembled molecule. These chains, designated the Aα, Bβ and γ-chains, are coordinately expressed, assembled and secreted by the liver. While it might be expected that recombinant DNA technology could provide an alternative to the isolation of fibrinogen from plasma, this goal has proven to be elusive. The three fibrinogen chains have been individually expressed in *E. coli* (Lord, DNA 4: 33–38, 1985; Bolyard and Lord, *Gene* 66: 183–192, 1988; Bolyard and Lord, *Blood* 73: 1202–1206), but functional fibrinogen has not been produced in a prokaryotic system. Expression of biologically competent fibrinogen in yeast has not been reported. Cultured transfected mammalian cells have been used to express biologically active fibrinogen (Farrell et al., *Blood* 74: 55a, 1989; Hartwig and Danishefsky, *J. Biol. Chem.* 266: 6578–6585, 1991; Farrell et al., *Biochemistry* 30: 9414–9420, 1991), but expression levels have been so low that production of recombinant fibrinogen in commercial quantities is not feasible. Experimental evidence suggests that lower transcription rates in cultured cells as compared to liver may be a factor in the low expression rates achieved to date, but increasing the amount of fibrinogen chain mRNA in transfected BHK cells did not produce corresponding increases in fibrinogen protein secretion (Prunkard and Foster, XIV Congress of the International Society on Thrombosis and Haemostasis, 1993). These latter results suggest that proper assembly and processing of fibrinogen involves tissue-specific mechanisms not present in common laboratory cell lines.

There remains a need in the art for methods of producing large quantities of high quality fibrinogen for use in tissue adhesives and other applications. There is a further need for fibrinogen that is free of blood-borne pathogens. The present invention fulfills these needs and provides other, related advantages.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide commercially useful quantities of recombinant fibrinogen, particularly recombinant human fibrinogen. It is a further object of the invention to provide materials and methods for expressing fibrinogen in the mammary tissue of transgenic animals, particularly livestock animals such as cattle, sheep, pigs and goats.

Within one aspect, the present invention provides a method for producing fibrinogen comprising (a) providing a first DNA segment encoding a secretion signal operably linked to a fibrinogen Aα chain, a second DNA segment encoding a secretion signal operably linked to a fibrinogen Bβ chain, and a third DNA segment encoding a secretion signal operably linked to a fibrinogen γ chain, wherein each of the first, second and third segments is operably linked to additional DNA segments required for its expression in the mammary gland of a host female mammal; (b) introducing the DNA segments into a fertilized egg of a non-human mammalian species; (c) inserting the egg into an oviduct or uterus of a female of the species to obtain offspring carrying the DNA constructs; (d) breeding the offspring to produce female progeny that express the first, second and third DNA segments and produce milk containing biocompetent fibrinogen encoded by the segments; (e) collecting milk from the female progeny; and (f) recovering the fibrinogen from the milk. Within one embodiment, the egg containing the introduced segments is cultured for a period of time prior to insertion.

Within another aspect, the invention provides a method of producing fibrinogen comprising the steps of (a) incorporating a first DNA segment encoding a secretion signal operably linked to an Aα chain of fibrinogen into a β-lactoglobulin gene to produce a first gene fusion; (b) incorporating a second DNA segment encoding a secretion signal operably linked to a Bβ chain of fibrinogen into a β-lactoglobulin gene to produce a second gene fusion; (c) incorporating a third DNA segment encoding a secretion signal operably linked to a γ chain of fibrinogen into a β-lactoglobulin gene to produce a third gene fusion; (d) introducing the first, second and third gene fusions into the germ line of a non-human mammal so that the DNA segments are expressed in a mammary gland of the mammal or its female progeny and biocompetent fibrinogen is secreted into milk of the mammal or its female progeny; (e) obtaining milk from the mammal or its female progeny; and (f) recovering the fibrinogen from the milk. Within preferred embodiments, the mammal is a sheep, pig, goat or bovine.

Within another aspect, the invention provides a method for producing fibrinogen comprising the steps of (a) providing a transgenic female non-human mammal carrying in its germline heterologous DNA segments encoding Aα, Bβ and γ chains of fibrinogen, wherein the DNA segments are expressed in a mammary gland of the mammal and fibrinogen encoded by the DNA segments is secreted into milk of the mammal; (b) collecting milk from the mammal; and (c) recovering the fibrinogen from the milk.

Within another aspect, the invention provides a non-human mammalian embryo containing in its nucleus heter-

ologous DNA segments encoding Aα, Bβ and γ chains of fibrinogen. Within a related aspect, the invention provides a transgenic non-human female mammal that produces recoverable amounts of human fibrinogen in its milk.

Within another aspect, the invention provides a method for producing a transgenic offspring of a mammal comprising the steps of (a) providing a first DNA segment encoding a fibrinogen Aα chain, a second DNA segment encoding a fibrinogen Bβ chain, and a third DNA segment encoding a fibrinogen γ chain, wherein each of said first, second and third segments is operably linked to additional DNA segments required for its expression in a mammary gland of a host female mammal and secretion into milk of the host female mammal; (b) introducing the DNA segments into a fertilized egg of a mammal of a non-human species; (c) inserting the egg into an oviduct or uterus of a female of the non-human species to obtain an offspring carrying the first, second and third DNA segments. In a related aspect, the invention provides non-human mammals produced according to this process.

Within an additional aspect, the invention provides a non-human mammal carrying its germline DNA segments encoding heterologous Aα, Bβ and γ chains of fibrinogen, wherein female progeny of the mammal express the DNA segments in a mammary gland to produce biocompetent fibrinogen.

These and other aspects of the invention will become evident to the skilled practitioner upon reference to the following detailed description and the attached drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the subcloning of a human fibrinogen Aα chain DNA sequence.

FIG. 2 is a partial restriction map of the vector Zem228. Symbols used are MT-1p, mouse metallothionein promoter; SV40t, SV40 terminator; and SV40p, SV40 promoter.

FIG. 3 illustrates the subcloning of a human fibrinogen Bβ chain DNA sequence.

FIG. 4 illustrates the subcloning of a human fibrinogen γ chain DNA sequence.

FIG. 5 is a partial restriction map of the vector Zem219b. Symbols used are MT-1p, mouse metallothionein promoter; hGHt, human growth hormone terminator; SV40p, SV40 promoter; DHFR, dihydrofolate reductase gene; and SV40t, SV40 terminator.

DETAILED DESCRIPTION OF THE INVENTION

Prior to setting forth the invention in detail, it will be helpful to define certain terms used herein:

As used herein, the term "biocompetent fibrinogen" is used to denote fibrinogen that polymerizes when treated with thrombin to form insoluble fibrin.

The term "egg" is used to denote an unfertilized ovum, a fertilized ovum prior to fusion of the pronuclei or an early stage embryo (fertilized ovum with fused pronuclei).

A "female mammal that produces milk containing biocompetent fibrinogen" is one that, following pregnancy and delivery, produces, during the lactation period, milk containing recoverable amounts of biocompetent fibrinogen. Those skilled in the art will recognized that such animals will produce milk, and therefore the fibrinogen, discontinuously.

The term "progeny" is used in its usual sense to include children and descendants.

The term "heterologous" is used to denote genetic material originating from a different species than that into which it has been introduced, or a protein produced from such genetic material.

Within the present invention, transgenic animal technology is employed to produce fibrinogen within the mammary glands of a host female mammal. Expression in the mammary gland and subsequent secretion of the protein of interest into the milk overcomes many difficulties encountered in isolating proteins from other sources. Milk is readily collected, available in large quantities, and well characterized biochemically. Furthermore, the major milk proteins are present in milk at high concentrations (from about 1 to 15 g/l).

From a commercial point of view, it is clearly preferable to use as the host a species that has a large milk yield. While smaller animals such as mice and rats can be used (and are preferred at the proof-of-concept stage), within the present invention it is preferred to use livestock mammals including, but not limited to, pigs, goats, sheep and cattle. Sheep are particularly preferred due to such factors as the previous history of transgenesis in this species, milk yield, cost and the ready availability of equipment for collecting sheep milk. See WO 88/00239 for a comparison of factors influencing the choice of host species. It is generally desirable to select a breed of host animal that has been bred for dairy use, such as East Friesland sheep, or to introduce dairy stock by breeding of the transgenic line at a later date. In any event, animals of known, good health status should be used.

Fibrinogen produced according to the present invention may be human fibrinogen or fibrinogen of a non-human animal. For medical uses, it is preferred to employ proteins native to the patient. The present invention thus provides fibrinogen for use in both human and veterinary medicine. Cloned DNA molecules encoding the component chains of human fibrinogen are disclosed by Rixon et al. (*Biochem.* 22: 3237, 1983), Chung et al. (*Biochem.* 22: 3244, 1983), Chung et al. (Biochem. 22: 3250, 1983), Chung et al. (*Adv. Exp. Med. Biol.* 281: 39–48, 1990) and Chung et al. (*Ann. NY Acad. Sci.* 408: 449–456, 1983). Bovine fibrinogen clones are disclosed by Brown et al. (*Nuc. Acids Res.* 17: 6397, 1989) and Chung et al. (*Proc. Natl. Acad. Sci. USA* 78: 1466–1470, 1981). Other mammalian fibrinogen clones are disclosed by Murakawa et al. (*Thromb. Haemost.* 69: 351–360, 1993). Representative sequences of human Aα, Bβ and γ chain genes are shown in SEQ ID NOS: 1, 3 and 5, respectively. Those skilled in the art will recognize that allelic variants of these sequences will exist; that additional variants can be generated by amino acid substitution, deletion, or insertion; and that such variants are useful within the present invention. In general, it is preferred that any engineered variants comprise only a limited number of amino acid substitutions, deletions, or insertions, and that any substitutions are conservative. Thus, it is preferred to produce fibrinogen chain polypeptides that are at least 90%, preferably at least 95, and more preferably 99% or more identical in sequence to the corresponding native chains. The term "γ chain" is meant to include the alternatively spliced γ′ chain of fibrinogen (Chung et al., *Biochem.* 23: 4232–4236, 1984). A human γ′ chain amino acid sequence is shown in SEQ ID NO: 6. The shorter γ chain is produced by alternative splicing at nucleotides 9511 and 10054 of SEQ ID NO: 5, resulting in translation terminating after nucleotide 10065 of SEQ ID NO: 5.

To obtain expression in the mammary gland, a transcription promoter from a milk protein gene is used. Milk protein genes include those genes encoding caseins, beta-

lactoglobulin (BLG), α-lactalbumin, and whey acidic protein. The beta-lactoglobulin promoter is preferred. In the case of the ovine beta-lactoglobulin gene, a region of at least the proximal 406 bp of 5' flanking sequence of the ovine BLG gene (contained within nucleotides 3844 to 4257 of SEQ ID NO:7) will generally be used. Larger portions of the 5' flanking sequence, up to about 5 kbp, are preferred. A larger DNA segment encompassing the 5' flanking promoter region and the region encoding the 5' non-coding portion of the beta-lactoglobulin gene (contained within nucleotides 1 to 4257 of SEQ ID NO:7) is particularly preferred. See Whitelaw et al., *Biochem J.* 28: 31–39, 1992. Similar fragments of promoter DNA from other species are also suitable.

Other regions of the beta-lactoglobulin gene may also be incorporated in constructs, as may genomic regions of the gene to be expressed. It is generally accepted in the art that constructs lacking introns, for example, express poorly in comparison with those that contain such DNA sequences (see Brinster et al., *Proc. Natl. Acad. Sci. USA* 85: 836–840, 1988; Palmiter et al., *Proc. Natl. Acad. Sci. USA* 88: 478–482, 1991; Whitelaw et al., *Transgenic Res.* 1: 3–13, 1991; WO 89/01343; WO 91/02318). In this regard, it is generally preferred, where possible, to use genomic sequences containing all or some of the native introns of a gene encoding the protein or polypeptide of interest. Within certain embodiments of the invention, the further inclusion of at least some introns from the beta-lactoglobulin gene is preferred. One such region is a DNA segment which provides for intron splicing and RNA polyadenylation from the 3' non-coding region of the ovine beta-lactoglobulin gene. When substituted for the natural 3' non-coding sequences of a gene, this ovine beta-lactoglobulin segment can both enhance and stabilize expression levels of the protein or polypeptide of interest. Within other embodiments, the region surrounding the initiation ATG of one or more of the fibrinogen sequences is replaced with corresponding sequences from a milk specific protein gene. Such replacement provides a putative tissue-specific initiation environment to enhance expression. It is convenient to replace the entire fibrinogen chain pre-pro and 5' non-coding sequences with those of, for example, the BLG gene, although smaller regions may be replaced.

For expression of fibrinogen, DNA segments encoding each of the three component polypeptide chains of fibrinogen are operably linked to additional DNA segments required for their expression to produce expression units. Such additional segments include the above-mentioned milk protein gene promoter, as well as sequences which provide for termination of transcription and polyadenylation of mRNA. The expression units will further include a DNA segment encoding a secretion signal operably linked to the segment encoding the fibrinogen polypeptide chain. The secretion signal may be a native fibrinogen secretion signal or may be that of another protein, such as a milk protein. The term "secretion signal" is used herein to denote that portion of a protein that directs it through the secretory pathway of a cell to the outside. Secretion signals are most commonly found at the amino-termini of proteins. See, for example, von Heinje, *Nuc. Acids Res.* 14: 4683–4690, 1986; and Meade et al., U.S. Pat. No. 4,873,316, which are incorporated herein by reference.

Construction of expression units is conveniently carried out by inserting a fibrinogen chain sequence into a plasmid or phage vector containing the additional DNA segments, although the expression unit may be constructed by essentially any sequence of ligations. It is particularly convenient

to provide a vector containing a DNA segment encoding a milk protein and to replace the coding sequence for the milk protein with that of a fibrinogen chain (including a secretion signal), thereby creating a gene fusion that includes the expression control sequences of the milk protein gene. In any event, cloning of the expression units in plasmids or other vectors facilitates the amplification of the fibrinogen sequences. Amplification is conveniently carried out in bacterial (e.g. *E. coli*) host cells, thus the vectors will typically include an origin of replication and a selectable marker functional in bacterial host cells.

In view of the size of the fibrinogen chain genes it is most practical to prepare three separate expression units, mix them, and introduce the mixture into the host. However, those skilled in the art will recognize that other protocols may be followed. For example, expression units for the three chains can be introduced individually into different embryos to be combined later by breeding. In a third approach, the three expression units can be linked in a single suitable vector, such as a yeast artificial chromosome or phage P1 clone. Coding sequences for two or three chains can be combined in polycistronic expression units (see, e.g., Levinson et al., U.S. Pat. No. 4,713,339).

The expression unit(s) is(are) then introduced into fertilized eggs (including early-stage embryos) of the chosen host species. Introduction of heterologous DNA can be accomplished by one of several routes, including microinjection (e.g. U.S. Pat. No. 4,873,191), retroviral infection (Jaenisch, *Science* 240: 1468–1474, 1988) or site-directed integration using embryonic stem (ES) cells (reviewed by Bradley et al., *Bio/Technology* 10: 534–539, 1992). The eggs are then implanted into the oviducts or uteri of pseudopregnant females and allowed to develop to term. Offspring carrying the introduced DNA in their germ line can pass the DNA on to their progeny in the normal, Mendelian fashion, allowing the development of transgenic herds. General procedures for producing transgenic animals are known in the art. See, for example, Hogan et al., *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1986; Simons et al., *Bio/Technology* 6: 179–183, 1988; Wall et al., *Biol. Reprod.* 32: 645–651, 1985; Buhler et al., *Bio/Technology :* 140–143, 1990; Ebert et al., *Bio/Technology :* 835–838, 1991; Krimpenfort et al., *Bio/Technology* 9: 844–847, 1991; Wall et al., *J. Cell. Biochem.* 49: 113–120, 1992; and WIPO publications WO 88/00239, WO 90/05188, WO 92/11757; and GB 87/00458, which are incorporated herein by reference. Techniques for introducing foreign DNA sequences into mammals and their germ cells were originally developed in the mouse. See, e.g., Gordon et al., *Proc. Natl. Acad. Sci. USA* 77: 7380–7384, 1980; Gordon and Ruddle, *Science* 214: 1244–1246, 1981; Palmiter and Brinster, *Cell* 41: 343–345, 1985; Brinster et al., *Proc. Natl. Acad. Sci. USA* 82: 4438–4442, 1985; and Hogan et al. (ibid.). These techniques were subsequently adapted for use with larger animals, including livestock species (see e.g., WIPO publications WO 88/00239, WO 90/05188, and WO 92/11757; and Simons et al., *Bio/Technology* 6: 179–183, 1988). To summarize, in the most efficient route used to date in the generation of transgenic mice or livestock, several hundred linear molecules of the DNA of interest are injected into one of the pro-nuclei of a fertilized egg. Injection of DNA into the cytoplasm of a zygote can also be employed.

It is preferred to obtain a balanced expression of each fibrinogen chain to allow for efficient formation of the mature protein. Ideally, the three expression units should be on the same DNA molecule for introduction into eggs. This approach, however, may generate technical problems at, for

example, the injection and manipulation stages. For example, the size of fibrinogen expression units may necessitate the use of yeast artificial chromosomes (YACs) or phage P1 to amplify and manipulate the DNA prior to injection. If this approach is followed, segments of DNA to be injected, containing all three expression units, would be very large, thus requiring modification of the injection procedure using, for example, larger bore needles. In a more simple approach, a mixture of each individual expression unit is used. It is preferred to combine equimolar amounts of the three expression units, although those skilled in the art will recognize that this ratio may be varied to compensate for the characteristics of a given expression unit. Some expression, generally a reduced level, will be obtained when lesser molar amounts of one or two chains are used, and expression efficiencies can generally be expected to decline in approximate proportion to the divergence from the preferred equimolar ratio. In any event, it is preferred to use a mixture having a ratio of Aα:Bβ:γ expression units in the range of 0.5–1:0.5–1:0.5–1. When the ratio is varied from equimolar, it is preferred to employ relatively more of the Bβ expression unit. Alternatively, one or a mixture of two of the expression units is introduced into individual eggs. However, animals derived by this approach will express only one or two fibrinogen chains. To generate an intact fibrinogen molecule by this approach requires a subsequent breeding program designed to combine all three expression units in individuals of a group of animals.

In general, female animals are superovulated by treatment with follicle stimulating hormone, then mated. Fertilized eggs are collected, and the heterologous DNA is injected into the eggs using known methods. See, for example, U.S. Pat. No. 4,873,191; Gordon et al., *Proc. Natl. Acad. Sci. USA* 77: 7380–7384, 1980; Gordon and Ruddle, *Science* 214: 1244–1246, 1981; Palmiter and Brinster, *Cell.* 41: 343–345, 1985; Brinster et al., *Proc. Natl. Acad. Sci. USA* 82: 4438–4442, 1985; Hogan et al., *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1986; Simons et al. *Bio/Technology* 6: 179–183, 1988; Wall et al., *Biol. Reprod.* 32: 645–651, 1985; Buhler et al., *Bio/Technology* 8: 140–143, 1990; Ebert et al., *Bio/Technology* 9: 835–838, 1991; Krimpenfort et al., *Bio/Technology* 9: 844–847, 1991; Wall et al., *J. Cell. Biochem.* 49: 113–120, 1992; WIPO publications WO 88/00239, WO 90/05118, and WO 92/11757; and GB 87/00458, which are incorporated herein by reference.

For injection into fertilized eggs, the expression units are removed from their respective vectors by digestion with appropriate restriction enzymes. For convenience, it is preferred to design the vectors so that the expression units are removed by cleavage with enzymes that do not cut either within the expression units or elsewhere in the vectors. The expression units are recovered by conventional methods, such as electro-elution followed by phenol extraction and ethanol precipitation, sucrose density gradient centrifugation, or combinations of these approaches.

DNA is injected into eggs essentially as described in Hogan et al., ibid. In a typical injection, eggs in a dish of an embryo culture medium are located using a stereo zoom microscope (×50 or ×63 magnification preferred). Suitable media include Hepes (N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid) or bicarbonate buffered media such as M2 or M16 (available from Sigma Chemical Co., St. Louis, USA) or synthetic oviduct medium (disclosed below). The eggs are secured and transferred to the center of a glass slide on an injection rig using, for example, a drummond pipette complete with capillary tube. Viewing at lower (e.g. ×4)

magnification is used at this stage. Using the holding pipette of the injection rig, the eggs are positioned centrally on the slide. Individual eggs are sequentially secured to the holding pipette for injection. For each injection process, the holding pipette/egg is positioned in the center of the viewing field. The injection needle is then positioned directly below the egg. Preferably using ×40 Nomarski objectives, both manipulator heights are adjusted to focus both the egg and the needle. The pronuclei are located by rotating the egg and adjusting the holding pipette assembly as necessary. Once the pronucleus has been located, the height of the manipulator is altered to focus the pronuclear membrane. The injection needle is positioned below the egg such that the needle tip is in a position below the center of the pronucleus. The position of the needle is then altered using the injection manipulator assembly to bring the needle and the pronucleus into the same focal plane. The needle is moved, via the joy stick on the injection manipulator assembly, to a position to the right of the egg. With a short, continuous jabbing movement, the pronuclear membrane is pierced to leave the needle tip inside the pronucleus. Pressure is applied to the injection needle via the glass syringe until the pronucleus swells to approximately twice its volume. At this point, the needle is slowly removed. Reverting to lower (e.g. ×4) magnification, the injected egg is moved to a different area of the slide, and the process is repeated with another egg.

After the DNA is injected, the eggs may be cultured to allow the pronuclei to fuse, producing one-cell or later stage embryos. In general, the eggs are cultured at approximately the body temperature of the species used in a buffered medium containing balanced salts and serum. Surviving embryos are then transferred to pseudopregnant recipient females, typically by inserting them into the oviduct or uterus, and allowed to develop to term. During embryogenesis, the injected DNA integrates in a random fashion in the genomes of a small number of the developing embryos.

Potential transgenic offspring are screened via blood samples and/or tissue biopsies. DNA is prepared from these samples and examined for the presence of the injected construct by techniques such as polymerase chain reaction (PCR; see Mullis, U.S. Pat. No. 4,683,202) and Southern blotting (Southern, *J. Mol. Biol.* 98:503, 1975; Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1982). Founder transgenic animals, or G0s, may be wholly transgenic, having transgenes in all of their cells, or mosaic, having transgenes in only a subset of cells (see, for example, Wilkie et al., *Develop. Biol.* 118: 9–18, 1986). In the latter case, groups of germ cells may be wholly or partially transgenic. In the latter case, the number of transgenic progeny from a founder animal will be less than the expected 50% predicted from Mendelian principles. Founder G0 animals are grown to sexual maturity and mated to obtain offspring, or G1s. The G1s are also examined for the presence of the transgene to demonstrate transmission from founder G0 animals. In the case of male G0s, these may be mated with several non-transgenic females to generate many offspring. This increases the chances of observing transgene transmission. Female G0 founders may be mated naturally, artificially inseminated or superovulated to obtain many eggs which are transferred to surrogate mothers. The latter course gives the best chance of observing transmission in animals having a limited number of young. The above-described breeding procedures are used to obtain animals that can pass the DNA on to subsequent generations of offspring in the normal, Mendelian fashion, allowing the development of, for example, colonies (mice), flocks (sheep), or herds (pigs, goats and cattle) of transgenic animals.

The milk from lactating G0 and G1 females is examined for the expression of the heterologous protein using immunological techniques such as ELISA (see Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988) and Western blotting (Towbin et al., *Proc. Natl. Acad. Sci. USA* 76: 4350–4354, 1979). For a variety of reasons known in the art, expression levels of the heterologous protein will be expected to differ between individuals.

A satisfactory family of animals should satisfy three criteria: they should be derived from the same founder G0 animal; they should exhibit stable transmission of the transgene; and they should exhibit stable expression levels from generation to generation and from lactation to lactation of individual animals. These principles have been demonstrated and discussed (Carver et al., *Bio/Technology* 11: 1263–1270, 1993). Animals from such a suitable family are referred to as a "line." Initially, male animals, G0 or G1, are used to derive a flock or herd of producer animals by natural or artificial insemination. In this way, many female animals containing the same transgene integration event can be quickly generated from which a supply of milk can be obtained.

The fibrinogen is recovered from milk using standard practices such as skimming, precipitation, filtration and protein chromatography techniques.

Fibrinogen produced according to the present invention is useful within human and veterinary medicine, such as in the formulation of surgical adhesives. Adhesives of this type are known in the art. See, for example, U.S. Pat. Nos. 4,377,572; 4,442,655; 4,462,567; and 4,627,879, which are incorporated herein by reference. In general, fibrinogen and factor XIII are combined to form a first component that is mixed just prior to use with a second component containing thrombin. The thrombin converts the fibrinogen to fibrin, causing the mixture to gel, and activates the factor XIII. The activated factor XIII cross links the fibrin to strengthen and stabilize the adhesive matrix. Such adhesives typically contain from about 30 mg/ml to about 100 mg/ml fibrinogen and from about 50 μg/ml to about 500 μg/ml factor XIII. They may also contain additional ingredients, such as aprotinin, albumin, fibronectin, bulking agents, and solubilizers. Methods for producing factor XIII are known in the art. See, for example, U.S. Pat. No. 5,204,447. The fibrinogen is also useful for coating surfaces of polymeric articles, e.g. synthetic vascular grafts, as disclosed in U.S. Pat. No. 5,272,074 (incorporated herein by reference).

The invention is further illustrated by the following non-limiting examples.

EXAMPLES

Example I

The multiple cloning site of the vector pUC18 (Yanisch-Perron et al., *Gene* 33:103–119, 1985) was removed and replaced with a synthetic double stranded oligonucleotide (the strands of which are shown in SEQ ID NO: 8 and SEQ ID NO: 27) containing the restriction sites Pvu I/Mlu I/Eco RV/Xba I/Pvu I/Mlu I, and flanked by 5' overhangs compatible with the restriction sites Eco RI and Hind III. pUC18 was cleaved with both Eco RI and Hind III, the 5' terminal phosphate groups were removed with calf intestinal phosphatase, and the oligonucleotide was ligated into the vector backbone. The DNA sequence across the junction was confirmed by sequencing, and the new plasmid was called pUCPM.

The β-lactoglobulin (BLG) gene sequences from pSS1tgXS (disclosed in WIPO publication WO 88/00239)

were excised as a Sal I-Xba I fragment and recloned into the vector pUCPM that had been cut with Sal I and Xba I to construct vector pUCXS. pUCXS is thus a pUC18 derivative containing the entire BLG gene from the Sal I site to the Xba I site of phage SS1 (Ali and Clark, *J. Mol. Biol.* 199: 415–426, 1988).

The plasmid pSS1tgSE (disclosed in WIPO publication WO 88/00239) contains a 1290 bp BLG fragment flanked by Sph I and EcoR I restriction sites, a region spanning a unique Not I site and a single Pvu II site which lies in the 5' untranslated leader of the BLG mRNA. Into this Pvu II site was ligated a double stranded, 8 bp DNA linker (5'-GGATATCC-3') encoding the recognition site for the enzyme Eco RV. This plasmid was called pSS1tgSE/RV. DNA sequences bounded by Sph I and Not I restriction sites in pSS1tgSE/RV were excised by enzymatic digestion and used to replace the equivalent fragment in pUCXS. The resulting plasmid was called pUCXSRV. The sequence of the BLG insert in pUCSXRV is shown in SEQ ID NO: 7, with the unique Eco RV site at nucleotide 4245 in the 5' untranslated leader region of the BLG gene. This site allows insertion of any additional DNA sequences under the control of the BLG promoter 3' to the transcription initiation site.

Using the primers BLGAMP3 (5'-TGG ATC CCC TGC CGG TGC CTC TGG-3'; SEQ ID NO: 9) and BLGAMP4 (5'-AAC GCG TCA TCC TCT GTG AGC CAG-3'; SEQ ID NO: 10) a PCR fragment of approximately 650 bp was produced from sequences immediately 3' to the stop codon of the BLG gene in pUCXSRV. The PCR fragment was engineered to have a BamH I site at its 5' end and an Mlu I site at its 3' end and was cloned as such into BamH I and Mlu I cut pGEM7zf(+) (Promega) to give pDAM200(+).

pUCXSRV was digested with Kpn I, and the largest, vector containing band was gel purified. This band contained the entire pUC plasmid sequences and some 3' non-coding sequences from the BLG gene. Into this backbone was ligated the small Kpn I fragment from pDAM200(+) which, in the correct orientation, effectively engineered a BamH I site at the extreme 5' end of the 2.6 Kbp of the BLG 3' flanking region. This plasmid was called pBLAC200. A 2.6 Kbp Cla I-Xba I fragment from pBLAC200 was ligated into Cla I-Xba I cut pSP72 vector (Promega), thus placing an EcoR V site immediately upstream of the BLG sequences. This plasmid was called pBLAC210.

The 2.6 Kbp Eco RV-Xba I fragment from pBLAC210 was ligated into Eco RV-Xba I cut pUCXSRV to form pMAD6. This, in effect, excised all coding and intron sequences from pUCXSRV, forming a BLG minigene consisting of 4.3 Kbp of 5' promoter and 2.6 Kbp of 3' downstream sequences flanking a unique EcoR V site. An oligonucleotide linker (ZC6839: ACTACGTAGT; SEQ ID NO: 11) was inserted into the Eco RV site of pMAD6. This modification destroyed the Eco RV site and created a Sna BI site to be used for cloning purposes. The vector was designated pMAD6-Sna. Messenger RNA initiates upstream of the Sna BI site and terminates downstream of the Sna BI site. The precursor transcript will encode a single BLG-derived intron, intron 6, which is entirely within the 3' untranslated region of the gene.

Example II

Clones encoding the individual fibrinogen chains were obtained from the laboratory of Dr. Earl W. Davie, University of Washington, Seattle. A genomic fibrinogen Aα-chain clone (Chung et al., 1990, ibid.) was obtained from the plasmid BS4. This plasmid contains the Aα clone inserted

into the Sal I and Bam HI sites of the vector pUC18, but lacks the coding sequence for the first four amino acids of the Aα chain. A genomic Bβ-chain DNA (Chung et al., ibid.) was isolated from a lambda Charon 4A phage clone (designated βλ4) as two EcoRI fragments of ca. 5.6 Kbp each. The two fragments were cloned separately into pUC19 that had been digested with Eco RI and treated with calf intestinal phosphatase. The resulting clones were screened by digestion with the restriction enzyme Pvu II to distinguish plasmids with the 5' and 3' Bβ inserts (designated Beta5'RI/puc and Beta3'RI/puc, respectively). Genomic γ-chain clones were isolated as described by Rixon et al. (*Biochemistry* 24: 2077–2086, 1985). Clone pγ12A9 comprises 5' non-coding sequences and approximately 4535 bp of γ-chain coding sequence. Clone pγ12F3 comprises the remaining coding sequence and 3' non-coding nucleotides. Both are pBR322-based plasmids with the fibrinogen sequences inserted at the EcoRI site. These plasmids were used as templates for the respective PCR reactions.

The fibrinogen chain coding sequences were tailored for insertion into expression vectors using the polymerase chain reaction (PCR) as generally described by Mullis (U.S. Pat. No. 4,683,202). This procedure removed native 5' and 3' untranslated sequences, added a 9 base sequence (CCT GCA GCC) upstream of the first ATG of each coding sequence, supplied the first four codons for the Aα-chain sequence, removed an internal Mlu I site in the Aα sequence and added restriction sites to facilitate subsequent cloning steps.

Referring to FIG. 1, the 5' end of the Aα coding sequence was tailored in a PCR reaction containing 20 pmole for each of primers ZC6632 (SEQ ID NO: 12) and ZC6627 (SEQ ID NO: 13), approximately 10 ng of plasmid BS4 template DNA, 10 µl of a mix containing 2.5 mM each dNTP, 7.5 µl 10× *Pyrococcus furiosus* (Pfu) DNA polymerase buffer #1 (200 mM Tris-HCl, pH 8.2, 100 mM KCl, 60 mM $(NH_4)_2SO_4$, 20 mM $MgCl_2$, 1% Triton X-100, 100 µg/ml nuclease free bovine serum albumin)(Stratagene, La Jolla, Calif.), and water to 75 µl. The mixture was heated to 94° C. in a DNA thermal cycler (Perkin-Elmer Corp., Norwalk, Conn.). To the heated mixture was added 25 µl of a mixture containing 2.5 µl 10× Pfu buffer #1, 22 µl H_2O and 1 µl 2.5 units/µl Pfu DNA polymerase (Stratagene). The reactions were run in a DNA thermal cycler (Perkin-Elmer) for five cycles of 94°, 45 seconds; 40°, 90 seconds; 72°, 120 seconds; 20 cycles of 94°, 45 seconds; 45°, 90 seconds; 72°, 120 seconds; then incubated at 72° for 7 minutes. The 5' PCR-generated fragment was digested with Bam HI and Hind III, and the Bam HI-Hind III fragment was then ligated to an internal 2.91 Kbp Hind III-Xba I fragment and Bam HI, Xba I-digested pUC18. PCR-generated exon sequences were sequenced.

Referring again to FIG. 1, the 3' end of the Aα coding sequence was tailored in a series of steps in which the Mlu I site 563 bases upstream from the stop codon of the Aα sequence was mutated using an overlap extension PCR reaction (Ho et al., *Gene* 77: 51–59, 1989). In the first reaction 40 pmole of each of primers ZC6521 (SEQ ID NO: 14) and ZC6520 (SEQ ID NO: 15) were combined with approximately 10 ng of plasmid BS4 template DNA in a reaction mixture as described above. The reaction was run for 5 cycles of 94°, 45 seconds; 40°, 60 seconds; 72°, 120 seconds; 15 cycles of 94°, 45 seconds; 45°, 60 seconds; 72°, 120 seconds; then incubated at 72° for 7 minutes. A second reaction was carried out in the same manner using 40 pmole of each of primers ZC6519 (SEQ ID NO: 16) and ZC6518 (SEQ ID NO: 17) and BS4 as template. The PCR-generated DNA fragments from the first and second reactions were

isolated by gel electrophoresis and elution from the gel. Approximately 1/10 of each recovered reaction product was combined with 40 pmole of each of primers ZC6521 (SEQ ID NO: 14) and ZC6518 (SEQ ID NO: 17) in a PCR reaction in which the complementary 3' ends of each fragment (containing the single base change) annealed and served as a primer for the 3' extension of the complementary strand. PCR was carried out using the same reaction conditions as in the first and second 3' PCR steps. The reaction product was then digested with Xba I and Bam HI, and the Xba I-Bam HI fragment was cloned into Xba I, Bam HI-digested pUC18. PCR-generated exons were sequenced.

As shown in FIG. 1, the 5' Bam HI-Xba I fragment (3.9 Kbp) and the 3' Xba I-Bam HI fragment (1.3 Kbp) were inserted into the Bam HI site of the vector Zem228. Zem228 is a pUC18 derivative comprising a Bam HI cloning site between a mouse MT-1 promoter and SV40 terminator, and a neomycin resistance marker flanked by SV40 promoter and terminator sequences. See European Patent Office Publication EP 319,944 and FIG. 2. The entire Aα coding sequence was isolated from the Zem228 vector as an Sna BI fragment, which was inserted into the Sna BI site of the plasmid pMAD6-Sna.

Referring to FIG. 3, the 5' end of the Bβ-chain was tailored by PCR using the oligonucleotides ZC6629 (SEQ ID NO: 18), ZC6630 (SEQ ID NO: 19) and ZC6625 (SEQ ID NO: 20). These primers were used in pairwise combinations (ZC6629+ZC6625 or ZC6630+ZC6625) to generate Bβ coding sequences beginning at the first ATG codon (position 470 in SEQ ID NO: 3)(designated N1-Beta) or the third ATG codon (position 512 in SEQ ID NO: 3)(designated N3-Beta). Approximately 5 ng of Beta5'RI/puc template DNA was combined with 20 pmole of each of the primers (N1-Beta:ZC6629, SEQ ID NO: 18+ZC6625, SEQ ID NO: 20; or N3-Beta:ZC6630, SEQ ID NO: 19+ZC6625, SEQ ID NO: 20) in a reaction mixture as described above. The mixtures were incubated for 5 cycles of 94°, 45 seconds; 40°, 120 seconds; (N1-Beta) or 90 seconds (N3-Beta); 72°, 120 seconds; 20 cycles of 94°, 45 seconds; 45°, 120 seconds; (N1-Beta) or 90 seconds (N3-Beta); 72°, 120 seconds; then incubated at 72° for 7 minutes. The two reaction products N1, 555 bp or N3, 510 bp) were each digested with Eco RI and Bgl II, and the fragments were ligated to the internal Bgl II-Xba I fragment and Eco RI+Xba I-digested pUC19. The 3' end of the Bβ sequence was tailored in a reaction mixture as described above using the oligonucleotide primers ZC6626 (SEQ ID NO: 21) and ZC6624 (SEQ ID NO: 22) and approximately 5 ng of Beta3'RI/puc template. The mixtures were incubated for 5 cycles of 94°, 45 seconds; 40°, 90 seconds; 72°, 120 seconds; 15 cycles of 94°, 45 seconds; 45°, 90 seconds; 72°, 120 seconds; then incubated at 72° for 7 minutes. A 990 bp Bgl II-Eco RI fragment was isolated. This 3' fragment was ligated to the adjacent coding fragment (340 bp, SphI-Bgl II) and Sph I+Eco RI-digested pUC19. The 3' and 5' PCR-generated exons were sequenced. A third intermediate vector was constructed by combining two internal fragments (4285 bp Xba I-Eco RI and 383 kb Eco RI-Sph I) in Xba I+Sph I-digested pUC19. The entire Bβ coding sequence (two forms) was then assembled by ligating one of the 5' Eco RI-Xba I fragments, the internal Xba I-Sph I fragment, the 3' Sph I-Eco RI fragment and Eco RI-digested vector pUC19. The Bβ sequence was then isolated as a 7.6 Kbp Sna BI fragment and inserted into the Sna BI site of pMAD6-Sna.

Referring to FIG. 4, the 5' end of the gamma chain sequence was tailored by PCR using the oligonucleotide primers ZC6514 (SEQ ID NO: 23) and ZC6517 (SEQ ID

NO: 24) and approximately 50 ng of pγ12A9 as template. The PCR reaction was run as described above using 40 pM of each primer. The reaction was run for 5 cycles of 94°, 45 seconds; 40°, 60 seconds, 72°, 120 seconds, followed by 15 cycles of 94°, 45 seconds; 45°, 60 seconds; 72°, 120 seconds. The resulting 213 bp fragment was digested with Bam HI and Spe I, and the resulting restriction fragment was ligated with the adjacent downstream 4.4 kb Spe I-Eco RI fragment and Bam HI+Eco RI digested pUC19. The 3' end of the gamma chain sequence was tailored using oligonucleotide primers ZC6516 (SEQ ID NO: 25) and ZC6515 (SEQ ID NO: 26) using 40 pM of each primer, approximately 50 ng of pγ12F3 template and the same thermal cycling schedule as used for the 5' fragment. The resulting 500 bp fragment was digested with Spe I and Bam HI, and the resulting restriction fragment was ligated with the upstream 2.77 kb Eco RI-Spe I fragment and Eco RI+Bam HI-digested pUC19. All PCR-generated exons were sequenced. The entire γ-chain coding sequence was then assembled by ligating a 4.5 Kbp Bam HI-Eco RI 5' fragment, a 1.1 Kbp Eco RI-Pst I internal fragment and a 2.14 Kbp Pst I-Xba I 3' fragment in Bam HI+Xba I-digested Zem219b. Zem219b is a pUC18-derived vector containing a mouse metallothionein promoter and a DHFR selectable marker operably linked to an SV40 promoter (FIG. 5). Plasmid Zem219b has been deposited with American Type Culture Collection as an *E. coli* XL1-blue transformant under Accession No. 68979. The entire γ-chain coding sequence was then isolated as a 7.8 Kbp Sna B1 fragment and inserted into the Sna BI site of pMAD6-Sna.

Example III

Mice for initial breeding stocks (C57BL6J, CBACA) were obtained from Harlan Olac Ltd. (Bicester, UK). These were mated in pairs to produce F1 hybrid cross (B6CBAF1) for recipient female, superovulated females, stud males and vasectomized males. All animals were kept on a 14 hour light/10 hour dark cycle and fed water and food (Special Diet Services RM3, Edinburgh, Scotland) ad libitum.

Transgenic mice were generated essentially as described in Hogan et al., *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1986, which is incorporated herein by reference in its entirety. Female B6CBAF1 animals were superovulated at 4–5 weeks of age by an i.p. injection of pregnant mares' serum gonadotrophin (FOLLIGON, Vet-Drug, Falkirk, Scotland) (5 iu) followed by an i.p. injection of human chorionic gonadotrophin (CHORULON, Vet-Drug, Falkirk, Scotland) (5 iu) 45 hours later. They were then mated with a stud male overnight. Such females were next examined for copulation plugs. Those that had mated were sacrificed, and their eggs were collected for microinjection.

DNA was injected into the fertilized eggs as described in Hogan et al. (ibid.) Briefly, each of the vectors containing the Aα, Bβ and γ expression units was digested with Mlu I, and the expression units were isolated by sucrose gradient centrifugation. All chemicals used were reagent grade (Sigma Chemical Co., St. Louis, Mo., U.S.A.), and all solutions were sterile and nuclease-free. Solutions of 20% and 40% sucrose in 1M NaCl , 20 mM Tris pH 8.0, 5 mM EDTA were prepared using UHP water and filter sterilized. A 30% sucrose solution was prepared by mixing equal volumes of the 20% and 40% solutions. A gradient was prepared by layering 0.5 ml steps of the 40%, 30% and 20% sucrose solutions into a 2 ml polyallomer tube and allowed to stand for one hour. 100 µl of DNA solution (max. 8 µg DNA) was loaded onto the top of the gradient, and the

gradient was centrifuged for 17–20 hours at 26,000 rpm, 15° C. in a Beckman TL100 ultracentrifuge using a TLS-55 rotor (Beckman Instruments, Fullerton, Calif., USA). Gradients were fractionated by puncturing the tube bottom with a 20 ga. needle and collecting drops in a 96 well microtiter plate. 3 µl aliquots were analyzed on a 1% agarose mini-gel. Fractions containing the desired DNA fragment were pooled and ethanol precipitated overnight at −20° C. in 0.3M sodium acetate. DNA pellets were resuspended in 50–100 µl UHP water and quantitated by fluorimetry. The expression units were diluted in Dulbecco's phosphate buffered saline without calcium and magnesium (containing, per liter, 0.2 g KCl, 0.2 g KH_2PO_4, 8.0 g NaCl, 1.15 g Na_2HPO_4), mixed (using either the N1-Beta or N3-Beta expression unit) in a 1:1:1 molar ratio, concentration adjusted to about 6 µg/ml, and injected into the eggs (~2 pl total DNA solution per egg).

Recipient females of 6–8 weeks of age are prepared by mating B6CBAF1 females in natural estrus with vasectomized males. Females possessing copulation plugs are then kept for transfer of microinjected eggs.

Following birth of potential transgenic animals, tail biopsies are taken, under anesthesia, at four weeks of age. Tissue samples are placed in 2 ml of tail buffer (0.3M Na acetate, 50 mM HCl, 1.5 mM $MgCl_2$, 10 mM Tris-HCl, pH 8.5, 0.5% NP40, 0.5% Tween 20) containing 200 µg/ml proteinase K (Boehringer Mannheim, Mannheim, Germany) and vortexed. The samples are shaken (250 rpm) at 55°–60° for 3 hours to overnight. DNA prepared from biopsy samples is examined for the presence of the injected constructs by PCR and Southern blotting. The digested tissue is vigorously vortexed, and 5 µl aliquots are placed in 0.5 ml microcentrifuge tubes. Positive and negative tail samples are included as controls. Forty µl of silicone oil (BDH, Poole, UK) is added to each tube, and the tubes are briefly centrifuged. The tubes are incubated in the heating block of a thermal cycler (e.g. Omni-gene, Hybaid, Teddington, UK) to 95° C. for 10 minutes. Following this, each tube has a 45 µl aliquot of PCR mix added such that the final composition of each reaction mix is: 50 mM KCl; 2 mM $MgCl_2$; 10 mM Tris-HCl (pH 8.3); 0.01% gelatin; 0.1% NP40, 10% DMSO; 500 nM each primer, 200 µM dNTPs; 0.02 U/µl Taq polymerase (Boehringer Mannheim, Mannheim, Germany). The tubes are then cycled through 30 repeated temperature changes as required by the particular primers used. The primers may be varied but in all cases must target the BLG promoter region. This is specific for the injected DNA fragments because the mouse does not have a BLG gene. Twelve µl of 5× loading buffer containing Orange G marker dye (0.25% Orange G [Sigma] 15% Ficoll type 400 [Pharmacia Biosystems Ltd., Milton Keynes, UK]) is then added to each tube, and the reaction mixtures are electrophoresed on a 1.6% agarose gel containing ethidium bromide (Sigma) until the marker dye has migrated ⅔ of the length of the gel. The gel is visualized with a UV light source emitting a wavelength of 254 nm. Transgenic mice having one or more of the injected DNA fragments are identified by this approach.

Positive tail samples are processed to obtain pure DNA. The DNA samples are screened by Southern blotting using a BLG promoter probe (nucleotides 2523–4253 of SEQ ID NO: 7). Specific cleavages with appropriate restriction enzymes (e.g. Eco RI) allow the distinction of the three constructs containing the Aα, Bβ and γ sequences.

Southern blot analysis of transgenic mice prepared essentially as described above demonstrated that more than 50% of progeny contained all three fibrinogen sequences. Examination of milk from positive animals by reducing SDS polyacrylamide gel electrophoresis demonstrated the pres-

ence of all three protein chains at concentrations up to 1 mg/ml. The amount of fully assembled fibrinogen was related to the ratios of individual subunits present in the milk. No apparent phenotype was associated with high concentrations of human fibrinogen in mouse milk.

Example IV

Donor ewes are treated with an intravaginal progesterone-impregnated sponge (CHRONOGEST Goat Sponge, Intervet, Cambridge, UK) on day 0. Sponges are left in situ for ten or twelve days.

Superovulation is induced by treatment of donor ewes with a total of one unit of ovine follicle stimulating hormone (OFSH) (OVAGEN, Horizon Animal Reproduction Technology Pty. Ltd., New Zealand) administered in eight intramuscular injections of 0.125 units per injection starting at 5:00 pm on day −4 and ending at 8:00 am on day 0. Donors are injected intramuscularly with 0.5 ml of a luteolytic agent (ESTRUMATE, Vet-Drug) on day −4 to cause regression of the corpus luteum, to allow return to estrus and ovulation. To synchronize ovulation, the donor animals are injected intramuscularly with 2 ml of a synthetic releasing hormone analog (RECEPTAL, Vet-Drug) at 5:00 pm on day 0.

Donors are starved of food and water for at least 12 hours before artificial insemination (A.I.). The animals are artificially inseminated by intrauterine laparoscopy under sedation and local anesthesia on day 1. Either xylazine (ROMPUN, Vet-Drug) at a dose rate of 0.05–0.1 ml per 10 kg bodyweight or ACP injection 10 mg/ml (Vet-Drug) at a dose rate of 0.1 ml per 10 kg bodyweight is injected intramuscularly approximately fifteen minutes before A.I. to provide sedation. A.I. is carried out using freshly collected semen from a Poll Dorset ram. Semen is diluted with equal parts of filtered phosphate buffered saline, and 0.2 ml of the diluted semen is injected per uterine horn. Immediately pre- or post-A.I., donors are given an intramuscular injection of AMOXYPEN (Vet-Drug).

Fertilized eggs are recovered on day 2 following starvation of donors of food and water from 5:00 pm on day 1. Recovery is carried out under general anesthesia induced by an intravenous injection of 5% thiopentone sodium (INTRAVAL SODIUM, Vet-Drug) at a dose rate of 3 ml per 10 kg bodyweight. Anesthesia is maintained by inhalation of 1–2% Halothane/O_2/N_2O after intubation. To recover the fertilized eggs, a laparotomy incision is made, and the uterus is exteriorized. The eggs are recovered by retrograde flushing of the oviducts with Ovum Culture Medium (Advanced Protein Products, Brierly Hill, West Midlands, UK) supplemented with bovine serum albumin of New Zealand origin. After flushing, the uterus is returned to the abdomen, and the incision is closed. Donors are allowed to recover post-operatively or are euthanized. Donors that are allowed to recover are given an intramuscular injection of Amoxypen L.A. at the manufacturer's recommended dose rate immediately pre- or post-operatively.

Plasmids containing the three fibrinogen chain expression units are digested with Mlu I, and the expression unit fragments are recovered and purified on sucrose density gradients. The fragment concentrations are determined by fluorimetry and diluted in Dulbecco's phosphate buffered saline without calcium and magnesium as described above. The concentration is adjusted to 6 μg/ml and approximately 2 pl of the mixture is microinjected into one pronucleus of each fertilized eggs with visible pronuclei.

All fertilized eggs surviving pronuclear microinjection are cultured in vitro at 38.5° C. in an atmosphere of 5%

CO_2:5% O_2:90% N_2 and about ~100% humidity in a bicarbonate buffered synthetic oviduct medium (see Table) supplemented with 20% v/v vasectomized ram serum. The serum may be heat inactivated at 56° C. for 30 minutes and stored frozen at −20° C. prior to use. The fertilized eggs are cultured for a suitable period of time to allow early embryo mortality (caused by the manipulation techniques) to occur. These dead or arrested embryos are discarded. Embryos having developed to 5 or 6 cell divisions are transferred to synchronized recipient ewes.

TABLE

Synthetic Oviduct Medium	
Stock A (Lasts 3 Months)	
NaCl	6.29 g
KCl	0.534 g
KH_2SO_4	0.162 g
$MgSO_4$:$7H_2O$	0.182 g
Penicillin	0.06 g
Sodium Lactate 60% syrup	0.6 mls
Super H_2O	99.4 mls
Stock B (Lasts 2 weeks)	
$NaHCO_3$	0.21 g
Phenol red	0.001 g
Super H_2O	10 mls
Stock C (Lasts 2 weeks)	
Sodium Pyruvate	0.051 g
Super H_2O	10 mls
Stock D (Lasts 3 months)	
$CaCl_2.2H_2O$	0.262 g
Super H_2O	10 mls
Stock E (Lasts 3 months)	
Hepes	0.651 g
Phenol red	0.001 g
Super H_2O	10 mls
To make up 10 mls of Bicarbonate Buffered Medium	
STOCK A	1 ml
STOCK B	1 ml
STOCK C	0.07 ml
STOCK D	0.1 ml
Super H_2O	7.83 ml
Osmolarity should be 265–285 mOsm. Add 2.5 ml of heat inactivated sheep serum and filter sterilize.	
To make up 10 mls HEPES Buffered Medium	
STOCK A	1 ml
STOCK B	0.2 ml
STOCK C	0.07 ml
STOCK D	0.1 ml
STOCK E	0.8 ml
Super H_2O	7.83 ml
Osmolarity should be 265–285 mOsm. Add 2.5 ml of heat inactivated sheep serum and filter sterilize.	

Recipient ewes are treated with an intravaginal progesterone-impregnated sponge (Chronogest Ewe Sponge or Chronogest Ewe-Lamb Sponge, Intervet) left in situ for 10 or 12 days. The ewes are injected intramuscularly with 1.5 ml (300 iu) of a follicle stimulating hormone substitute (P.M.S.G., Intervet) and with 0.5 ml of a luteolytic agent (Estrumate, Coopers Pitman-Moore) at sponge removal on day −1. The ewes are tested for estrus with a vasectomized ram between 8:00 am and 5:00 pm on days 0 and 1.

Embryos surviving in vitro culture are returned to recipients (starved from 5:00 pm on day 5 or 6) on day 6 or 7. Embryo transfer is carried out under general anesthesia as

described above. The uterus is exteriorized via a laparotomy incision with or without laparoscopy. Embryos are returned to one or both uterine horns only in ewes with at least one suitable corpora lutea. After replacement of the uterus, the abdomen is closed, and the recipients are allowed to recover. The animals are given an intramuscular injection of Amoxypen L.A. at the manufacturer's recommended dose rate immediately pre- or post-operatively.

Lambs are identified by ear tags and left with their dams for rearing. Ewes and lambs are either housed and fed complete diet concentrates and other supplements and or ad lib. hay, or are let out to grass.

Within the first week of life (or as soon thereafter as possible without prejudicing health), each lamb is tested for the presence of the heterologous DNA by two sampling procedures. A 10 ml blood sample is taken from the jugular vein into an EDTA vacutainer. If fit enough, the lambs also have a second 10 ml blood sample taken within one week of the first. Tissue samples are taken by tail biopsy as soon as possible after the tail has become desensitized after the application of a rubber elastrator ring to its proximal third (usually within 200 minutes after "tailing"). The tissue is placed immediately in a solution of tail buffer. Tail samples are kept at room temperature and analyzed on the day of collection. All lambs are given an intramuscular injection of Amoxypen L.A. at the manufacturer's recommended dose rate immediately post-biopsy, and the cut end of the tail is sprayed with an antibiotic spray.

DNA is extracted from sheep blood by first separating white blood cells. A 10 ml sample of blood is diluted in 20 ml of Hank's buffered saline (HBS; obtained from Sigma

Chemical Co.). Ten ml of the diluted blood is layered over 5 ml of Histopaque (Sigma) in each of two 15 ml screw-capped tubes. The tubes are centrifuged at 3000 rpm (2000× g max.), low brake for 15 minutes at room temperature. White cell interfaces are removed to a clean 15 ml tube and diluted to 15 ml in HBS. The diluted cells are spun at 3000 rpm for 10 minutes at room temperature, and the cell pellet is recovered and resuspended in 2–5 ml of tail buffer.

To extract DNA from the white cells, 10% SDS is added to the resuspended cells to a final concentration of 1%, and the tube is inverted to mix the solution. One mg of fresh proteinase K solution is added, and the mixture is incubated overnight at 45° C. DNA is extracted using an equal volume of phenol/chloroform (×3) and chloroform/isoamyl alcohol (×1). The DNA is then precipitated by adding 0.1 volume of 3M NaOAc and 2 volumes of ethanol, and the tube is inverted to mix. The precipitated DNA is spooled out using a clean glass rod with a sealed end. The spool is washed in 70% ethanol, and the DNA is allowed to partially dry, then is redissolved in TE (10 mM Tris-HCl, 1 mM EDTA, pH 7.4).

DNA samples from blood and tail are analyzed by Southern blotting using probes for the BLG promoter region and the fibrinogen chain coding regions.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i i i) NUMBER OF SEQUENCES: 27

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5943 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(v i i) IMMEDIATE SOURCE:
(B) CLONE: Human Fibrinogen A-alpha chain

(i x) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: join(31..84, 1154..1279, 1739..1922, 3055..3200, 3786..5210)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GTCTAGGAGC CAGCCCCACC CTTAGAAAAG ATG TTT TCC ATG AGG ATC GTC TGC        54
                                     Met Phe Ser Met Arg Ile Val Cys
                                       1               5

CTA GTT CTA AGT GTG GTG GGC ACA GCA TGG GTATGGCCCT TTTCATTTTT          104
Leu Val Leu Ser Val Val Gly Thr Ala Trp
     10                  15

TCTTCTTGCT TTCTCTCTGG TGTTTATTCC ACAAAGAGCC TGGAGGTCAG AGTCTACCTG     164

CTCTATGTCC TGACACACTC TTAGCTTTAT GACCCCAGGC CTGGGAGGAA ATTTCCTGGG     224
```

-continued

```
TGGGCTTGAC ACCTCAAGAA TACAGGGTAA TATGACACCA AGAGGAAGAT CTTAGATGGA    284

TGAGAGTGTA CAACTACAAG GGAAACTTTA GCATCTGTCA TTCAGTCTTA CCACATTTTG    344

TTTTGTTTTG TTTTAAAAAG GGCAAGAATT ATTTGCCATC CTTGTACCTA TAAAGCCTTG    404

GTGCATTATA ATGCTAGTTA ATGGAATAAA ACATTTTATG GTAAGATTTG TTTTCTTTAG    464

TTATTAATTT CTTGCTACTT GTCCATAATA AGCAGAACTT TTAGTGTTAG TACAGTTTTG    524

CTGAAAGGTT ATTGTTGTGT TTGTCAAGAC AGAAGAAAAA GCAAACGAAT TATCTTTGGA    584

AATATCTTTG CAGTATCAGA AGAGATTAGT TAGTAAGGCA ATACGCTTTT CCGCAGTAAT    644

GGTATTCTTT TAAATTATGA ATCCATCTCT AAAGGTTACA TAGAAACTTG AAGGAGAGAG    704

GAACATTCAG TTAAGATAGT CTAGGTTTTT CTACTGAAGC AGCAATTACA GGAGAAAGAG    764

CTCTACAGTA GTTTTCAACT TTCTGTCTGC AGTCATTAGT AAAAATGAAA AGGTAAAATT    824

TAACTGATTT TATAGATTCA AATAATTTTC CTTTTAGGAT GGATTCTTTA AAACTCCTAA    884

TATTTATCAA ATGCTTATTT AAGTGTCACA CACAGTTAAG AAATTTGTAC ACCTTGTCTC    944

CTTTAATTCT CATAACAACT CCATAAAATG GGTCCTAGGA TTTCCATTTG AAGATAAGAA   1004

ACCTGAAGCT TGCCGAAGCC CTGTGTCTGC TCTCCTTAAT CTCTGTGAGA GTGCCATCTC   1064

TTCCTGGGGA CTTGTAGGCA TGCCACTGTC TCCTCTTCTG GCTAACATTG CTGTTGCTCT   1124

CTTTTGTGTA TGTGAATGAA TCTTTAAAG ACT GCA GAT AGT GGT GAA GGT GAC      1177
                               Thr Ala Asp Ser Gly Glu Gly Asp
                                20                  25

TTT CTA GCT GAA GGA GGA GGC GTG CGT GGC CCA AGG GTT GTG GAA AGA      1225
Phe Leu Ala Glu Gly Gly Gly Val Arg Gly Pro Arg Val Val Glu Arg
            30                  35                  40

CAT CAA TCT GCC TGC AAA GAT TCA GAC TGG CCC TTC TGC TCT GAT GAA      1273
His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu
        45                  50                  55

GAC TGG GTAAGCAGTC AGCGGGGGAA GCAGGAGATT CCTTCCCTCT GATGCTAGAG      1329
Asp Trp
    60

GGGCTCACAG GCTGACCTGA TTGGTCCCAG AAACTTTTTT AAATAGAAAA TAATTGAATA   1389

GTTACCTACA TAGCAAATAA AGAAAAGGAA CCTACTCCCA AGAGCACTGT TTATTTACCT   1449

CCCCAACTCT GGATCATTAG TGGGTGAACA GACAGGATTT CAGTTGCATG CTCAGGCAAA   1509

ACCAGGCTCC TGAGTATTGT GGCCTCAATT TCCTGGCACC TATTTATGGC TAAGTGGACC   1569

CTCATTCCAG AGTTTCTCTG CGACCTCTAA CTAGTCCTCT TACCTACTTT TAAGCCAACT   1629

TATCTGGAAG AGAAAGGGTA GGAAGAAATG GGGGCTGCAT GGAAACATGC AAAATTATTC   1689

TGAATCTGAG AGATAGATCC TTACTGTAAT TTTCTCCCTT CACTTTCAG AAC TAC       1744
                                                    Asn Tyr
AAA TGC CCT TCT GGC TGC AGG ATG AAA GGG TTG ATT GAT GAA GTC AAT      1792
Lys Cys Pro Ser Gly Cys Arg Met Lys Gly Leu Ile Asp Glu Val Asn
        65                  70                  75

CAA GAT TTT ACA AAC AGA ATA AAT AAG CTC AAA AAT TCA CTA TTT GAA      1840
Gln Asp Phe Thr Asn Arg Ile Asn Lys Leu Lys Asn Ser Leu Phe Glu
    80                  85                  90

TAT CAG AAG AAC AAT AAG GAT TCT CAT TCG TTG ACC ACT AAT ATA ATG      1888
Tyr Gln Lys Asn Asn Lys Asp Ser His Ser Leu Thr Thr Asn Ile Met
 95                 100                 105                 110

GAA ATT TTG AGA GGC GAT TTT TCC TCA GCC AAT  A GTAAGTATTA            1932
Glu Ile Leu Arg Gly Asp Phe Ser Ser Ala Asn
                115                 120

CATATTTACT TCTTTGACTT TATAACAGAA ACAACAAAAA TCCTAAATAA ATATGATATC   1992
```

-continued

```
CGCTTATATC TATGACAATT TCATCCCAAA GTACTTAGTG TAGAAACACA TACCTTCATA    2052

ATATCCCTGA AAATTTTAAG AGGGAGCTTT TGTTTTCGTT ATTTTTTCAA AGTAAAAGAT    2112

GTTAACTGAG ATTGTTTAAG GTCACAAAAT AAGTCAGAAT TTTGGATTAA AACAAGAATT    2172

TAAATGTGTT CTTTTCAACA GTATATACTG AAAGTAGGAT GGGTCAGACT CTTTGAGTTG    2232

ATATTTTTGT TTCTGCTTTG TAAAGGTGAA AACTGAGAGG TCAAGGAACT TGTTCAAAGA    2292

CACAGAGCTG GGAATTCAAC TCCCAGACTC CACTGAGCTG ATTAGGTAGA TTTTTAAATT    2352

TAAAATATAG GGTCAAGCTA CGTCATTCTC ACAGTCTACT CATTAGGGTT AGGAAACATT    2412

GCATTCACTC TGGGCATGGA CAGCGAGTCT AGGGAGTCCT CAGTTTCTCA AGTTTTGCTT    2472

TGCCTTTTTA CACCTTCACA AACACTTGAC ATTTAAAATC AGTGATGCCA ACACTAGCTG    2532

GCAAGTGAGT GATCCTGTTG ACCCAAAACA GCTTAGGAAC CATTTCAAAT CTATAGAGTT    2592

AAAAAGAAAA GCTCATCAGT AAGAAAATCC AATATGTTCA AGTCCCTTGA TTAAGGATGT    2652

TATAAAATAA TTGAAATGCA ATCAAACCAA CTATTTTAAC TCCAAATTAC ACCTTTAAAA    2712

TTCCAAAGAA AGTTCTTCTT CTATATTTCT TTGGGATTAC TAATTGCTAT TAGGACATCT    2772

TAACTGGCAT TCATGGAAGG CTGCAGGGCA TAACATTATC CAAAAGTCAA ATGCCCCATA    2832

GGTTTTGAAC TCACAGATTA AACTGTAACC AAAATAAAAT TAGGCATATT TACAAGCTAG    2892

TTTCTTTCTT TCTTTTTTCT CTTTCTTTCT TTCTTTCTTT CTTTCTTTCT TTCTTTCTTT    2952

CTTTCTTTCT TTCTCCTTCC TTCCTTTCTT CCTTTCTTTT TTGCTGGCAA TTACAGACAA    3012

ATCACTCAGC AGCTACTTCA ATAACCATAT TTTCGATTTC AG  AC CGT GAT AAT       3065
                                                   Asn Arg Asp Asn
                                                                125

ACC TAC AAC CGA GTG TCA GAG GAT CTG AGA AGC AGA ATT GAA GTC CTG      3113
Thr Tyr Asn Arg Val Ser Glu Asp Leu Arg Ser Arg Ile Glu Val Leu
                    130                 135                 140

AAG CGC AAA GTC ATA GAA AAA GTA CAG CAT ATC CAG CTT CTG CAG AAA      3161
Lys Arg Lys Val Ile Glu Lys Val Gln His Ile Gln Leu Leu Gln Lys
                145                 150                 155

AAT GTT AGA GCT CAG TTG GTT GAT ATG AAA CGA CTG GAG GTAAGTATGT       3210
Asn Val Arg Ala Gln Leu Val Asp Met Lys Arg Leu Glu
            160                 165                 170

GGCTGTGGTC CCGAGTGTCC TTGTTTTTGA GTAGAGGGAA AAGGAAGGCG ATAGTTATGC    3270

ACTGAGTGTC TACTATATGC AGAGAAAAGT GTTATATCCA TCATCTACCT AAAAGTAGGT    3330

ATTATTTTCC TCACTCCACA GTTGAAGAAA AAAAAATTCA GAGATATTAA GTAAATTTTC    3390

CAACGTACAT AGATAGTAAT TCAAAGCAAT GTTCAGTCCC TGTCTATTCC AAGCCATTAC    3450

ATCACCACAC CTCTGAGCCC TCAGCCTGAG TTCACCAAGG ATCATTTAAT TAGCGTTTCC    3510

TTTGAGAGGG AATAGCACCT TACTCTTGAT CCATTCTGAG GCTAAGATGA ATTAAACAGC    3570

ATCCATTGCT TATCCTGGCT AGCCCTGCAA TACCCAACAT CTCTTCCACT GAGGGTGCTC    3630

GATAGGCAGA AAACAGAGAA TATTAAGTGG TAGGTCTCCG AGTCAAAAAA AATGAAACCA    3690

GTTTCCAGAA GGAAAATTAA CTACCAGGAA CTCAATAGAC GTAGTTTATG TATTTGTATC    3750

TACATTTTCT CTTTATTTTT CTCCCCTCTC TCTAG GTG GAC ATT GAT ATT AAG       3803
                                    Val Asp Ile Asp Ile Lys
                                                        175

ATC CGA TCT TGT CGA GGG TCA TGC AGT AGG GCT TTA GCT CGT GAA GTA      3851
Ile Arg Ser Cys Arg Gly Ser Cys Ser Arg Ala Leu Ala Arg Glu Val
            180                 185                 190

GAT CTG AAG GAC TAT GAA GAT CAG CAG AAG CAA CTT GAA CAG GTC ATT      3899
```

-continued

Asp Leu Lys Asp Tyr Glu Asp Gln Gln Lys Gln Leu Glu Gln Val Ile
195 200 205

GCC AAA GAC TTA CTT CCC TCT AGA GAT AGG CAA CAC TTA CCA CTG ATA 3947
Ala Lys Asp Leu Leu Pro Ser Arg Asp Arg Gln His Leu Pro Leu Ile
210 215 220

AAA ATG AAA CCA GTT CCA GAC TTG GTT CCC GGA AAT TTT AAG AGC CAG 3995
Lys Met Lys Pro Val Pro Asp Leu Val Pro Gly Asn Phe Lys Ser Gln
225 230 235 240

CTT CAG AAG GTA CCC CCA GAG TGG AAG GCA TTA ACA GAC ATG CCG CAG 4043
Leu Gln Lys Val Pro Pro Glu Trp Lys Ala Leu Thr Asp Met Pro Gln
245 250 255

ATG AGA ATG GAG TTA GAG AGA CCT GGT GGA AAT GAG ATT ACT CGA GGA 4091
Met Arg Met Glu Leu Glu Arg Pro Gly Gly Asn Glu Ile Thr Arg Gly
260 265 270

GGC TCC ACC TCT TAT GGA ACC GGA TCA GAG ACG GAA AGC CCC AGG AAC 4139
Gly Ser Thr Ser Tyr Gly Thr Gly Ser Glu Thr Glu Ser Pro Arg Asn
275 280 285

CCT AGC AGT GCT GGA AGC TGG AAC TCT GGG AGC TCT GGA CCT GGA AGT 4187
Pro Ser Ser Ala Gly Ser Trp Asn Ser Gly Ser Ser Gly Pro Gly Ser
290 295 300

ACT GGA AAC CGA AAC CCT GGG AGC TCT GGG ACT GGA GGG ACT GCA ACC 4235
Thr Gly Asn Arg Asn Pro Gly Ser Ser Gly Thr Gly Gly Thr Ala Thr
305 310 315 320

TGG AAA CCT GGG AGC TCT GGA CCT GGA AGT GCT GGA AGC TGG AAC TCT 4283
Trp Lys Pro Gly Ser Ser Gly Pro Gly Ser Ala Gly Ser Trp Asn Ser
325 330 335

GGG AGC TCT GGA ACT GGA AGT ACT GGA AAC CAA AAC CCT GGG AGC CCT 4331
Gly Ser Ser Gly Thr Gly Ser Thr Gly Asn Gln Asn Pro Gly Ser Pro
340 345 350

AGA CCT GGT AGT ACC GGA ACC TGG AAT CCT GGC AGC TCT GAA CGC GGA 4379
Arg Pro Gly Ser Thr Gly Thr Trp Asn Pro Gly Ser Ser Glu Arg Gly
355 360 365

AGT GCT GGG CAC TGG ACC TCT GAG AGC TCT GTA TCT GGT AGT ACT GGA 4427
Ser Ala Gly His Trp Thr Ser Glu Ser Ser Val Ser Gly Ser Thr Gly
370 375 380

CAA TGG CAC TCT GAA TCT GGA AGT TTT AGG CCA GAT AGC CCA GGC TCT 4475
Gln Trp His Ser Glu Ser Gly Ser Phe Arg Pro Asp Ser Pro Gly Ser
385 390 395 400

GGG AAC GCG AGG CCT AAC AAC CCA GAC TGG GGC ACA TTT GAA GAG GTG 4523
Gly Asn Ala Arg Pro Asn Asn Pro Asp Trp Gly Thr Phe Glu Glu Val
405 410 415

TCA GGA AAT GTA AGT CCA GGG ACA AGG AGA GAG TAC CAC ACA GAA AAA 4571
Ser Gly Asn Val Ser Pro Gly Thr Arg Arg Glu Tyr His Thr Glu Lys
420 425 430

CTG GTC ACT TCT AAA GGA GAT AAA GAG CTC AGG ACT GGT AAA GAG AAG 4619
Leu Val Thr Ser Lys Gly Asp Lys Glu Leu Arg Thr Gly Lys Glu Lys
435 440 445

GTC ACC TCT GGT AGC ACA ACC ACC ACG CGT CGT TCA TGC TCT AAA ACC 4667
Val Thr Ser Gly Ser Thr Thr Thr Thr Arg Arg Ser Cys Ser Lys Thr
450 455 460

GTT ACT AAG ACT GTT ATT GGT CCT GAT GGT CAC AAA GAA GTT ACC AAA 4715
Val Thr Lys Thr Val Ile Gly Pro Asp Gly His Lys Glu Val Thr Lys
465 470 475 480

GAA GTG GTG ACC TCC GAA GAT GGT TCT GAC TGT CCC GAG GCA ATG GAT 4763
Glu Val Val Thr Ser Glu Asp Gly Ser Asp Cys Pro Glu Ala Met Asp
485 490 495

TTA GGC ACA TTG TCT GGC ATA GGT ACT CTG GAT GGG TTC CGC CAT AGG 4811
Leu Gly Thr Leu Ser Gly Ile Gly Thr Leu Asp Gly Phe Arg His Arg
500 505 510

CAC CCT GAT GAA GCT GCC TTC TTC GAC ACT GCC TCA ACT GGA AAA ACA 4859

-continued

```
His Pro Asp Glu Ala Ala Phe Phe Asp Thr Ala Ser Thr Gly Lys Thr
          515                 520                 525

TTC CCA GGT TTC TTC TCA CCT ATG TTA GGA GAG TTT GTC AGT GAG ACT      4907
Phe Pro Gly Phe Phe Ser Pro Met Leu Gly Glu Phe Val Ser Glu Thr
    530                 535                 540

GAG TCT AGG GGC TCA GAA TCT GGC ATC TTC ACA AAT ACA AAG GAA TCC      4955
Glu Ser Arg Gly Ser Glu Ser Gly Ile Phe Thr Asn Thr Lys Glu Ser
545                 550                 555                 560

AGT TCT CAT CAC CCT GGG ATA GCT GAA TTC CCT TCC CGT GGT AAA TCT      5003
Ser Ser His His Pro Gly Ile Ala Glu Phe Pro Ser Arg Gly Lys Ser
                565                 570                 575

TCA AGT TAC AGC AAA CAA TTT ACT AGT AGC AGG AGT TAC AAC AGA GGA      5051
Ser Ser Tyr Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn Arg Gly
            580                 585                 590

GAC TCC ACA TTT GAA AGC AAG AGC TAT AAA ATG GCA GAT GAG GCC GGA      5099
Asp Ser Thr Phe Glu Ser Lys Ser Tyr Lys Met Ala Asp Glu Ala Gly
        595                 600                 605

AGT GAA GCC GAT CAT GAA GGA ACA CAT AGC ACC AAG AGA GGC CAT GCT      5147
Ser Glu Ala Asp His Glu Gly Thr His Ser Thr Lys Arg Gly His Ala
    610                 615                 620

AAA TCT CGC CCT GTC AGA GGT ATC CAC ACT TCT CCT TTG GGG AAG CCT      5195
Lys Ser Arg Pro Val Arg Gly Ile His Thr Ser Pro Leu Gly Lys Pro
625                 630                 635                 640

TCC CTG TCC CCC TAGACTAAGT TAAATATTTC TGCACAGTGT TCCCATGGCC           5247
Ser Leu Ser Pro
                645

CCTTGCATTT CCTTCTTAAC TCTCTGTTAC ACGTCATTGA AACTACACTT TTTTGGTCTG    5307

TTTTTGTGCT AGACTGTAAG TTCCTTGGGG GCAGGGCCTT TGTCTGTCTC ATCTCTGTAT    5367

TCCCAAATGC CTAACAGTAC AGAGCCATGA CTCAATAAAT ACATGTTAAA TGGATGAATG    5427

AATTCCTCTG AAACTCTATT TGAGCTTATT TAGTCAAATT CTTTCACTAT TCAAAGTGTG    5487

TGCTATTAGA ATTGTCACCC AACTGATTAA TCACATTTTT AGTATGTGTC TCAGTTGACA    5547

TTTAGGTCAG GCTAAATACA AGTTGTGTTA GTATTAAGTG AGCTTAGCTA CCTGTACTGG    5607

TTACTTGCTA TTAGTTTGTG CAAGTAAAAT TCCAAATACA TTTGAGGAAA ATCCCCTTTG    5667

CAATTTGTAG GTATAAATAA CCGCTTATTT GCATAAGTTC TATCCCACTG TAAGTGCATC    5727

CTTTCCCTAT GGAGGGAAGG AAAGGAGGAA GAAAGAAAGG AAGGGAAAGA AACAGTATTT    5787

GCCTTATTTA ATCTGAGCCG TGCCTATCTT TGTAAAGTTA AATGAGAATA ACTTCTTCCA    5847

ACCAGCTTAA TTTTTTTTTT AGACTGTGAT GATGTCCTCC AAACACATCC TTCAGGTACC    5907

CAAAGTGGCA TTTTCAATAT CAAGCTATCC GGATCC                               5943
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 644 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Phe Ser Met Arg Ile Val Cys Leu Val Leu Ser Val Val Gly Thr
  1               5                  10                  15

Ala Trp Thr Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly
            20                  25                  30

Gly Val Arg Gly Pro Arg Val Val Glu Arg His Gln Ser Ala Cys Lys
        35                  40                  45
```

-continued

Asp	Ser	Asp	Trp	Pro	Phe	Cys	Ser	Asp	Glu	Asp	Trp	Asn	Tyr	Lys	Cys
	50					55					60				
Pro	Ser	Gly	Cys	Arg	Met	Lys	Gly	Leu	Ile	Asp	Glu	Val	Asn	Gln	Asp
65					70					75					80
Phe	Thr	Asn	Arg	Ile	Asn	Lys	Leu	Lys	Asn	Ser	Leu	Phe	Glu	Tyr	Gln
				85					90					95	
Lys	Asn	Asn	Lys	Asp	Ser	His	Ser	Leu	Thr	Thr	Asn	Ile	Met	Glu	Ile
			100					105					110		
Leu	Arg	Gly	Asp	Phe	Ser	Ser	Ala	Asn	Asn	Arg	Asp	Asn	Thr	Tyr	Asn
		115					120					125			
Arg	Val	Ser	Glu	Asp	Leu	Arg	Ser	Arg	Ile	Glu	Val	Leu	Lys	Arg	Lys
	130					135					140				
Val	Ile	Glu	Lys	Val	Gln	His	Ile	Gln	Leu	Leu	Gln	Lys	Asn	Val	Arg
145					150					155					160
Ala	Gln	Leu	Val	Asp	Met	Lys	Arg	Leu	Glu	Val	Asp	Ile	Asp	Ile	Lys
				165					170					175	
Ile	Arg	Ser	Cys	Arg	Gly	Ser	Cys	Ser	Arg	Ala	Leu	Ala	Arg	Glu	Val
			180					185					190		
Asp	Leu	Lys	Asp	Tyr	Glu	Asp	Gln	Gln	Lys	Gln	Leu	Glu	Gln	Val	Ile
		195					200					205			
Ala	Lys	Asp	Leu	Leu	Pro	Ser	Arg	Asp	Arg	Gln	His	Leu	Pro	Leu	Ile
	210					215					220				
Lys	Met	Lys	Pro	Val	Pro	Asp	Leu	Val	Pro	Gly	Asn	Phe	Lys	Ser	Gln
225					230					235					240
Leu	Gln	Lys	Val	Pro	Pro	Glu	Trp	Lys	Ala	Leu	Thr	Asp	Met	Pro	Gln
				245					250					255	
Met	Arg	Met	Glu	Leu	Glu	Arg	Pro	Gly	Gly	Asn	Glu	Ile	Thr	Arg	Gly
			260					265					270		
Gly	Ser	Thr	Ser	Tyr	Gly	Thr	Gly	Ser	Glu	Thr	Glu	Ser	Pro	Arg	Asn
		275					280					285			
Pro	Ser	Ser	Ala	Gly	Ser	Trp	Asn	Ser	Gly	Ser	Ser	Gly	Pro	Gly	Ser
	290					295					300				
Thr	Gly	Asn	Arg	Asn	Pro	Gly	Ser	Ser	Gly	Thr	Gly	Gly	Thr	Ala	Thr
305					310					315					320
Trp	Lys	Pro	Gly	Ser	Ser	Gly	Pro	Gly	Ser	Ala	Gly	Ser	Trp	Asn	Ser
				325					330					335	
Gly	Ser	Ser	Gly	Thr	Gly	Ser	Thr	Gly	Asn	Gln	Asn	Pro	Gly	Ser	Pro
			340					345					350		
Arg	Pro	Gly	Ser	Thr	Gly	Thr	Trp	Asn	Pro	Gly	Ser	Ser	Glu	Arg	Gly
		355					360					365			
Ser	Ala	Gly	His	Trp	Thr	Ser	Gln	Ser	Ser	Val	Ser	Gly	Ser	Thr	Gly
	370					375					380				
Gln	Trp	His	Ser	Glu	Ser	Gly	Ser	Phe	Arg	Pro	Asp	Ser	Pro	Gly	Ser
385					390					395					400
Gly	Asn	Ala	Arg	Pro	Asn	Asn	Pro	Asp	Trp	Gly	Thr	Phe	Glu	Glu	Val
				405					410					415	
Ser	Gly	Asn	Val	Ser	Pro	Gly	Thr	Arg	Arg	Glu	Tyr	His	Thr	Glu	Lys
			420					425					430		
Leu	Val	Thr	Ser	Lys	Gly	Asp	Lys	Glu	Leu	Arg	Thr	Gly	Lys	Glu	Lys
		435					440					445			
Val	Thr	Ser	Gly	Ser	Thr	Thr	Thr	Thr	Arg	Arg	Ser	Cys	Ser	Lys	Thr
	450					455					460				
Val	Thr	Lys	Thr	Val	Ile	Gly	Pro	Asp	Gly	His	Lys	Glu	Val	Thr	Lys
465					470					475					480

-continued

```
Glu Val Val Thr Ser Glu Asp Gly Ser Asp Cys Pro Glu Ala Met Asp
                485                 490                 495

Leu Gly Thr Leu Ser Gly Ile Gly Thr Leu Asp Gly Phe Arg His Arg
            500                 505                 510

His Pro Asp Glu Ala Ala Phe Phe Asp Thr Ala Ser Thr Gly Lys Thr
        515                 520                 525

Phe Pro Gly Phe Phe Ser Pro Met Leu Gly Glu Phe Val Ser Glu Thr
    530                 535                 540

Glu Ser Arg Gly Ser Glu Ser Gly Ile Phe Thr Asn Thr Lys Glu Ser
545                 550                 555                 560

Ser Ser His His Pro Gly Ile Ala Glu Phe Pro Ser Arg Gly Lys Ser
                565                 570                 575

Ser Ser Tyr Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn Arg Gly
            580                 585                 590

Asp Ser Thr Phe Glu Ser Lys Ser Tyr Lys Met Ala Asp Glu Ala Gly
        595                 600                 605

Ser Glu Ala Asp His Glu Gly Thr His Ser Thr Lys Arg Gly His Ala
    610                 615                 620

Lys Ser Arg Pro Val Arg Gly Ile His Thr Ser Pro Leu Gly Lys Pro
625                 630                 635                 640

Ser Leu Ser Pro
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8878 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(v i i) IMMEDIATE SOURCE:
(B) CLONE: human fibrinogen B-beta chain

(i x) FEATURE:
(A) NAME/KEY: misc_RNA
(B) LOCATION: 1..469

(i x) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 470..583

(i x) FEATURE:
(A) NAME/KEY: intron
(B) LOCATION: 584..3257

(i x) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 3258..3449

(i x) FEATURE:
(A) NAME/KEY: intron
(B) LOCATION: 3450..3938

(i x) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 3939..4122

(i x) FEATURE:
(A) NAME/KEY: intron
(B) LOCATION: 4123..5042

(i x) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 5043..5270

(i x) FEATURE:

-continued

(A) NAME/KEY: intron
(B) LOCATION: 5271..5830

(i x) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 5831..5944

(i x) FEATURE:
(A) NAME/KEY: intron
(B) LOCATION: 5945..6632

(i x) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 6633..6758

(i x) FEATURE:
(A) NAME/KEY: intron
(B) LOCATION: 6759..6966

(i x) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 6967..7252

(i x) FEATURE:
(A) NAME/KEY: intron
(B) LOCATION: 7253..7870

(i x) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION: 7871..8102

(i x) FEATURE:
(A) NAME/KEY: 3'UTR
(B) LOCATION: 8103..8537

(i x) FEATURE:
(A) NAME/KEY: misc_RNA
(B) LOCATION: 8538..8878

(i x) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: join(470..583, 3258..3449, 3939..4122,
5043..5270, 5831..5944, 6633..6758, 6967..7252,
7871..8102)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
GAATTCATGC CCCTTTTGAA ATAGACTTAT GTCATTGTCA GAAAACATAA GCATTTATGG      60

TATATCATTA ATGAGTCACG ATTTTAGTGG TTGCCTTGTG AGTAGGTCAA ATTTACTAAG     120

CTTAGATTTG TTTTCTCACA TATTCTTTCG GAGCTTGTGT AGTTTCCACA TTAATTTACC     180

AGAAACAAGA TACACACTCT CTTTGAGGAG TGCCCTAACT TCCCATCATT TTGTCCAATT     240

AAATGAATTG AAGAAATTTA ATGTTTCTAA ACTAGACCAA CAAAGAATAA TAGTTGTATG     300

ACAAGTAAAT AAGCTTTGCT GGGAAGATGT TGCTTAAATG ATAAAATGGT TCAGCCAACA     360

AGTGAACCAA AAATTAAATA TTAACTAAGG AAAGGTAACC ATTTCTGAAG TCATTCCTAG     420

CAGAGGACTC AGATATATAT AGGATTGAAG ATCTCTCAGT TAAGTCTAC ATG AAA          475
                                                      Met Lys
                                                        1

AGG ATG GTT TCT TGG AGC TTC CAC AAA CTT AAA ACC ATG AAA CAT CTA        523
Arg Met Val Ser Trp Ser Phe His Lys Leu Lys Thr Met Lys His Leu
          5                  10                  15

TTA TTG CTA CTA TTG TGT GTT TTT CTA GTT AAG TCC CAA GGT GTC AAC        571
Leu Leu Leu Leu Leu Cys Val Phe Leu Val Lys Ser Gln Gly Val Asn
      20                  25                  30

GAC AAT GAG GAG GTGAATTTTT TAAAGCATTA TTATATTATT AGTAGTATTA            623
Asp Asn Glu Glu
  35

TTAATATAAG ATGTAACATA ATCATATTAT GTGCTTATTT TAATGAAATT AGCATTGCTT     683
```

-continued

```
ATAGTTATGA AATGGAATTG TTAACCTCTG ACTTATTGTA TTTAAAGAAT GTTTCATAGT    743
ATTTCTTATA TAAAAACAAA GTAATTTCTT GTTTTCTAGT TTATCACCTT TGTTTTCTTA    803
AGATGAGGAT GGCTTAGCTA ATGTAAGATG TGTTTTTCTC ACTTGCTATT CTGAGTACTG    863
TGATTTTCAT TTACTTCTAG CAATACAGGA TTACAATTAA GAGGACAAGA TCTGAAAATC    923
TCACAAACTA TAAAATAATA AAAGAGCAGA ATTTTAAGAT AAAAGAAACT GGTGGTAGGT    983
AGATTGTTCT TTGGTGAAGG AAGGTAATAT ATATTGTTAC TGAGATTACT ATTTATAAAA   1043
ATTATAACTA AGCCTAAAAG CAAAATACAT CAAGTGTAAT GATAGAAAAT GAAATATTGC   1103
TTTTTTCAGA TGAAAAGTTC AAATTAGAGT TAGTGTGTAT TGTTATTATT AATAGTTATG   1163
AAACACGGTT CAGTCTAATT TATTTATTTG TAGAACAGTT TGTCCTCAAC TATTATTTTT   1223
GCTGACTTAT TGCTGTTAAT TTGCAGTTAC TAAAAATACA GAAATGCATT TAGGACAATG   1283
GATATTTAAG AAATTTAAAT TTTATCATCA AACGTATCAT GGCCAAATTT CTTACATATA   1343
GCATAGTATC ATTAAACTAG AAATAAGAAT ACACAATAAT ATTTAAATGA AGTGATTCAT   1403
TTCGGATCAT TATTGAGTTT CAAGGGAACT TGAGTGTTGT ACTTATCAGA CTCTACATGT   1463
AAGAACATAT AGTTAATCTG GTTGTGTGTG TAAAAACATA TGGTTAATCT GGTTAAGTCT   1523
GGTTAATCAT ATTAGGTAAG AAAAATGTAA AGAATGTGTA AGACGAAATT TTTGTAAAGT   1583
ACTCTGCAAA GCACTTTCAC ATTTCTGCTT ATCAACTAAA CCTCACAGAG ATAGTTTAAT   1643
AGTTTAGGCT TTAAAATGGA TTTTGATTAT TCAACAAGTG GCCTTCATAA TTTCTTTAAG   1703
TGTTTTTCTT TAAGTATATA CTTTCTTTAA ATATTTTTTA AAATTTCCTT TTCTCTAGTA   1763
AAGCCAGACC ATCCATGCTA CCTCTCTAGT GGCACTCTGA AATAAAAAGA AAATAGTTTT   1823
CTCTGTTATA ATTGTATTTG TAATAAGCAG ATGAATCACA TTTCTTAAAA TTTGTTTTAG   1883
AGAGGGTAAG CTCTGACTAG GACCATGACT TCAATGTGAA ATATGTATAT ATCCTCCGAA   1943
TCTTTACATA TTAAGAATGT ATATAGTCAA CTGGTTAAAC AGGAAAATCT GGAACAGCCT   2003
GGCTGGGTTT TAATCTTAGC ACCATCCTAC TAAATGTTAA ATAATATTAT AATCTAATGA   2063
ATAAATGACA ATGCAATTCC AAATAGAGTT CATCTGATGA CTTCTAGACT CACAAAATTG   2123
CAAGAGAGCT CAGTTGTTGC TCAGTTGTTC CAAATCATGT CGTTTGTTAA TTTGTAATTA   2183
AGCTCCAAAG GATGTATAGC TACTGACAAA AAAAAAAATG AGAATGTAGT TAATCCAAAT   2243
CAAAACTTTC CTATTGCAAT GCGTATTTTC TGCTTCATTA TCCTTTAATA TAATATTTTA   2303
AGTTAGCAAG TAATTTTAAT TACAATGCAC AAGCCTTGAG AATTATTTTA AATATAAGAA   2363
AATCATAATG TTTGATAAAG AAATCATGTA AGAAATTTCA AGATAATGGT TTAACAAATA   2423
ATTTTGTTGA TAGAAGATAA GACTAAAAGT GAAATTCGAA GTGGAGAGGA CACTTAAACT   2483
GTAGTACTTG TTATGTGTGA TTCCAGTAAA AATAGTAATG AGCACTTATT ATTGCCAAGT   2543
ACTGTTCTGA GGGTACCATA TGCAATAAGT TATTTAATCC TTACAATAAT CTTGTAAGGC   2603
AGATTCAAAC TATCATTACA CTTATTTTAC AGATGAGAAA ACTGGGGCAC AGATAAAGCA   2663
ACTTGCCCAA GGTCTCATAG CTGTAAGTCA ACCCTACGGT CAAGACCTAC AAGTAGCCGA   2723
GCTCCAGAGT ACATTATGAG GGTCAAAGAT TGTCTTATTA CAAATAAATT CCAAGTAGAA   2783
TCAACCTTTA ATAAGTCTTT AATGTCTCTT AAATATGTTT ATATAGGAGT CTAATCACCA   2843
ATTCACAAAA ATGAAAGTAG GGAAATGATT AACAATAATC ATAGGAATCT AACAATCCAA   2903
GTGGCTTGAG AATATTCATT CTTCTTGACA GTATAGATTC TTTACAATTT CGTAAGTTCC   2963
AATGTATGTT TTAGGAATAT GAGGTCATTA CTATTCATAA TCTGATACAG CTTTATCCTA   3023
AGGCCTCTCT TTAAAAACTA CACTGCATCA TAGCTTTTTT GTGCAGTTGG TCTTTCTACT   3083
```

-continued

```
GTTACTGAAC AGTAAGCAAC CTACAGATTC ACTATCACCA ACCAGCCAGT TGATGGATCT    3143

TAAGCAAATT ATCAAGCTTG TGATAACCTA AATTATAAAA TGAGGGTGTT GGAATAGTTA    3203

CATTCCAAAT CTTCTATAAC ACTCTGTATT ATATTTCTGC CTCATTCCTT GTAG GGT      3260
                                                            Gly

TTC TTC AGT GCC CGT GGT CAT CGA CCC CTT GAC AAG AAG AGA GAA GAG      3308
Phe Phe Ser Ala Arg Gly His Arg Pro Leu Asp Lys Lys Arg Glu Glu
 40                  45                  50                  55

GCT CCC AGC CTG AGG CCT GCC CCA CCG CCC ATC AGT GGA GGT GGC TAT      3356
Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr
                 60                  65                  70

CGG GCT CGT CCA GCC AAA GCA GCT GCC ACT CAA AAG AAA GTA GAA AGA      3404
Arg Ala Arg Pro Ala Lys Ala Ala Ala Thr Gln Lys Lys Val Glu Arg
             75                  80                  85

AAA GCC CCT GAT GCT GGA GGC TGT CTT CAC GCT GAC CCA GAC CTG          3449
Lys Ala Pro Asp Ala Gly Gly Cys Leu His Ala Asp Pro Asp Leu
         90                  95                 100

GTGGGTGCAC TGATGTTTCT TGCAGTGGTG GCTCTCTCAT GCAGAGAAAG CCTGTAGTCA    3509

TGGCAGTCTG CTAATGTTTC ACTGACCCAC ATTACCATCA CTGTTATTTT GTTTGTTTAT    3569

TTTGGAAATA AAATTCAAAA CATAAACATA TTGGGCCTTT GGTTTAGGCT TTCTTTCTTG    3629

TTTTCTTTGG TCTGGGCCCA AAATTTCAAA TTAGGATATG TGGGTGCCAC CTTTCCATTT    3689

GTATTTTGCC ACTGCCTTTG TTTAGTTGGT AAAATTTTCA TAGCCCAATT ATATTTTTTC    3749

TGGGGTAAGT AATATTTTAA ATCTCTATGA GAGTATGATG ATGACTTTCG AATTTCTGGT    3809

CTTACAGAAA ACCAAATAAT AAATTTTTAT GTTGGCTAAT CGTATCGCTG AATTTTCCTA    3869

TGTGCTATTT TAACAAATGT CCATGACCCA AATCCTTCAT CTAATGCCTG CTATTTTCTT    3929

TGTTTTTAG GGG GTG TTG TGT CCT ACA GGA TGT CAG TTG CAA GAG GCT         3977
          Gly Val Leu Cys Pro Thr Gly Cys Gln Leu Gln Glu Ala
                  105                 110                 115

TTG CTA CAA CAG GAA AGG CCA ATC AGA AAT AGT GTT GAT GAG TTA AAT      4025
Leu Leu Gln Gln Glu Arg Pro Ile Arg Asn Ser Val Asp Glu Leu Asn
                 120                 125                 130

AAC AAT GTG GAA GCT GTT TCC CAG ACC TCC TCT TCT TCC TTT CAG TAC      4073
Asn Asn Val Glu Ala Val Ser Gln Thr Ser Ser Ser Ser Phe Gln Tyr
             135                 140                 145

ATG TAT TTG CTG AAA GAC CTG TGG CAA AAG AGG CAG AAG CAA GTA AAA  G   4122
Met Tyr Leu Leu Lys Asp Leu Trp Gln Lys Arg Gln Lys Gln Val Lys
         150                 155                 160

GTAGATATCC TTGTGCTTTC CATTCGATTT TCAGCTATAA AATTGGAACC GTTAGACTGC    4182

CACGAGAATG CATGGTTGTG AGAAGATTAA CATTTCTGGG TTAGTGAATA GCATTCATAC    4242

GCTTTTGGGC ACCTTCCCCT GCAACTTGCC AGATAAGCAC TATTCAGCTC TTATTCCCAG    4302

TCTGACATCA GCAAGTGTGA TTTTCTATGA AAAATTCTAC TATGACTCCT TATTTTAAGT    4362

ATACAAGAAA CTTGTGACTC AGAAGATAAT ATTTACAGAG TGGAAAAAAA CCCCTAGCAT    4422

TTATAGTTTT AACATTTGAG GTTTTGAATG AGAGAGTTAT CCATAATATA TTCAATTGTG    4482

TTGTGGATAA TGACACCTAA CCTGTGAATC TTGAGGTCAG AATGTTGAGT GCTGTTGACT    4542

TGGTGGTCAG GAAACAGCTA GTGCGTGAGC CTGGCACAGG CATCTCAGTG AGTAGCATAC    4602

CCACAGTTGG AAATTTTTCA AAGAAATCAA AGGAATCATG ACATCTTATA AATTTCAAGG    4662

TTCTGCTATA CTTATGTGAA ATGGATAAAT AAATCAAGCA TATCCACTCT GTAAGATTGA    4722

ACTTCTCAGA TGGAAGACCC CAATACTGCT TTCTCCTCTT TTCCCTCACC AAAGAAATAA    4782

ACAACCTATT TCATTTATTA CTGGACACAA TCTTTAGCGT ATACCTATGG TAAATTACTA    4842
```

-continued

```
GTATGGTGGT TAGGATTTAT GTTAATTTGT ATATGTCATG CGCCAAATCA TTTCCACTAA   4902

ATATGACTAT ATATCATAAC TGCTTGGTGA TAGCTCAGTG TTTAATAGTT TATTCTCAGA   4962

AAATCAAAAT TGTATAGTTA AATACATTAG TTTTATGAGG CAAAAATGCT AACTATTTCT   5022

ACATAATTTC ATTTTTCCAG  AT AAT GAA AAT GTA GTC AAT GAG TAC TCC        5071

                          Asp Asn Glu Asn Val Val Asn Glu Tyr Ser
                              165                 170

TCA GAA CTG GAA AAG CAC CAA TTA TAT ATA GAT GAG ACT GTG AAT AGC     5119
Ser Glu Leu Glu Lys His Gln Leu Tyr Ile Asp Glu Thr Val Asn Ser
    175                 180                 185

AAT ATC CCA ACT AAC CTT CGT GTG CTT CGT TCA ATC CTG GAA AAC CTG     5167
Asn Ile Pro Thr Asn Leu Arg Val Leu Arg Ser Ile Leu Glu Asn Leu
190                 195                 200                 205

AGA AGC AAA ATA CAA AAG TTA GAA TCT GAT GTC TCA GCT CAA ATG GAA     5215
Arg Ser Lys Ile Gln Lys Leu Glu Ser Asp Val Ser Ala Gln Met Glu
                210                 215                 220

TAT TGT CGC ACC CCA TGC ACT GTC AGT TGC AAT ATT CCT GTG GTG TCT     5263
Tyr Cys Arg Thr Pro Cys Thr Val Ser Cys Asn Ile Pro Val Val Ser
            225                 230                 235

GGC AAA  G GTAACTGATT CATAAACATA TTTTTAGAGA GTTCCAGAAG AACTCACACA   5320
Gly Lys
CCAAAAATAA GAGAACAACA ACAACAACAA AAATGCTAAG TGGATTTTCC CAACAGATCA   5380

TAATGACATT ACAGTACATC ATAAAAATAT CCTTAGCCAG TTGTGTTTTG GACTGGCCTG   5440

GTGCATTTGC TGGTTTTGAT GAGCAGGATG GGGCACAGGT AGTCCCAGGG GTGGCTGATG   5500

TGTGCATCTG CGTACTGGCT TGAACAGATG GCAGAACCAC AGATAGATGT AGAAGTTTCT   5560

CCATTTTGTG TGTTCTGGGA GCTCATGGAT ATTCCAGGAC ACAAAAGGTG GAGAAGAGCT   5620

TTGTTCATCC TCTTAGCAGA TAAACGTCCT CAAAACTGGG TTGGACTTAC TAAAGTAAAA   5680

TGAAAATCTA ATATTTGTTA TATTATTTTC AAAGGTCTAT AATAACACAC TCCTTAGTAA   5740

CTTATGTAAT GTTATTTTAA AGAATTGGTG ACTAAATACA AAGTAATTAT GTCATAAACC   5800

CCTGAACATA ATGTTGTCTT ACATTTGCAG  AA TGT GAG GAA ATT ATC AGG AAA     5853

                                 Glu Cys Glu Glu Ile Ile Arg Lys
                                 240                 245

GGA GGT GAA ACA TCT GAA ATG TAT CTC ATT CAA CCT GAC AGT TCT GTC     5901
Gly Gly Glu Thr Ser Glu Met Tyr Leu Ile Gln Pro Asp Ser Ser Val
        250                 255                 260

AAA CCG TAT AGA GTA TAC TGT GAC ATG AAT ACA GAA AAT GGA  G          5944
Lys Pro Tyr Arg Val Tyr Cys Asp Met Asn Thr Glu Asn Gly
    265                 270                 275

GTAAGCTTTC GACAGTTGTT GACCTGTTGA TCTGTAATTA TTTGGATACC GTAAAATGCC   6004

AGGAAACAAG GCCAGGTGTG GTGGCTCATA CCTGTAATTC CAGCACCTTG GGAGGCCAAA   6064

GTGGGCTGAT AGCTTGAGCC TAGGAGTTTG AAACTAGCCT GGGCAACATA ATGAGACCCT   6124

AACTCTACAA AAAAAAAAAA AATACCAAAA AAAAAAAAAA AATCAGCTGT GTTGGTAGTA   6184

TGTGCCTGTA GTCCCAGCTA TCCAGGAGGC TGAGATGGGA GATCACCTGA GCCCACAACC   6244

TGGAGTCTTG ATCATGCTAC TGAACTGTAG CCTGGGCAAC AGAGGATAGT GAGATCCTGT   6304

CTCAAAAAAA AAAATTAATT AAAAAGCCAG GAAACAAGAC TTAGCTCTAA CATCTAACAT   6364

AGCTGACAAA GGAGTAATTT GATGTGGAAT TCAACCTGAT ATTTAAAAGT TATAAAATAT   6424

CTATAATTCA CAATTTGGGG TAAGATAAAG CACTTGCAGT TTCCAAAGAT TTTACAAGTT   6484

TACCTCTCAT ATTTATTTCC TTATTGTGTC TATTTTAGAG CACCAAATAT ATACTAAATG   6544

GAATGGACAG GGGATTCAGA TATTATTTTC AAAGTGACAT TATTTGCTGT TGGTTAATAT   6604
```

-continued

```
ATGCTCTTTT TGTTTCTGTC AACCAAAG  GA TGG ACA GTG ATT CAG AAC CGT        6655

                                  Gly Trp Thr Val Ile Gln Asn Arg
                                      280                 285

CAA GAC GGT AGT GTT GAC TTT GGC AGG AAA TGG GAT CCA TAT AAA CAG      6703
Gln Asp Gly Ser Val Asp Phe Gly Arg Lys Trp Asp Pro Tyr Lys Gln
            290                 295                 300

GGA TTT GGA AAT GTT GCA ACC AAC ACA GAT GGG AAG AAT TAC TGT GGC      6751
Gly Phe Gly Asn Val Ala Thr Asn Thr Asp Gly Lys Asn Tyr Cys Gly
        305                 310                 315

CTA CCA  G GTAACGAACA GGCATGCAAA ATAAAATCAT TCTATTTGAA ATGGGATTTT    6808
Leu Pro
TTTTAATTAA AAAACATTCA TTGTTGGAAG CCTGTTTTAG GCAGTTAAGA GGAGTTTCCT    6868

GACAAAAATG TGGAAGCTAA AGATAAGGGA AGAAAGGCAG TTTTTAGTTT CCCAAAATTT    6928

TATTTTTGGT GAGAGATTTT ATTTTGTTTT TCTTTTAG  GT GAA TAT TGG CTT        6980

                                              Gly Glu Tyr Trp Leu
                                                  320

GGA AAT GAT AAA ATT AGC CAG CTT ACC AGG ATG GGA CCC ACA GAA CTT      7028
Gly Asn Asp Lys Ile Ser Gln Leu Thr Arg Met Gly Pro Thr Glu Leu
325                 330                 335                 340

TTG ATA GAA ATG GAG GAC TGG AAA GGA GAC AAA GTA AAG GCT CAC TAT      7076
Leu Ile Glu Met Glu Asp Trp Lys Gly Asp Lys Val Lys Ala His Tyr
                345                 350                 355

GGA GGA TTC ACT GTA CAG AAT GAA GCC AAC AAA TAC CAG ATC TCA GTG      7124
Gly Gly Phe Thr Val Gln Asn Glu Ala Asn Lys Tyr Gln Ile Ser Val
            360                 365                 370

AAC AAA TAC AGA GGA ACA GCC GGT AAT GCC CTC ATG GAT GGA GCA TCT      7172
Asn Lys Tyr Arg Gly Thr Ala Gly Asn Ala Leu Met Asp Gly Ala Ser
        375                 380                 385

CAG CTG ATG GGA GAA AAC AGG ACC ATG ACC ATT CAC AAC GGC ATG TTC      7220
Gln Leu Met Gly Glu Asn Arg Thr Met Thr Ile His Asn Gly Met Phe
    390                 395                 400

TTC AGC ACG TAT GAC AGA GAC AAT GAC GGC  TG  GTATGTGTGG              7262
Phe Ser Thr Tyr Asp Arg Asp Asn Asp Gly  Trp
405                 410                 415

CACTCTTTGC TCCTGCTTTA AAAATCACAC TAATATCATT ACTCAGAATC ATTAACAATA    7322

TTTTTAATAG CTACCACTTC CTGGGCACTT ACTGTCAGCC ACTGTCCTAA GCTCTTTATG    7382

CATCACTCGA AAGCATTTCA ACTATAAGGT AGACATTCTT ATTCTCATTT TACAGATGAG    7442

ATTTAGAGAG ATTACGTGAT TTGTCCAATG TCACACAACT ACCCAGAGAT AAAACTAGAA    7502

TTTGAGCACA GTTACTTTCT GAATAATGAG CATTTAGATA AATACCTATA TCTCTATATT    7562

CTAAAGTGTG TGTGAAAACT TTCATTTTCA TTTCCAGGGT TCTCTGATAC TAAGGGTTGT    7622

AAAAGCTATT ATTCCAGTAT AAAGTAACAA ACACAGTCCC TAGATGGATT GCCACAAAGG    7682

CCCAGTTATC TCTCTTTCTT GCTATAGGGC ACAGGAGGTC TTTGGTGTAT TAGTGTGACT    7742

CTATGTATAG CACCCAAAGG AAAGACTACT GTGCACACGA GTGTAGCAGT CTTTTATGGG    7802

TAATCTGCAA AACGTAACTT GACCACCGTA GTTCTGTTTC TAATAACGCC AAACACATTT    7862

TCTTTCAG G TTA ACA TCA GAT CCC AGA AAA CAG TGT TCT AAA GAA GAC        7910

          Leu Thr Ser Asp Pro Arg Lys Gln Cys Ser Lys Glu Asp
                              420                 425

GGT GGT GGA TGG TGG TAT AAT AGA TGT CAT GCA GCC AAT CCA AAC GGC      7958
Gly Gly Gly Trp Trp Tyr Asn Arg Cys His Ala Ala Asn Pro Asn Gly
    430                 435                 440

AGA TAC TAC TGG GGT GGA CAG TAC ACC TGG GAC ATG GCA AAG CAT GGC      8006
Arg Tyr Tyr Trp Gly Gly Gln Tyr Thr Trp Asp Met Ala Lys His Gly
```

-continued

```
445                 450                 455                 460

ACA GAT GAT GGT GTA GTA TGG ATG AAT TGG AAG GGG TCA TGG TAC TCA      8054
Thr Asp Asp Gly Val Val Trp Met Asn Trp Lys Gly Ser Trp Tyr Ser
            465                 470                 475

ATG AGG AAG ATG AGT ATG AAG ATC AGG CCC TTC TTC CCA CAG CAA TAGTCCCC8109
Met Arg Lys Met Ser Met Lys Ile Arg Pro Phe Phe Pro Gln Gln
        480                 485                 490

TACGTAGATT TTTGCTCTTC TGTATGTGAC AACATTTTTG TACATTATGT TATTGGAATT    8169

TTCTTTCATA CATTATATTC CTCTAAAACT CTCAAGCAGA CGTGAGTGTG ACTTTTTGAA    8229

AAAAGTATAG GATAAATTAC ATTAAAATAG CACATGATTT TCTTTTGTTT TCTTCATTTC    8289

TCTTGCTCAC CCAAGAAGTA ACAAAAGTAT AGTTTTGACA GAGTTGGTGT TCATAATTTC    8349

AGTTCTAGTT GATTGCGAGA ATTTTCAAAT AAGGAAGAGG GGTCTTTTAT CCTTGTCGTA    8409

GGAAAACCAT GACGGAAAGG AAAAACTGAT GTTTAAAAGT CCACTTTTAA AACTATATTT    8469

ATTTATGTAG GATCTGTCAA AGAAAACTTC CAAAAAGATT TATTAATTAA ACCAGACTCT    8529

GTTGCAATAA GTTAATGTTT TCTTGTTTTG TAATCCACAC ATTCAATGAG TTAGGCTTTG    8589

CACTTGTAAG GAAGGAGAAG CGTTCACAAC CTCAAATAGC TAATAAACCG GTCTTGAATA    8649

TTTGAAGATT TAAAATCTGA CTCTAGGACG GGCACGGTGG CTCACGACTA TAATCCCAAC    8709

ACTTTGGGAG GCTGAGGCGG GCGGTCACAA GGTCAGGAGT TCAAGACCAG CCTGACCAAT    8769

ATGGTGAAAC CCCATCTCTA CTAAAAATAC AAAAATTAGC CAGGCGTGGT GGCAGGTGCC    8829

TGTAGGTCCC AGCTAGCCTG TGAGGTGGAG ATTGCATTGA GCCAAGATC                8878
```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 491 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
Met Lys Arg Met Val Ser Trp Ser Phe His Lys Leu Lys Thr Met Lys
 1               5                  10                  15

His Leu Leu Leu Leu Leu Leu Cys Val Phe Leu Val Lys Ser Gln Gly
            20                  25                  30

Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg Gly His Arg Pro
        35                  40                  45

Leu Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro
    50                  55                  60

Pro Ile Ser Gly Gly Gly Tyr Arg Ala Arg Pro Ala Lys Ala Ala Ala
65                  70                  75                  80

Thr Gln Lys Lys Val Glu Arg Lys Ala Pro Asp Ala Gly Gly Cys Leu
                85                  90                  95

His Ala Asp Pro Asp Leu Gly Val Leu Cys Pro Thr Gly Cys Gln Leu
            100                 105                 110

Gln Glu Ala Leu Leu Gln Gln Glu Arg Pro Ile Arg Asn Ser Val Asp
        115                 120                 125

Glu Leu Asn Asn Asn Val Glu Ala Val Ser Gln Thr Ser Ser Ser Ser
    130                 135                 140

Phe Gln Tyr Met Tyr Leu Leu Lys Asp Leu Trp Gln Lys Arg Gln Lys
145                 150                 155                 160

Gln Val Lys Asp Asn Glu Asn Val Val Asn Glu Tyr Ser Ser Glu Leu
                165                 170                 175
```

-continued

```
Glu Lys His Gln Leu Tyr Ile Asp Glu Thr Val Asn Ser Asn Ile Pro
            180                 185                 190

Thr Asn Leu Arg Val Leu Arg Ser Ile Leu Glu Asn Leu Arg Ser Lys
        195                 200                 205

Ile Gln Lys Leu Glu Ser Asp Val Ser Ala Gln Met Glu Tyr Cys Arg
    210                 215                 220

Thr Pro Cys Thr Val Ser Cys Asn Ile Pro Val Val Ser Gly Lys Glu
225                 230                 235                 240

Cys Glu Glu Ile Ile Arg Lys Gly Gly Glu Thr Ser Glu Met Tyr Leu
                245                 250                 255

Ile Gln Pro Asp Ser Ser Val Lys Pro Tyr Arg Val Tyr Cys Asp Met
            260                 265                 270

Asn Thr Glu Asn Gly Gly Trp Thr Val Ile Gln Asn Arg Gln Asp Gly
        275                 280                 285

Ser Val Asp Phe Gly Arg Lys Trp Asp Pro Tyr Lys Gln Gly Phe Gly
    290                 295                 300

Asn Val Ala Thr Asn Thr Asp Gly Lys Asn Tyr Cys Gly Leu Pro Gly
305                 310                 315                 320

Glu Tyr Trp Leu Gly Asn Asp Lys Ile Ser Gln Leu Thr Arg Met Gly
                325                 330                 335

Pro Thr Glu Leu Leu Ile Glu Met Glu Asp Trp Lys Gly Asp Lys Val
            340                 345                 350

Lys Ala His Tyr Gly Gly Phe Thr Val Gln Asn Glu Ala Asn Lys Tyr
        355                 360                 365

Gln Ile Ser Val Asn Lys Tyr Arg Gly Thr Ala Gly Asn Ala Leu Met
    370                 375                 380

Asp Gly Ala Ser Gln Leu Met Gly Glu Asn Arg Thr Met Thr Ile His
385                 390                 395                 400

Asn Gly Met Phe Phe Ser Thr Tyr Asp Arg Asp Asn Asp Gly Trp Leu
                405                 410                 415

Thr Ser Asp Pro Arg Lys Gln Cys Ser Lys Glu Asp Gly Gly Gly Trp
            420                 425                 430

Trp Tyr Asn Arg Cys His Ala Ala Asn Pro Asn Gly Arg Tyr Tyr Trp
        435                 440                 445

Gly Gly Gln Tyr Thr Trp Asp Met Ala Lys His Gly Thr Asp Asp Gly
    450                 455                 460

Val Val Trp Met Asn Trp Lys Gly Ser Trp Tyr Ser Met Arg Lys Met
465                 470                 475                 480

Ser Met Lys Ile Arg Pro Phe Phe Pro Gln Gln
                485                 490
```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10564 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(v i i) IMMEDIATE SOURCE:
(B) CLONE: human fibrinogen gamma chain

(i x) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: join(1799..1876, 1973..2017, 2207..2390, 2510
. . 2603, 4211..4341, 4645..4778, 5758..5942, 7426
. . 7703, 9342..9571)

-continued

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
CTACACACTT CTTGAAGGCA AAGGCAATGC TGAAGTCACC TTTCATGTTC AAATCATATT      60

AAAAAGTTAG CAAGATGTAA TTATCAGTGT ACTATGTAAA TCTTTGTGAA TGATCAATAA     120

TTACATATTT TCATTATATA TATTTTAGTA GATAATATTT ATATACATTC AACATTCTAA     180

ATATAGAAAG TTTACAGAGA AAAATAAAGC CTTTTTTTCC AATCCTGTCC TCCACCTCTG     240

CATCCCATTC TTCTTCACAG AGGCAACTGA TTCAAGTCAT TACATAGTTA TTGAGTGTTA     300

ACTACAACTA TGTTAAGTAC AGCTATATAT GTTAGATGCC GTAGCCACAG AAATCAGTTT     360

ACAATCTAAT GCAGTGGATA CAGCATGTAT ACATATAATA TAAGGTTGCT ACAAATGCTA     420

TCTGAGGTAG AGCTGTTTGA AAGAATACTA ATACTTAAAT GTTTAATTCA ACTGACTTGA     480

TTGACAACTG ATTAGCTGAG TGGAAAAGAT GGATGAGAAA GATTGTGAGA CTTAATTGGC     540

TGGTGGTATG GTGATATGAT TGACAATAAC TGCTAAGTCA GAGAGGGATA TATTAAGGAG     600

GAGAAGAAAA GCAACAAATC TGGTTTTGAT GTGTTCACTT TGTTATAATT ATTGATTATT     660

TACTGAATAT GAATATTTAT CTTTGTTTTT GAGTCAATAA ATATACCTTT GTAAAGACAG     720

AATTAAAGTA TTAGTATTTC TTTCAAACTG GAGGCATTTC TCCCACTAAC ATATTTCATC     780

AAAACTTATA ATAAGCTTGG TTCCAGAGGA AGAAATGAGG GATAACCAAA AATAGAGACA     840

TTAATAATAG TGTAACGCCC AGTGATAAAT CTCAATAGGC AGTGATGACA GACATGTTTT     900

CCCAAACACA AGGATGCTGT AAGGGCCAAA CAGAAATGAT GGCCCCTCCC CAGCACCTCA     960

TTTTGCCCCT TCCTTCAGCT ATGCCTCTAC TCTCCTTTAG ATACAAGGGA GGTGGATTTT    1020

TCTCTTCTCT GAGATAGCTT GATGGAACCA CAGGAACAAT GAAGTGGGCT CCTGGCTCTT    1080

TTCTCTGTGG CAGATGGGGT GCCATGCCCA CCTTCAGACA AAGGGAAGAT TGAGCTCAAA    1140

AGCTCCCTGA GAAGTGAGAG CCTATGAACA TGGTTGACAC AGAGGGACAG GAATGTATTT    1200

CCAGGGTCAT TCATTCCTGG GAATAGTGAA CTGGGACATG GGGGAAGTCA GTCTCCTCCT    1260

GCCACAGCCA CAGATTAAAA ATAATAATGT TAACTGATCC CTAGGCTAAA ATAATAGTGT    1320

TAACTGATCC CTAAGCTAAG AAAGTTCTTT TGGTAATTCA GGTGATGGCA GCAGGACCCA    1380

TCTTAAGGAT AGACTAGGTT TGCTTAGTTC GAGGTCATAT CTGTTTGCTC TCAGCCATGT    1440

ACTGGAAGAA GTTGCATCAC ACAGCCTCCA GGACTGCCCT CCTCCTCACA GCAATGGATA    1500

ATGCTTCACT AGCCTTTGCA GATAATTTTG GATCAGAGAA AAAACCTTGA GCTGGGCCAA    1560

AAAGGAGGAG CTTCAACCTG TGTGCAAAAT CTGGGAACCT GACAGTATAG GTTGGGGGCC    1620

AGGATGAGGA AAAAGGAACG GGAAAGACCT GCCCACCCTT CTGGTAAGGA GGCCCCGTGA    1680

TCAGCTCCAG CCATTTGCAG TCCTGGCTAT CCCAGGAGCT TACATAAAGG GACAATTGGA    1740

GCCTGAGAGG TGACAGTGCT GACACTACAA GGCTCGGAGC TCCGGGCACT CAGACATC      1798

ATG AGT TGG TCC TTG CAC CCC CGG AAT TTA ATT CTC TAC TTC TAT GCT      1846
Met Ser Trp Ser Leu His Pro Arg Asn Leu Ile Leu Tyr Phe Tyr Ala
 1               5                  10                  15

CTT TTA TTT CTC TCT TCA ACA TGT GTA GCA GTAAGTGTGC TCTTCACAAA       1896
Leu Leu Phe Leu Ser Ser Thr Cys Val Ala
            20                  25

ACGTTGTTTA AAATGGAAAG CTGGAAAATA AAACAGATAA TAAACTAGTG AAATTTTCGT   1956

ATTTTTTCTC TTTTAG TAT GTT GCT ACC AGA GAC AAC TGC TGC ATC TTA       2005
                  Tyr Val Ala Thr Arg Asp Asn Cys Cys Ile Leu
                      30                  35

GAT GAA AGA TTC GTAAGTAGTT TTTATGTTTC TCCCTTTGTG TGTGAACTGG        2057
Asp Glu Arg Phe
```

-continued

```
          40
AGAGGGGCAG AGGAATAGAA ATAATTCCCT CATAAATATC ATCTGGCACT TGTAACTTTT   2117

TAAAAACATA GTCTAGGTTT TACCTATTTT TCTTAATAGA TTTTAAGAGT AGCATCTGTC   2177

TACATTTTTA ATCACTGTTA TATTTTCAG GGT AGT TAT TGT CCA ACT ACC TGT      2230

                                  Gly Ser Tyr Cys Pro Thr Thr Cys
                                              45

GGC ATT GCA GAT TTC CTG TCT ACT TAT CAA ACC AAA GTA GAC AAG GAT      2278
Gly Ile Ala Asp Phe Leu Ser Thr Tyr Gln Thr Lys Val Asp Lys Asp
 50                  55                  60                  65

CTA CAG TCT TTG GAA GAC ATC TTA CAT CAA GTT GAA AAC AAA ACA TCA      2326
Leu Gln Ser Leu Glu Asp Ile Leu His Gln Val Glu Asn Lys Thr Ser
                 70                  75                  80

GAA GTC AAA CAG CTG ATA AAA GCA ATC CAA CTC ACT TAT AAT CCT GAT      2374
Glu Val Lys Gln Leu Ile Lys Ala Ile Gln Leu Thr Tyr Asn Pro Asp
             85                  90                  95

GAA TCA TCA AAA CCA  A GTGAGAAAAT AAAGACTACT GACCAAAAAA              2420
Glu Ser Ser Lys Pro
        100

TAATAATAAT AATCTGTGAA GTTCTTTTGC TGTTGTTTTA GTTGTTCTAT TTGCTTAAGG   2480

ATTTTTATGT CTCTGATCCT ATATTACAG  AT ATG ATA GAC GCT GCT ACT TTG      2532

                                  Asn Met Ile Asp Ala Ala Thr Leu
                                          105                 110

AAG TCC AGG ATA ATG TTA GAA GAA ATT ATG AAA TAT GAA GCA TCG ATT      2580
Lys Ser Arg Ile Met Leu Glu Glu Ile Met Lys Tyr Glu Ala Ser Ile
                 115                 120                 125

TTA ACA CAT GAC TCA AGT ATT  CG  GTAAGGATTT TTGTTTTAAT TTGCTCTGCA   2633
Leu Thr His Asp Ser Ser Ile  Arg
             130

AGACTGATTT AGTTTTTATT TAATATTCTA TACTTGAGTG AAAGTAATTT TTAATGTGTT   2693

TTCCCCATTT ATAATATCCC AGTGACATTA TGCCTGATTA TGTTGAGCAT AGTAGAGATA   2753

GAAGTTTTTA GTGCAATATA AATTATACTG GGTTATAATT GCTTATTAAT AATCACATTG   2813

AAGAAAGATG TTCTAGATGT CTTCAAATGC TAGTTTGACC ATATTTATCA AAAATTTTTT   2873

CCCCATCCCC CATTTATCTT ACAACATAAA ATCAATCTCA TAGGAATTTG GGTGTTGAAA   2933

ATAAAATCCT CTTTATAAAA ATGCTGACAA ATTGGTGGTT AAAAAAATTA GCAAGCAGAG   2993

GCATAGTAAG GATTTTGGCT CCTAAAGTAA ATTATATTGA ATGTGGAGCA GGAAGAAACA   3053

TGTCTTGAGA GACTAAGTGT GGCAAATATT GCAAAGCTCA TATTGATCAT TGCAGAATGA   3113

ACCTGCATAG TCTCTTCCCT TCATTTGGAA GTGAATGTCT CTGTTAAAGC TTCTCAGGGA   3173

CTCATAAACT TTCTGAACAT AAGGTCTCAG ATACAGTTTT AATATTTTTC CCCAATTTTT   3233

TTTTCTGAAT TTTTCTCAAA GCAGCTTGAG AAATTGAGAT AAATAGTAGC TAGGGAGAAG   3293

TGGCCCAGGA AAGATTTCTC CTCTTTTTGC TATCAGAGGG CCCTTGTTAT TATTGTTATT   3353

ATTATTACTT GCATTATTAT TGTCCATCAT TGAAGTTGAA GGAGGTTATT GTACAGAAAT   3413

TGCCTAAGAC AAGGTAGAGG GAAAACGTGG ACAAATAGTT TGTCTACCCT TTTTTACTTC   3473

AAAGAAAGAA CGGTTTATGC ATTGTAGACA GTTTTCTATC ATTTTTGGAT ATTTGCAAGC   3533

CACCCTGTAA GTAACTACAA AAGGAGGGTT TTTACTTCCC CCAGTCCATT CCCAAAGCTA   3593

TGTAACCAGA AGCATTAAAG AAGAAAGGGG AAGTATCTGT TGTTTTATTT TACATACAAT   3653

AACGTTCCAG ATCATGTCCC TGTGTAAGTT ATATTTTAGA TTGAAGCTTA TATGTATAGC   3713

CTCAGTAGAT CCACAAGTGA AAGGTATACT CCTTCAGCAC ATGTGAATTA CTGAACTGAG   3773
```

-continued

```
CTTTTCCTGC TTCTAAAGCA TCAGGGGGTG TTCCTATTAA CCAGTCTCGC CACTCTTGCA   3833

GGTTGCTATC TGCTGTCCCT TATGCATAAA GTAAAAAGCA AAATGTCAAT GACATTTGCT   3893

TATTGACAAG GACTTTGTTA TTTGTGTTGG GAGTTGAGAC AATATGCCCC ATTCTAAGTA   3953

AAAAGATTCA GGTCCACATT GTATTCCTGT TTTAATTGAT TTTTTGATTT GTTTTTCTTT   4013

TTCAAAAAGT TTATAATTTT AATTCATGTT AATTTAGTAA TATAATTTTA CATTTTCCTC   4073

AAGAATGGAA TAATTTATCA GAAAGCACTT CTTAAGAAAA TACTTAGCAG TTTCCAAAGA   4133

AAATATAAAA TTACTCTTCT GAAAGGAATA CTTATTTTTG TCTTCTTATT TTTGTTATCT   4193

TATGTTTCTG TTTGTAG A TAT TTG CAG GAA ATA TAT AAT TCA AAT AAT CAA     4244

                      Tyr Leu Gln Glu Ile Tyr Asn Ser Asn Asn Gln
                      135                 140                 145

AAG ATT GTT AAC CTG AAA GAG AAG GTA GCC CAG CTT GAA GCA CAG TGC     4292
Lys Ile Val Asn Leu Lys Glu Lys Val Ala Gln Leu Glu Ala Gln Cys
                150                 155                 160

CAG GAA CCT TGC AAA GAC ACG GTG CAA ATC CAT GAT ATC ACT GGG AAA  G  4341
Gln Glu Pro Cys Lys Asp Thr Val Gln Ile His Asp Ile Thr Gly Lys
            165                 170                 175

GTAACTGATG AAGGTTATAT TGGGATTAGG TTCATCAAAG TAAGTAATGT AAAGGAGAAA   4401

GTATGTACTG GAAAGTATAG GAATAGTTTA GAAAGTGGCT ACCCATTAAG TCTAAGAATT   4461

TCAGTTGTCT AGACCTTTCT TGAATAGCTA AAAAAAACAG TTTAAAAGGA ATGCTGATGT   4521

GAAAAGTAAG AAAATTATTC TTGGAAAATG AATAGTTTAC TACATGTTAA AAGCTATTTT   4581

TCAAGGCTGG CACAGTCTTA CCTGCATTTC AAACCACAGT AAAAGTCGAT TCTCCTTCTC   4641

TAG  AT TGT CAA GAC ATT GCC AAT AAG GGA GCT AAA CAG AGC GGG CTT     4688
     Asp Cys Gln Asp Ile Ala Asn Lys Gly Ala Lys Gln Ser Gly Leu
             180                 185                 190

TAC TTT ATT AAA CCT CTG AAA GCT AAC CAG CAA TTC TTA GTC TAC TGT     4736
Tyr Phe Ile Lys Pro Leu Lys Ala Asn Gln Gln Phe Leu Val Tyr Cys
        195                 200                 205

GAA ATC GAT GGG TCT GGA AAT GGA TGG ACT GTG TTT CAG AAG             4778
Glu Ile Asp Gly Ser Gly Asn Gly Trp Thr Val Phe Gln Lys
    210                 215                 220

GTAATTTTTT CCCCACCATG TGTATTTAAT AAATTCCTAC ATTGTTTCTG CCATATGGCA   4838

GATACTTTTC TAAGCACCTT GTGAACCGTA GCTCATTTAA TCCTTGCAAT AGCCCTAAGA   4898

GGAAGGTACT TCTGTTACTC CTATTTACAG AAAAGGAAAC TGAGGCACAC AAGGTTAAAT   4958

AACTTGCCCA AGACCACATA ACTAATAAGC AACAGAGTCA GCATTTGAAC CTAGGCAGTA   5018

TAGTTTCAGA GTTTGTGACT TGACTCTATA TTGTACTGGC ACTGACTTTG TAGATTCATG   5078

GTGGCACATA ATCATAGTAC CACAGTGACA AATAAAAAGA AGGAAACTCT TTTGTCAGGT   5138

AGGTCAAGAC CTGAGGTTTC CCATCACAAG ATGAGGAAGC CCAACACCAC CCCCCACCAC   5198

CCCACCACCA TCACCACCCT TTCACACACC AGAGGATACA CTTGGGCTGC TCCAAGACAA   5258

GGAACCTGTG TTGCATCTGC CACTTGCTGA TACCCACTAG GAATCTTGGC TCCTTTACTT   5318

TCTGTTTACC TCCCACCACT GTTATAACTG TTTCTACAGG GGGCGCTCAG AGGGAATGAA   5378

TGGTGGAAGC ATTAGTTGCC AGACACCGAT TGAGCAATGG GTTCCATCAT AAGTGTAAGA   5438

ATCAGTAATA TCCAGCTAGA GTTCTGAAGT CGTCTAGGTG TCTTTTTAAT ATTACCACTC   5498

ATTTAGAATT TATGATGTGC CAGAAACCCT CTTAAGTATT TCTCTTATAT TCTCTCTCAT   5558

GATCCTTGCA GCAACCCTAA GAAGTAACCA TCATTTTTCC TATTTGATAC ATGAGGAAAC   5618

TGAGGTAGCT TGGCCAAGAT CACTTAGTTG GGAGTTGATA GAACCAGTGC TCTGTATTTT   5678

TGACAAAATG TTGACAGCAT TCTCTTTACA TGCATTGATA GTCTATTTTC TCCTTTTGCT   5738
```

-continued

```
CTTGCAAATG TGTAATTAG AGA CTT GAT GGC AGT GTA GAT TTC AAG AAA AAC      5790

                      Arg Leu Asp Gly Ser Val Asp Phe Lys Lys Asn
                          225                 230

TGG ATT CAA TAT AAA GAA GGA TTT GGA CAT CTG TCT CCT ACT GGC ACA      5838
Trp Ile Gln Tyr Lys Glu Gly Phe Gly His Leu Ser Pro Thr Gly Thr
    235                 240                 245

ACA GAA TTT TGG CTG GGA AAT GAG AAG ATT CAT TTG ATA AGC ACA CAG      5886
Thr Glu Phe Trp Leu Gly Asn Glu Lys Ile His Leu Ile Ser Thr Gln
250                 255                 260                 265

TCT GCC ATC CCA TAT GCA TTA AGA GTG GAA CTG GAA GAC TGG AAT GGC      5934
Ser Ala Ile Pro Tyr Ala Leu Arg Val Glu Leu Glu Asp Trp Asn Gly
                270                 275                 280

AGA ACC  AG  GTACTGTTTT GAAATGACTT CCAACTTTTT ATTGTAAAGA             5982
Arg Thr  Ser
TTGCCTGGAA TGTGCACTTT CCAACTATCA ATAGACAATG GCAAATGCAG CCTGACAAAT    6042

GCAAACAGCA CATCCAGCCA CCATTTTCTC CAGGAGTCTG TTTGGTTCTT GGGCAATCCA    6102

AAAAGGTAAA TTCTATTCAG GATGAATCTA AGTGTATTGG TACAATCTAA TTACCCTGGA    6162

ACCATTCAGA GTAATAGCTA ATTACTGAAC TTTTAATCAG TCCCAGGAAT TGAGCATAAA    6222

ATTATAATTT TATCTAGTCT AAATTACTAT TTCATGAAGC AGGTATTATT ATTAATCCCA    6282

TTTTATAGAT TAACTTGCTC AAAGTCACAT TGCTGATAAG TGGTAGAGGT AGAATTCAGA    6342

CTCAAGTAGT TTAACTTTAG AGCCTGTCCT CTTAACAACT ATCCTGGTTG AAAAGCAAAT    6402

ACAGCCTCTT CAGACTTCTC AGTGCCTTGA TGGCCATTTA TTCTGTCAAA TCATGAGCTA    6462

CCCTAAAAGT AAACCAGCTA GCTCTTTTGA TGATCTAGAG GCTTCTTTTT GCTTGAGATA    6522

TTTGAAGGTT TTAAGCATTG TTACCTAATT AAAATGCAGA AAAATATCCA ACCCTCTTGT    6582

TATGTTTAAG GAATAGTGAA ATATATTGTC TTCAAACACA TGGACTTTTT TTTATTGCTT    6642

GGTTGGTTTT TAATCCAGAA AGTGCTATAG TCAGTAGACC TTCTTCTAGG AAAGGACCTT    6702

CCATTTCCCA GCCACTGGAG ATTAGAAAAT AAGCTAAATA TTTTCTGGAA ATTTCTGTTC    6762

ATTCATTAAG GCCCATCCTT TCCCCCACTC TATAGAAGTG TTGTCCACTT GCACAATTTT    6822

TTCCAGGAAA GAATCTCTCT AACTCCTTCA GCTCACATGC TTTGGACCAC ACAGGGAAGA    6882

CTTTGATTGT GTAATGCCCT CAGAAGCTCT CCTTCTTGCC ACTACCACAC TGATTTGAGG    6942

AAGAAAATCC CTTTAGCACC TAACCCTTCA GGTGCTATGA GTGGCTAATG GAACTGTACC    7002

TCCTTCAAGT TTTGTGCAAT AATTAAGGGT CACTCACTGT CAGATACTTT CTGTGATCTA    7062

TGATAATGTG TGTGCAACAC ATAACATTTC AATAAAAGTA GAAAATATGA AATTAGAGTC    7122

ATCTACACAT CTGGATTTGA TCTTAGAATG AAACAAGCAA AAAAGCATCC AAGTGAGTGC    7182

AATTATTAGT TTTCAGAGAT GCTTCAAAGG CTTCTAGGCC CATCCCGGGA AGTGTTAATG    7242

AGCTGTGGAC TGGTTCACAT ATCTATTGCC TCTTGCCAGA TTTGCAAAAA ACTTCACTCA    7302

ATGAGCAAAT TTCAGCCTTA AGAAACAAAG TCAAAAATTC CAAGGAAGCA TCCTACGAAA    7362

GAGGGAACTT CTGAGATCCC TGAGGAGGGT CAGCATGTGA TGGTTGTATT TCCTTCTTCT    7422

CAG T ACT GCA GAC TAT GCC ATG TTC AAG GTG GGA CCT GAA GCT GAC         7468
      Thr Ala Asp Tyr Ala Met Phe Lys Val Gly Pro Glu Ala Asp
      285                 290                 295

AAG TAC CGC CTA ACA TAT GCC TAC TTC GCT GGT GGG GAT GCT GGA GAT      7516
Lys Tyr Arg Leu Thr Tyr Ala Tyr Phe Ala Gly Gly Asp Ala Gly Asp
    300                 305                 310

GCC TTT GAT GGC TTT GAT TTT GGC GAT GAT CCT AGT GAC AAG TTT TTC      7564
Ala Phe Asp Gly Phe Asp Phe Gly Asp Asp Pro Ser Asp Lys Phe Phe
315                 320                 325                 330
```

-continued

```
ACA TCC CAT AAT GGC ATG CAG TTC AGT ACC TGG GAC AAT GAC AAT GAT      7612
Thr Ser His Asn Gly Met Gln Phe Ser Thr Trp Asp Asn Asp Asn Asp
                335                 340                 345

AAG TTT GAA GGC AAC TGT GCT GAA CAG GAT GGA TCT GGT TGG TGG ATG      7660
Lys Phe Glu Gly Asn Cys Ala Glu Gln Asp Gly Ser Gly Trp Trp Met
            350                 355                 360

AAC AAG TGT CAC GCT GGC CAT CTC AAT GGA GTT TAT TAC CAA  G           7703
Asn Lys Cys His Ala Gly His Leu Asn Gly Val Tyr Tyr Gln
        365                 370                 375

GTATGTTTTC CTTTCTTAGA TTCCAAGTTA ATGTATAGTG TATACTATTT TCATAAAAAA    7763

TAATAAATAG ATATGAAGAA ATGAAGAATA ATTTATAAAG ATAGTAGGGA TTTTATCATG    7823

TTCTTTATTT CAACTAAGTT CTTTGAAACT GGAAGTGGAT AATACCAAGT TCATGCCTAA    7883

AATTAGCCCT TCTAAAGAAA TCCACCTGCT GCAAAATATC CAGTAGTTTG GCATTATATG    7943

TGAAACTATC ACCATCATAG CTGGCACTGT GGGTTGTGGG ATCTCCTTTA GACATACAAC    8003

ATAAATGATC TGGATGGATT AACATTACTA CATGGATGCT TGTTGACACA TTAACCTGGC    8063

TTCCCATGAG CTTTGTGTCA GATACACGCA GTGAACAGGT GTTTGGAGGA ACAGAATAAA    8123

GAGAAGGCAA GCACTGGTAA GGGCAGGGGT TTGTGAAAGC TTGAGAGAAG AGACCAGTCT    8183

GAGGACAGTA GACACTTATT TTAGGATGGG GGTTGGATGA GGAGGCTATA GTTTGCTATA    8243

AGCTTGGAAT GGTTTGGAAC ACTGGTTTCA CTCACCTACC CAGCAGTTAT GTGTGGGGAA    8303

GCCTTACCGA TGCTAAAGGA TCCATGTTAC AATAATGGCA TTATTTGGAA ATCCCAGTGG    8363

TATTCCATGA ATAAAACCAC TATGAAGATA ATCCCACTCA ACAGACTCTC CGTTGGAGAA    8423

GGACAGCAAC ACCACCCTGG GAAAGCCAAA CAGTCAGACC AGACCTGTTT AGCATCAGTA    8483

GGACTTCCCT ACCATATCTG CTGGGTAGAT GAGTGAAACC AGTGTTCCAA ACCACTCCGG    8543

GCTTGTAGCA AACCATAGTC TCCTCATCTA CCAAGATGAG CAACCTTACC TCCTGATGTC    8603

CTAGCCAATC ACCAACTAGG AAACTTTGCA CAGTTTATTT AAAGTAACAG TTTGATTTTC    8663

ACAATATTTT TAAATTGGAG AAACATAACT TATCTTTGCA CTCACAAACC ACATAATGAG    8723

AAGAAACTCT AAGGGAAAAT GCTTGATCTG TGTGACCCGG GGCGCCATGC CAGAGCTGTA    8783

GTTCATGCCA GTGTTGTGCT CTGACAAGCC TTTTACAGAA TTACATGAGA TCTGCTTCCC    8843

TAGGACAAGG AGAAGGCAAA TCAACAGAGG CTGCACTTTA AAATGGAGAC ATAAAATAAC    8903

ATGCCAGAAC CATTTCCTAA AGCTCCTCAA TCAACCAACA AAATTGTGCT TTCAAATAAC    8963

CTGAGTTGAC CTCATCAGGA ATTTTGTGGC TCCTTCTCTT CTAACCTGCC TGAAGAAAGA    9023

TGGTCCACAG CAGCTGAGTC CGGGATGGAT AAGCTTAGGG ACAGAGGCCA ATTAGGGAAC    9083

TTTGGGTTTC TAGCCCTACT AGTAGTGAAT AAATTTAAAG TGTGGATGTG ACTATGAGTC    9143

ACAGCACAGA TGTTGTTTAA TAATATGTTT ATTTTATAAA TTGATATTTT AGGAATCTTT    9203

GGAGATATTT TCAGTTAGCA GATAATACTA TAAATTTTAT GTAACTGGCA ATGCACTTCG    9263

TAATAGACAG CTCTTCATAG ACTTGCAGAG GTAAAAAGAT TCCAGAATAA TGATATGTAC    9323

ATCTACGACT TGTTTTAG  GT GGC ACT TAC TCA AAA GCA TCT ACT CCT AAT      9373

                    Gly Gly Thr Tyr Ser Lys Ala Ser Thr Pro Asn
                            380                 385

GGT TAT GAT AAT GGC ATT ATT TGG GCC ACT TGG AAA ACC CGG TGG TAT      9421
Gly Tyr Asp Asn Gly Ile Ile Trp Ala Thr Trp Lys Thr Arg Trp Tyr
        390                 395                 400

TCC ATG AAG AAA ACC ACT ATG AAG ATA ATC CCA TTC AAC AGA CTC ACA      9469
Ser Met Lys Lys Thr Thr Met Lys Ile Ile Pro Phe Asn Arg Leu Thr
    405                 410                 415

ATT GGA GAA GGA CAG CAA CAC CAC CTG GGG GGA GCC AAA CAG GTC AGA      9517
```

-continued

```
Ile Gly Glu Gly Gln Gln His His Leu Gly Gly Ala Lys Gln Val Arg
420                 425                 430                 435

CCA GAG CAC CCT GCG GAA ACA GAA TAT GAC TCA CTT TAC CCT GAG GAT      9565
Pro Glu His Pro Ala Glu Thr Glu Tyr Asp Ser Leu Tyr Pro Glu Asp
                440                 445                 450

GAT TTG TAGAAAATTA ACTGCTAACT TCTATTGACC CACAAAGTTT CAGAAATTCT      9621
Asp Leu
CTGAAAGTTT CTTCCTTTTT TCTCTTACTA TATTTATTGA TTTCAAGTCT TCTATTAAGG   9681

ACATTTAGCC TTCAATGGAA ATTAAAACTC ATTTAGGACT GTATTTCCAA ATTACTGATA   9741

TCAGAGTTAT TTAAAAATTG TTTATTTGAG GAGATAACAT TTCAACTTTG TTCCTAAATA   9801

TATAATAATA AAATGATTGA CTTTATTTGC ATTTTTATGA CCACTTGTCA TTTATTTTGT   9861

CTTCGTAAAT TATTTTCATT ATATCAAATA TTTTAGTATG TACTTAATAA AATAGGAGAA   9921

CATTTTAGAG TTTCAAATTC CCAGGTATTT TCCTTGTTTA TTACCCCTAA ATCATTCCTA   9981

TTTAATTCTT CTTTTTAAAT GGAGAAAATT ATGTCTTTTT AATATGGTTT TTGTTTTGTT  10041

ATATATTCAC AGGCTGGAGA CGTTTAAAAG ACCGTTTCAA AAGAGATTTA CTTTTTTAAA  10101

GGACTTTATC TGAACAGAGA GATATAATAT TTTTCCTATT GGACAATGGA CTTGCAAAGC  10161

TTCACTTCAT TTTAAGAGCA AAAGACCCCA TGTTGAAAAC TCCATAACAG TTTTATGCTG  10221

ATGATAATTT ATCTACATGC ATTTCAATAA ACCTTTTGTT TCCTAAGACT AGATACATGG  10281

TACCTTTATT GACCATTAAA AAACCACCAC TTTTTGCCAA TTTACCAATT ACAATTGGGC  10341

AACCATCAGT AGTAATTGAG TCCTCATTTT ATGCTAAATG TTATGCCTAA CTCTTTGGGA  10401

GTTACAAAGG AAATAGCAAT TATGGCTTTT GCCCTCTAGG AGATACAGGA CAAATACAGG  10461

AAAATACAGC AACCCAAACT GACAATACTC TATACAAGAA CATAATCACT AAGCAGGAGT  10521

CACAGCCACA CAACCAAGAT GCATAGTATC CAAAGTGCAG CTG                     10564
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 453 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: protein

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Met Ser Trp Ser Leu His Pro Arg Asn Leu Ile Leu Tyr Phe Tyr Ala
 1               5                  10                  15

Leu Leu Phe Leu Ser Ser Thr Cys Val Ala Tyr Val Ala Thr Arg Asp
            20                  25                  30

Asn Cys Cys Ile Leu Asp Glu Arg Phe Gly Ser Tyr Cys Pro Thr Thr
        35                  40                  45

Cys Gly Ile Ala Asp Phe Leu Ser Thr Tyr Gln Thr Lys Val Asp Lys
    50                  55                  60

Asp Leu Gln Ser Leu Glu Asp Ile Leu His Gln Val Glu Asn Lys Thr
65                  70                  75                  80

Ser Glu Val Lys Gln Leu Ile Lys Ala Ile Gln Leu Thr Tyr Asn Pro
                85                  90                  95

Asp Glu Ser Ser Lys Pro Asn Met Ile Asp Ala Ala Thr Leu Lys Ser
            100                 105                 110

Arg Ile Met Leu Glu Glu Ile Met Lys Tyr Glu Ala Ser Ile Leu Thr
        115                 120                 125

His Asp Ser Ser Ile Arg Tyr Leu Gln Glu Ile Tyr Asn Ser Asn Asn
    130                 135                 140
```

-continued

```
Gln Lys Ile Val Asn Leu Lys Glu Lys Val Ala Gln Leu Glu Ala Gln
145                 150                 155                 160

Cys Gln Glu Pro Cys Lys Asp Thr Val Gln Ile His Asp Ile Thr Gly
                165                 170                 175

Lys Asp Cys Gln Asp Ile Ala Asn Lys Gly Ala Lys Gln Ser Gly Leu
            180                 185                 190

Tyr Phe Ile Lys Pro Leu Lys Ala Asn Gln Gln Phe Leu Val Tyr Cys
        195                 200                 205

Glu Ile Asp Gly Ser Gly Asn Gly Trp Thr Val Phe Gln Lys Arg Leu
    210                 215                 220

Asp Gly Ser Val Asp Phe Lys Lys Asn Trp Ile Gln Tyr Lys Glu Gly
225                 230                 235                 240

Phe Gly His Leu Ser Pro Thr Gly Thr Thr Glu Phe Trp Leu Gly Asn
                245                 250                 255

Glu Lys Ile His Leu Ile Ser Thr Gln Ser Ala Ile Pro Tyr Ala Leu
            260                 265                 270

Arg Val Glu Leu Glu Asp Trp Asn Gly Arg Thr Ser Thr Ala Asp Tyr
        275                 280                 285

Ala Met Phe Lys Val Gly Pro Glu Ala Asp Lys Tyr Arg Leu Thr Tyr
    290                 295                 300

Ala Tyr Phe Ala Gly Gly Asp Ala Gly Asp Ala Phe Asp Gly Phe Asp
305                 310                 315                 320

Phe Gly Asp Asp Pro Ser Asp Lys Phe Phe Thr Ser His Asn Gly Met
                325                 330                 335

Gln Phe Ser Thr Trp Asp Asn Asp Asn Asp Lys Phe Glu Gly Asn Cys
            340                 345                 350

Ala Glu Gln Asp Gly Ser Gly Trp Trp Met Asn Lys Cys His Ala Gly
        355                 360                 365

His Leu Asn Gly Val Tyr Tyr Gln Gly Gly Thr Tyr Ser Lys Ala Ser
    370                 375                 380

Thr Pro Asn Gly Tyr Asp Asn Gly Ile Ile Trp Ala Thr Trp Lys Thr
385                 390                 395                 400

Arg Trp Tyr Ser Met Lys Lys Thr Thr Met Lys Ile Ile Pro Phe Asn
                405                 410                 415

Arg Leu Thr Ile Gly Glu Gly Gln Gln His His Leu Gly Gly Ala Lys
            420                 425                 430

Gln Val Arg Pro Glu His Pro Ala Glu Thr Glu Tyr Asp Ser Leu Tyr
        435                 440                 445

Pro Glu Asp Asp Leu
    450
```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10807 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ovine beta- lactoglobulin

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
ACGCGTGTCG ACCTGCAGGT CAACGGATCT CTGTGTCTGT TTTCATGTTA GTACCACACT      60

GTTTTGGTGG CTGTAGCTTT CAGCTACAGT CTGAAGTCAT AAAGCCTGGT ACCTCCAGCT     120

CTGTTCTCTC TCAAGATTGT GTTCTGCTGT TTGGGTCTTT AGTGTCTCCA CACAATTTTT     180
```

-continued

AGAATTGTTT GTTCTAGTTC TGTGAAAAAT GATGCTGGTA TTTTGATAAG GATTGCATTG 240

AATCTGTAAA GCTACAGATA TAGTCATTGG GTAGTACAGT CACTTTAACA ATATTAACTC 300

TTCACATCTG TGAGCATGAT ATATTTTCCC CCTCTATATC ATCTTCAATT CCTCCTATCA 360

GTTTCTTTCA TTGCAGTTTT CTGAGTACAG GTCTTACACC TCCTTGGTTA GAGTCATTCC 420

TCAGTATTTT ATTCCTTTGA TACAATTGTG AATGAGGTAA TTTTCTTAGT TTCTCTTTCT 480

GATAGCTCAT TGTTAGTGTA TATATAGAAA AGCAACAGAT TTCTATGTAT TAATTTTGTA 540

TCCTGCAACA GATTTCTATG TATTAATTTT GTATCCTGCT ACTTTACGGA ATTCACTTAT 600

TAGCTTTTTG GTGACATCTT GAGGATTTTC TGAAGAAAAT GGCATGGTAT GGTAGGACAA 660

GGTGTCATGT CATCTGCAAA CAGTGGCAGT TTTCCTTCTT CCCTTCCAAC CTGGATTTCT 720

TTGATTTCTT TCTGTCTGAG TACGACTAGG ATTCCCAATA CTATACCGAA TAAAAGTGGC 780

AAGAGTGGAC ATCCTTGTCT TATTTTTCTG ACCTTAGAGG AAATGCTTTC AGTTTTTCAC 840

CATTAATTAT AATGTTTACT GTGGGCTTGT CATATGTGGC CTTCATTATA TGGAGGTCTA 900

TTCCCTCTAT ACCCACCTTG TTGAGAGTTT TTATCATAAA AGTATGTTGA ATTTTGTCAA 960

AAGTTTTTCC TGCATCTATT GAGATGATTT TTACTCTTCA ATTCATTAAT GATTTTTATT 1020

CTTCATTTTG TTAATGATTT CCATTCTTCA ATTTGTTAAC GTGGTATATC ACATTGATTG 1080

ATTTGTGGAT ACCTTTGTAT CCCTGGGATA AACCTCACTT GATCATGAGC TTTCAATGTA 1140

TTTTTGAATT CACTTTGCTA ATATTCTGTT GGGTATTTTT GCATCTCTAT TCATCAATGA 1200

TATTGGCCTA AGAAAGGTTT TGTCTGGTTT TAGTATCAGG GTGATGCTGG CCTCATAGAG 1260

AGAGTTTAGA AGCATTTCCT CCTCTTTGAT TTTTCGGAAT AGTTTGAGTA GGATAGGTAT 1320

TAACTCTTCT TTAAATGTTT GGGGACTTCC CTGGTGAGCC GGTGGTTGAG AATCCGCCTC 1380

AGGGATGTGG GTTTGATCCC TGGTCAGGGA ACCATTAATA AGATCCCACA TGCTGCAGGC 1440

AACAAGCCCC CAAGCTGCAA CCACTGAGCT GCAACCGCTG CAGTGCCCAC AGGCCACGAC 1500

CAGAGAAAGC CCACATACAG CAGGGAAGAC CCAGCACAAC CGGAAAAAGG AGTTTGGTGG 1560

AATACAGCTG TGAAGCCGTC TGGTCCTGGA CTCCTGCTTG AGGGAATTTT TTAAAAATTA 1620

TTGATTCAAT TTCATTACTG GTAACTGGTC TGTTCATATT TTCTATTTCT TCCGGGTTCA 1680

GTCTTGGGAG ATTGTACATG CCTAGGAATG TGTCCGTTTC TTCTAGGTTG TCCATTTTAT 1740

TGGACATGCA TGGGAGCACA CAGCACCGAC CAGCGAGACT CATGCTGGCT TCCTGGGGCC 1800

AGGCTGGGGC CCCAAGCAGC ATGGCATCCT AGAGTGTGTG AAAGCCCACT GACCCTGCCC 1860

AGCCCCACAA TTTCATTCTG AGAAGTGATT CCTTGCTTCT GCACTTACAG GCCCAGGATC 1920

TGACCTGCTT CTGAGGAGCA GGGGTTTTGG CAGGACGGGG AGATGCTGAG AGCCGACGGG 1980

GGTCCAGGTC CCCTCCCAGG CCCCCCTGTC TGGGGCAGCC CTTGGGAAAG ATTGCCCCAG 2040

TCTCCCTCCT ACAGTGGTCA GTCCCAGCTG CCCCAGGCCA GAGCTGCTTT ATTTCCGTCT 2100

CTCTCTCTGG ATGGTATTCT CTGGAAGCTG AAGGTTCCTG AAGTTATGAA TAGCTTTGCC 2160

CTGAAGGGCA TGGTTTGTGG TCACGGTTCA CAGGAACTTG GGAGACCCTG CAGCTCAGAC 2220

GTCCCGAGAT TGGTGGCACC CAGATTTCCT AAGCTCGCTG GGGAACAGGG CGCTTGTTTC 2280

TCCCTGGCTG ACCTCCCTCC TCCCTGCATC ACCCAGTTCT GAAAGCAGAG CGGTGCTGGG 2340

GTCACAGCCT CTCGCATCTA ACGCCGGTGT CCAAACCACC CGTGCTGGTG TTCGGGGGC 2400

TACCTATGGG GAAGGGCTTC TCACTGCAGT GGTGCCCCCC GTCCCCTCTG AGATCAGAAG 2460

TCCCAGTCCG GACGTCAAAC AGGCCGAGCT CCCTCCAGAG GCTCCAGGGA GGGATCCTTG 2520

CCCCCCCGCT GCTGCCTCCA GCTCCTGGTG CCGCACCCTT GAGCCTGATC TTGTAGACGC 2580

-continued

CTCAGTCTAG TCTCTGCCTC CGTGTTCACA CGCCTTCTCC CCATGTCCCC TCCGTGTCCC 2640

CGTTTTCTCT CACAAGGACA CCGGACATTA GATTAGCCCC TGTTCCAGCC TCACCTGAAC 2700

AGCTCACATC TGTAAAGACC TAGATTCCAA ACAAGATTCC AACCTGAAGT TCCCGGTGGA 2760

TGTGAGTTCT GGGGCGACAT CCTTCAACCC CATCACAGCT TGCAGTTCAT CGCAAAACAT 2820

GGAACCTGGG GTTTATCGTA AAACCCAGGT TCTTCATGAA ACACTGAGCT TCGAGGCTTG 2880

TTGCAAGAAT TAAAGGTGCT AATACAGATC AGGGCAAGGA CTGAAGCTGG CTAAGCCTCC 2940

TCTTTCCATC ACAGGAAAGG GGGGCCTGGG GGCGGCTGGA GGTCTGCTCC CGTGAGTGAG 3000

CTCTTTCCTG CTACAGTCAC CAACAGTCTC TCTGGGAAGG AAACCAGAGG CCAGAGAGCA 3060

AGCCGGAGCT AGTTTAGGAG ACCCCTGAAC CTCCACCCAA GATGCTGACC AGCCAGCGGG 3120

CCCCCTGGAA AGACCCTACA GTTCAGGGGG GAAGAGGGGC TGACCCGCCA GGTCCCTGCT 3180

ATCAGGAGAC ATCCCCGCTA TCAGGAGATT CCCCCACCTT GCTCCCGTTC CCCTATCCCA 3240

ATACGCCCAC CCCACCCCTG TGATGAGCAG TTTAGTCACT TAGAATGTCA ACTGAAGGCT 3300

TTTGCATCCC CTTTGCCAGA GGCACAAGGC ACCCACAGCC TGCTGGGTAC CGACGCCCAT 3360

GTGGATTCAG CCAGGAGGCC TGTCCTGCAC CCTCCCTGCT CGGGCCCCCT CTGTGCTCAG 3420

CAACACACCC AGCACCAGCA TTCCCGCTGC TCCTGAGGTC TGCAGGCAGC TCGCTGTAGC 3480

CTGAGCGGTG TGGAGGGAAG TGTCCTGGGA GATTTAAAAT GTGAGAGGCG GGAGGTGGGA 3540

GGTTGGGCCC TGTGGGCCTG CCCATCCCAC GTGCCTGCAT TAGCCCCAGT GCTGCTCAGC 3600

CGTGCCCCCG CCGCAGGGGT CAGGTCACTT TCCCGTCCTG GGGTTATTAT GACTCTTGTC 3660

ATTGCCATTG CCATTTTTGC TACCCTAACT GGGCAGCAGG TGCTTGCAGA GCCCTCGATA 3720

CCGACCAGGT CCTCCCTCGG AGCTCGACCT GAACCCCATG TCACCCTTGC CCCAGCCTGC 3780

AGAGGGTGGG TGACTGCAGA GATCCCTTCA CCCAAGGCCA CGGTCACATG GTTTGGAGGA 3840

GCTGGTGCCC AAGGCAGAGG CCACCCTCCA GGACACACCT GTCCCCAGTG CTGGCTCTGA 3900

CCTGTCCTTG TCTAAGAGGC TGACCCCGGA AGTGTTCCTG GCACTGGCAG CCAGCCTGGA 3960

CCCAGAGTCC AGACACCCAC CTGTGCCCCC GCTTCTGGGG TCTACCAGGA ACCGTCTAGG 4020

CCCAGAGGGG ACTTCCTGCT TGGCCTTGGA TGGAAGAAGG CCTCCTATTG TCCTCGTAGA 4080

GGAAGCCACC CCGGGGCCTG AGGATGAGCC AAGTGGGATT CCGGGAACCG CGTGGCTGGG 4140

GGCCCAGCCC GGGCTGGCTG GCCTGCATGC CTCCTGTATA AGGCCCCAAG CCTGCTGTCT 4200

CAGCCCTCCA CTCCCTGCAG AGCTCAGAAG CACGACCCCA GGGATATCCC TGCAGCCATG 4260

AAGTGCCTCC TGCTTGCCCT GGGCCTGGCC CTCGCCTGTG GCGTCCAGGC CATCATCGTC 4320

ACCCAGACCA TGAAAGGCCT GGACATCCAG AAGGTTCGAG GGTTGGCCGG GTGGGTGAGT 4380

TGCAGGGCGG GCAGGGGAGC TGGGCCTCAG AGAGCCAAGA GAGGCTGTGA CGTTGGGTTC 4440

CCATCAGTCA GCTAGGGCCA CCTGACAAAT CCCCGCTGGG GCAGCTTCAA CCAGGCGTTC 4500

ACTGTCTTGC ATTCTGGAGG CTGGAAGCCC AAGATCCAGG TGTTGGCAGG GCTGGCTTCT 4560

CCTGCGGCCG CTCTCTGGGG AGCAGACGGC CGTCTTCTCC AGTCCTCTGC GCGCCCTGAT 4620

TTCCTCTTCC TGTGAGGCCA CCAGGCCTGC TGGAAACACG CCTGCCTGCG CAGCTTCACA 4680

CGACCTTTGT CATCTCTTTA AAGGCCATGT CTCCAGAGTC ATGTGTTGAA GTTCTGGGGG 4740

TTAGTGGGAC ACAGTTCAGC CCCTAAAAGA GTCTCTCTGC CCCTCAAATT TTCCCCACCT 4800

CCAGCCATGT CTCCCCAAGA TCCAAATGTT GCTACATGTG GGGGGGCTCA TCTGGGTCCC 4860

TCTTTGGGTT CAGTGTGAGT CTGGGGAGAG CATTCCCCAG GGTGCAGAGT TGGGGGGAGT 4920

ATCTCAGGGC TGCCCAGGCC GGGGTGGGAC AGAGAGCCCA CTGTGGGGCT GGGGGCCCCT 4980

-continued

TCCCACCCCC AGAGTGCAAC TCAAGGTCCC TCTCCAGGTG GCGGGGACTT GGCACTCCTT	5040
GGCTATGGCG GCCAGCGACA TCTCCCTGCT GGATGCCCAG AGTGCCCCCC TGAGAGTGTA	5100
CGTGGAGGAG CTGAAGCCCA CCCCCGAGGG CAACCTGGAG ATCCTGCTGC AGAAATGGTG	5160
GGCGTCTCTC CCCAACATGG AACCCCCACT CCCCAGGGCT GTGGACCCCC CGGGGGGTGG	5220
GGTGCAGGAG GGACCAGGGC CCCAGGGCTG GGGAAGAGGG CTCAGAGTTT ACTGGTACCC	5280
GGCGCTCCAC CCAAGGCTGC CCACCCAGGG CTTTTTTTTT TTTTAAACTT TTATTAATTT	5340
GATGCTTCAG AACATCATCA AACAAATGAA CATAAAACAT TCATTTTTGT TTACTTGGAA	5400
GGGGAGATAA AATCCTCTGA AGTGGAAATG CATAGCAAAG ATACATACAA TGAGGCAGGT	5460
ATTCTGAATT CCCTGTTAGT CTGAGGATTA CAAGTGTATT TGAGCAACAG AGAGACATTT	5520
TCATCATTTC TAGTCTGAAC ACCTCAGTAT CTAAAATGAA CAAGAAGTCC TGGAAACGAA	5580
GCAGTGTGGG GATAGGCCCG TGTGAAGGCT GCTGGGAGGC AGCAGACCTG GGTCTTCGGG	5640
CTCAAGCAGT TCCCGCTACC AGCCCTGTCC ACCTCAGACG GGGGTCAGGG TGCAGGAGAG	5700
AGCTGGATGG GTGTGGGGGC AGAGATGGGG ACCTGAACCC CAGGGCTGCC TTTTGGGGGT	5760
GCCTGTGGTC AAGGCTCTCC CTGACCTTTT CTCTCTGGCT TCATCTGACT TCTCCTGGCC	5820
CATCCACCCG GTCCCCTGTG GCCTGAGGTG ACAGTGAGTG CGCCGAGGCT AGTTGGCCAG	5880
CTGGCTCCTA TGCCCATGCC ACCCCCCTCC AGCCCTCCTG GGCCAGCTTC TGCCCCTGGC	5940
CCTCAGTTCA TCCTGATGAA AATGGTCCAT GCCAATGGCT CAGAAAGCAG CTGTCTTTCA	6000
GGGAGAACGG CGAGTGTGCT CAGAAGAAGA TTATTGCAGA AAAAACCAAG ATCCCTGCGG	6060
TGTTCAAGAT CGATGGTGAG TCCGGGTCCC TGGGGGACAC CCACCACCCC CGCCCCCGGG	6120
GACTGTGGAC AGGTTCAGGG GGCTGGCGTC GGGCCCTGGG ATGCTAAGGG ACTGGTGGTG	6180
ATGAAGACAC TGCCTTGACA CCTGCTTCAC TTGCCTCCCC TGCCACCTGC CCGGGGCCTT	6240
GGGGCGGTGG CCATGGGCAG GTCCCGGCTG GCGGGCTAAC CCACCAGGGT GACACCCGAG	6300
CTCTCTTTGC TGGGGGGCGG GCGGTGCTCT GGGCCCTCAG GCTGAGCTCA GGAGGTACCT	6360
GTGCCCTCCC AGGGGTAACC GAGAGCCGTT GCCCACTCCA GGGGCCCAGG TGCCCCACGA	6420
CCCCAGCCCG CTCCACAGCT CCTTCATCTC CTGGAGACAA ACTCTGTCCG CCCTCGCTCA	6480
TTCACTTGTT CGTCCTAAAT CCGAGATGAT AAAGCTTCGA GGGGGGGTTG GGGTTCCATC	6540
AGGGCTGCCC TTCCGCCGGG CAGCCTGGGC CACATCTGCC CTTGGCCCCC TCAGGACTCA	6600
CTCTGACTGG AGGCCCTGCA CTGACTGACG CCAGGGTGCC CAGCCCAGGG TCTCTGGCGC	6660
CATCCAGCTG CACTGGGTTT GGGTGCTGGT CCTGCCCCCA AGCTGCCCGG ACACCACAGG	6720
CAGCCGGGGC TGCCCACTGG CCTCGGTCAG GGTGAGCCCC AGCTGCCCCC GCTCAGGGCT	6780
TGCCCCGACA ATGACCCCAT CCTCAGGACG CACCCCCCTT CCCTTGCTGG GCAGTGTCCA	6840
GCCCCACCCG AGATCGGGGG AAGCCCTATT TCTTGACAAC TCCAGTCCCT GGGGGAGGGG	6900
GCCTCAGACT GAGTGGTGAG TGTTCCCAAG TCCAGGAGGT GGTGGAGGGT CCTGGCGGAT	6960
CCAGAGTTGA CAGTGAGGGC TTCCTGGGCC CCATGCGCCT GGCAGTGGCA GCAGGGAAGA	7020
GGAAGCACCA TTTCAGGGGT GGGGGATGCC AGAGGCGCTC CCCACCCCGT CTTCGCCGGG	7080
TGGTGACCCC GGGGGAGCCC CGCTGGTCGT GGAGGGTGCT GGGGGCTGAC TAGCAACCCC	7140
TCCCCCCCCG TTGGAACTCA CTTTTCTCCC GTCTTGACCG CGTCCAGCCT TGAATGAGAA	7200
CAAAGTCCTT GTGCTGGACA CCGACTACAA AAAGTACCTG CTCTTCTGCA TGGAAAACAG	7260
TGCTGAGCCC GAGCAAAGCC TGGCCTGCCA GTGCCTGGGT GGGTGCCAAC CCTGGCTGCC	7320
CAGGGAGACC AGCTGCGTGG TCCTTGCTGC AACAGGGGGT GGGGGGTGGG AGCTTGATCC	7380

-continued

CCAGGAGGAG GAGGGGTGGG GGGTCCCTGA GTCCCGCCAG GAGAGAGTGG TCGCATACCG	7440
GGAGCCAGTC TGCTGTGGGC CTGTGGGTGG CTGGGGACGG GGGCCAGACA CACAGGCCGG	7500
GAGACGGGTG GGCTGCAGAA CTGTGACTGG TGTGACCGTC GCGATGGGGC CGGTGGTCAC	7560
TGAATCTAAC AGCCTTTGTT ACCGGGGAGT TTCAATTATT TCCCAAAATA AGAACTCAGG	7620
TACAAAGCCA TCTTTCAACT ATCACATCCT GAAAACAAAT GGCAGGTGAC ATTTTCTGTG	7680
CCGTAGCAGT CCCACTGGGC ATTTTCAGGG CCCCTGTGCC AGGGGGGCGC GGGCATCGGC	7740
GAGTGGAGGC TCCTGGCTGT GTCAGCCGGC CCAGGGGGAG GAAGGGACCC GGACAGCCAG	7800
AGGTGGGGGG CAGGCTTTCC CCCTGTGACC TGCAGACCCA CTGCACTGCC CTGGGAGGAA	7860
GGGAGGGGAA CTAGGCCAAG GGGGAAGGGC AGGTGCTCTG GAGGGCAAGG GCAGACCTGC	7920
AGACCACCCT GGGGAGCAGG GACTGACCCC CGTCCCTGCC CCATAGTCAG GACCCCGGAG	7980
GTGGACAACG AGGCCCTGGA GAAATTCGAC AAAGCCCTCA AGGCCCTGCC CATGCACATC	8040
CGGCTTGCCT TCAACCCGAC CCAGCTGGAG GGTGAGCACC CAGGCCCCGC CCTTCCCCAG	8100
GGCAGGAGCC ACCCGGCCCC GGGACGACCT CCTCCCATGG TGACCCCCAG CTCCCCAGGC	8160
CTCCCAGGAG GAAGGGGTGG GGTGCAGCAC CCCGTGGGGG CCCCCTCCCC ACCCCCTGCC	8220
AGGCCTCTCT TCCCGAGGTG TCCAGTCCCA TCCTGACCCC CCCATGACTC TCCCTCCCCC	8280
ACAGGGCAGT GCCACGTCTA GGTGAGCCCC TGCCGGTGCC TCTGGGGTAA GCTGCCTGCC	8340
CTGCCCCACG TCCTGGGCAC ACACATGGGG TAGGGGGTCT TGGTGGGGCC TGGGACCCCA	8400
CATCAGGCCC TGGGGTCCCC CCTGTGAGAA TGGCTGGAAG CTGGGGTCCC TCCTGGCGAC	8460
TGCAGAGCTG GCTGGCCGCG TGCCACTCTT GTGGGTGACC TGTGTCCTGG CCTCACACAC	8520
TGACCTCCTC CAGCTCCTTC CAGCAGAGCT AAGGCTAAGT GAGCCAGAAT GGTACCTAAG	8580
GGGAGGCTAG CGGTCCTTCT CCCGAGGAGG GGCTGTCCTG GAACCACCAG CCATGGAGAG	8640
GCTGGCAAGG GTCTGGCAGG TGCCCCAGGA ATCACAGGGG GGCCCCATGT CCATTTCAGG	8700
GCCCGGGAGC CTTGGACTCC TCTGGGGACA GACGACGTCA CCACCGCCCC CCCCCCATCA	8760
GGGGGACTAG AAGGGACCAG GACTGCAGTC ACCCTTCCTG GGACCCAGGC CCCTCCAGGC	8820
CCCTCCTGGG GCTCCTGCTC TGGGCAGCTT CTCCTTCACC AATAAAGGCA TAAACCTGTG	8880
CTCTCCCTTC TGAGTCTTTG CTGGACGACG GGCAGGGGGT GGAGAAGTGG TGGGGAGGGA	8940
GTCTGGCTCA GAGGATGACA GCGGGGCTGG GATCCAGGGC GTCTGCATCA CAGTCTTGTG	9000
ACAACTGGGG GCCCACACAC ATCACTGCGG CTCTTTGAAA CTTTCAGGAA CCAGGGAGGG	9060
ACTCGGCAGA GACATCTGCC AGTTCACTTG GAGTGTTCAG TCAACACCCA AACTCGACAA	9120
AGGACAGAAA GTGGAAAATG GCTGTCTCTT AGTCTAATAA ATATTGATAT GAAACTCAAG	9180
TTGCTCATGG ATCAATATGC CTTTATGATC CAGCCAGCCA CTACTGTCGT ATCAACTCAT	9240
GTACCCAAAC GCACTGATCT GTCTGGCTAA TGATGAGAGA TTCCCAGTAG AGAGCTGGCA	9300
AGAGGTCACA GTGAGAACTG TCTGCACACA CAGCAGAGTC CACCAGTCAT CCTAAGGAGA	9360
TCAGTCCTGG TGTTCATTGG AGGACTGATG TTGAAGCTGA AACTCCAATG CTTTGGCCAC	9420
CTGATGTGAA GAGCTGACTC ATTTGAAAAG ACCCTGATGC TGGGAAAGAT TGAGGGCAGG	9480
AGGAGAAGGG GACGACAGAG GATGAGATGG TTGGATGGCA TCACCAACAC AATGGACATG	9540
GGTTTGGGTG GACTCCAGGA GTTGGTGATG GACAGGGAGG CCTGGCGTGC TACGGAAGCG	9600
GTTTATGGGG TCACAAAGAC TGAGTGACTG AACTGAGCTG AACTGAATGG AAATGAGGTA	9660
TACAGCAAAG TGGGGATTTT TTAGATAATA AGAATATACA CATAACATAG TGTATACTCA	9720
TATTTTTATG CATACCTGAA TGCTCAGTCA CTCAGTCGTA TCTGACTCTG TGACCTATGG	9780

-continued

ACCGTAGCCT TCCAGGTTTC TTCTGTCCAC AGAATTCTCC AAGGCAAGAA TACTGGAGTG 9840

GGTAGCCATT TCCTCCTCCA GGGGATCCTC CCGACCCAGG GATTGAACCG GCATCTCCTG 9900

TATTGGCAGG TGGATTCTTT ACCACTGTGC CACCAGGGAA GCCCGTGTTA CTCTCTATGT 9960

CCCACTTAAT TACCAAAGCT GCTCCAAGAA AAAGCCCCTG TGCCCTCTGA GCTTCCCGGC 10020

CTGCAGAGGG TGGTGGGGGT AGACTGTGAC CTGGGAACAC CCTCCCGCTT CAGGACTCCC 10080

GGGCCACGTG ACCCACAGTC CTGCAGACAG CCGGGTAGCT CTGCTCTTCA AGGCTCATTA 10140

TCTTTAAAAA AAACTGAGGT CTATTTTGTG ACTTCGCTGC CGTAACTTCT GAACATCCAG 10200

TGCGATGGAC AGGACCTCCT CCCCAGGCCT CAGGGGCTTC AGGGAGCCAG CCTTCACCTA 10260

TGAGTCACCA GACACTCGGG GGTGGCCCCG CCTTCAGGGT GCTCACAGTC TTCCCATCGT 10320

CCTGATCAAA GAGCAAGACC AATGACTTCT TAGGAGCAAG CAGACACCCA CAGGACACTG 10380

AGGTTCACCA GAGCTGAGCT GTCCTTTTGA ACCTAAAGAC ACACAGCTCT CGAAGGTTTT 10440

CTCTTTAATC TGGATTTAAG GCCTACTTGC CCCTCAAGAG GGAAGACAGT CCTGCATGTC 10500

CCCAGGACAG CCACTCGGTG GCATCCGAGG CCACTTAGTA TTATCTGACC GCACCCTGGA 10560

ATTAATCGGT CCAAACTGGA CAAAAACCTT GGTGGGAAGT TTCATCCCAG AGGCCTCAAC 10620

CATCCTGCTT TGACCACCCT GCATCTTTTT TTCTTTTATG TGTATGCATG TATATATATA 10680

TATATATTTT TTTTTTTTTC ATTTTTTGGC TGTGCTGGCT GTTCGTTGCA GTTCGGTGCG 10740

CAGGCTTCTC TCTAGTTTCT CTCTAGTCTT CTCTTATCAC AGAGCAGTCT CTAGACGATC 10800

GACGCGT 10807

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8

AATTCCGATC GACGCGTCGA CGATATACTC TAGACGATCG ACGCGTA 47

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: BLGAMP3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TGGATCCCCT GCCGGTGCCT CTGG 24

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS.
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
(B) CLONE: BLGAMP4

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AACGCGTCAT CCTCTGTGAG CCAG 24

-continued

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6839

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ACTACGTAGT 10

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6632

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CGACGCGGAT CCTACGTACC TGCAGCCATG TTTTCCATGA GG 42

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6627

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AGGGCTTCGG CAAGCTTCAG G 21

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6521

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GCCAAAGACT TACTTCCCTC TAGA 24

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6520

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GCATGAACGT CGCGTGGTGG TTGTGCTACC 30

-continued

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6519

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ACCACGCGAC GTTCATGCTC TAAAACCGTT 30

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6518

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GCTGCGGGAT CCTACGTACT AGGGGGACAG GGAAGG 36

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6629

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CGACGCGAAT TCTACGTACC TGCAGCCATG AAAAGGATGG TTTCT 45

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6630

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CGACGCGAAT TCTACGTACC TGCAGCCATG AAACATCTAT TATTG 45

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6625

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GTGAGATTTT CAGATCTTGT C 21

-continued

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6626

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AAGAATTACT GTGGCCTACC A 21

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6624

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GCTGCGGAAT TCTACGTACT ATTGCTGTGG GAA 33

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: ZC6514

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CGACGCGGAT CCTACGTACC TGCAGCCATG AGTTGGTCCT TGCAC 45

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: zc6517

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GTCTCTGGTA GCAACATACT A 21

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: zc6516

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GGGTTTCTAG CCCTACTAGT AG 22

-continued

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v i i) IMMEDIATE SOURCE:
(B) CLONE: zc6515

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GGGTTTCTAG CCCTACTAGT AG 22

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:27:

AAGCTACGCG TCGATCGTCT AGAGTATATC GTCGACGCGT CGATCGG 47

We claim:

1. A method for producing biocompetent fibrinogen comprising:

providing a first DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen Aα chain,

the DNA segment comprising genomic DNA encoding the Aα chain;

a second DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen Bβ chain,

the DNA segment comprising genomic DNA encoding the Bβ chain; and

a third DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen γ chain,

the DNA segment comprising genomic DNA encoding the γ chain,

wherein each chain is from the same species, and wherein each of said first, second and third segments is operably linked to additional DNA segments required for its expression in the mammary gland of a host female mammal;

introducing said DNA segments into a fertilized egg of a non-human mammalian species heterologous to the species of origin of said fibrinogen chains;

inserting said egg into an oviduct or uterus of a female of said mammalian species to obtain offspring carrying said DNA segments;

breeding said offspring to produce female progeny that express said first, second and third DNA segments and produce milk containing biocompetent fibrinogen encoded by said segments;

collecting milk from said female progeny; and

and recovering the biocompetent fibrinogen from the milk.

2. A method according to claim 1 wherein said species into which said DNA segments are introduced is selected from the group consisting of sheep, pigs, goats, and cattle.

3. A method according to claim 1 wherein each of said first, second and third DNA segments comprises an intron.

4. A method according to claim 1 wherein the molar ratio of said first, second and third DNA segments is within the range of 0.5–1:0.5–1:0.5–1.

5. A method according to claim 1 wherein each of said first, second and third DNA segments is operably linked to a transcription promoter selected from the group consisting of casein, β-lactoglobulin, α-lactalbumin and whey acidic protein gene promoters.

6. A method according to claim 1 wherein said first, second and third DNA segments are expressed under the control of a β-lactoglobulin promoter.

7. A method according to claim 1 wherein said introducing step comprises injecting said first, second and third DNA segments into a pronucleus of said fertilized egg.

8. A method according to claim 1 wherein said fibrinogen is human fibrinogen.

9. A method according to claim 1 wherein said second DNA segment comprises a sequence of nucleotides as shown in SEQ ID NO: 3 from nucleotide 470 to nucleotide 8100.

10. A method according to claim 1 wherein said second DNA segment comprises a sequence of nucleotides as shown in SEQ ID NO: 3 from nucleotide 512 to nucleotide 8100.

11. A method according to claim 1 wherein said species into which said DNA segments is introduced is sheep.

12. A method of producing biocompetent fibrinogen comprising:

incorporating a first DNA segment encoding a secretion signal operably linked to an Aα chain of fibrinogen into a β-lactoglobulin gene to produce a first gene fusion comprising a β-lactoglobulin promoter operably linked to the first DNA segment

, the DNA segment comprising genomic DNA encoding the Aα chain;

incorporating a second DNA segment encoding a secretion signal operably linked to a Bβ chain of fibrinogen into a β-lactoglobulin gene to produce a second gene fusion comprising a β-lactoglobulin promoter operably linked to the second DNA segment

, the DNA segment comprising genomic DNA encoding the Bβ chain;

incorporating a third DNA segment encoding a secretion signal operably linked to a γ chain of fibrinogen into a β-lactoglobulin gene to produce a third gene fusion comprising a β-lactoglobulin promoter operably linked to the third DNA segment

, the DNA segment comprising genomic DNA encoding the γ chain,

wherein each of said first, second and third segments are of the same species;

introducing said first, second and third gene fusions into the germ line of a non-human mammal so that said DNA segments are expressed in a mammary gland of

said mammal or its female progeny and biocompetent fibrinogen is secreted into milk of said mammal or its female progeny;

obtaining milk from said mammal or its female progeny; and

recovering said fibrinogen from said milk.

13. A method according to claim 12 wherein said mammal is a sheep, pig, goat or cow.

14. A method according to claim 12 wherein each of said first, second and third gene fusions comprises an intron.

15. A method according to claim 12 wherein the molar ratio of said first, second and third gene fusions introduced is within the range of 0.5–1:0.5–1:0.5–1.

16. A method according to claim 12 wherein said introducing step comprises injecting said first, second and third gene fusions into a pronucleus of a fertilized egg and inserting said egg into an oviduct of a pseudopregnant female to produce female offspring carrying said gene fusions in the germ line, wherein said egg and said pseudopregnant female are of the same species.

17. A method according to claim 12 wherein said mammal is a sheep.

18. A method for producing biocompetent fibrinogen comprising:

providing a transgenic female non-human mammal carrying in its germline heterologous

genomic

DNA segments encoding Aα, Bβ and γ chains of fibrinogen, wherein said segments are expressed in a mammary gland of said mammal and biocompetent fibrinogen encoded by said segments is secreted into milk of said mammal;

collecting milk from said mammal; and

recovering said biocompetent fibrinogen from said milk.

19. A method according to claim 18 wherein said mammal is a sheep, pig, goat or cow.

20. A method according to claim 18 wherein said mammal is a sheep.

21. A transgenic non-human female mammal that produces recoverable amounts of biocompetent human fibrinogen in its milk, wherein said mammal comprises:

a first DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen Aα chain,

the DNA segment comprising heterologous genomic DNA encoding the Aα chain;

a second DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen Bβ chain,

the DNA segment comprising heterologous genomic DNA encoding the Bβ chain;

and

a third DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen γ chain.

the DNA segment comprising heterologous genomic DNA encoding the γ chain;

and

further wherein each chain is derived from the same species and is operably linked to additional DNA segments required for its expression in the mammary gland of a host female mammal.

22. A mammal according to claim 21 wherein said mammal is a sheep.

23. A process for producing a transgenic offspring of a mammal comprising:

providing a first DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen Aα chain,

the DNA segment comprising genomic DNA encoding the Aα chain;

a second DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen Bβ chain,

the DNA segment comprising genomic DNA encoding the Bβ chain;

and a third DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen γ chain,

the DNA segment comprising genomic DNA encoding the γ chain,

wherein each chain is derived from the same species, and wherein each of said first, second and third segments is operably linked to additional DNA segments required for its expression in the mammary gland of a host female mammal;

introducing said DNA segments into a fertilized egg of a non-human mammalian species heterologous to the species of origin of said fibrinogen chains;

inserting said fertilized egg into an oviduct or uterus of a female of said mammalian species; and

allowing said fertilized egg to develop thereby producing transgenic offspring carrying said first, second and third DNA segments, wherein female progeny of said mammal express said DNA segments in a mammary gland to produce biocompetent fibrinogen.

24. A process according to claim 23 wherein said offspring is female.

25. A process according to claim 23 wherein said offspring is male.

26. A non-human mammal produced according to the process of claim 23.

27. A non-human mammal according to claim 26 wherein said mammal is female.

28. A non-human female mammal according to claim 27 that produces milk containing biocompetent fibrinogen encoded by said DNA segments.

29. A non-human mammal according to claim 26 wherein said mammal is male.

30. A non-human mammal carrying in its germline

heterologous genomic

DNA

segments encoding human Aα, Bβ and γ chains of fibrinogen, wherein female progeny of said mammal express said DNA segments in a mammary gland to produce biocompetent human fibrinogen.

31. A mammal non-human according to claim 30 wherein said mammal is female.

32. A mammal non-human according to claim 30 wherein said mammal is male.

33. A mammal according to claim 30, wherein said mammal is a sheep.

* * * * *

34. A set of DNA sequences comprising:

a first DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen Aα chain, the DNA segment comprising genomic DNA encoding the Aα chain;

a second DNA segment encoding a secretion signal operably linked to a heterologous fibrinogen Bβ chain, the DNA segment comprising genomic DNA encoding the Bβ chain; and

a third DNA segment encoding a secretion signal operably linked to a to a heterologous fibrinogen γ chain, the DNA segment comprising genomic DNA encoding the γ chain, wherein each chain is from the same species, and wherein each of said first, second and third segments is operably linked to additional DNA segments required for its expression in the mammary gland of a host female mammal.

PPL1 - Reissue

FIGURE 1



FIGURE 2


HindIII,176
EcoRI,523
BamHI,689
XbaI,936
HindIII,960
SV40p
neomycin
MT-1p
SV40t
Zem228
5774 bps
SV40t
pUC18
3609,XbaI
3596,EcoRI

FIGURE 3


EcoRI
Bgl II
Xba I
912
2107
EcoRI
Sph I
Bgl II
6392
6775
7115
lambda
ATG
ATG
STOP
EcoRI
lambda
470
512
8100
approx 12000
1ST MET:ZC6629
3RD MET:ZC6630
EcoRI
6392
EcoRI
~5.6 Kb
ZC6625
Bgl II
pUC 19
EcoRI
Bgl II
6392
~5.6 Kb
ZC6626
EcoRI
Sph I
ZC6624
pUC 19
EcoRI
Bgl II
PCR
Xba I
pUC 19
Xba I
EcoRI
Sph I
pUC 19
Sph I
Bgl II
EcoRI
PCR
pUC 19
EcoRI
Sna BI
Xba I
Sph I
Sna BI
EcoRI
Xba I
Sph I
EcoRI
EcoRI
pUC 19
Sna BI
Sna BI
BETA
Sna BI
Sna BI
pMAD6-Sna

FIGURE 4


Spe I
1941
EcoRI
6335
Pst I
7433
BamHI
8322
Spe I
9102
ATG
1798
STOP
9572
EcoRI
ATG
EcoRI
pγ12A9
pBR 322
EcoRI
STOP
EcoRI
pγ12F3
pBR 322
ZC6514
Spe I
PCR
ZC6517
4.4 kb
Spe I
EcoRI
2.77 kb
EcoRI
Spe I
ZC6516
PCR
ZC6515
Spe I
BamHI
EcoRI
PCR
Spe I
pUC 19
BamHI
EcoRI
BamHI
PCR
Spe I
pUC 19
BamHI
Sna BI
EcoRI
Pst I
BamHI
SnaBI
Xba I
EcoRI
Pst I
BamHI
Xba I
Zem 219b
Sna BI
Sna BI
gamma
Sna BI
Sna BI
pMAD6-Sna

FIGURE 5


HindIII,307
4159,XbaI
4146,EcoRI
DHFR
EcoRI,654
SV40t
SV40p
BamHI,821
XbaI,831
MT-1p
Zem219b
4766 bps
hGHt
EcoRI,1462
HindIII,1510
pUC 18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Reissue Application	:	Not yet assigned
Serial No.	:	Not yet assigned
Filed	:	January 15, 1999
Patent	:	5,639,940
Patentee	:	Ian Garner, Michael A.. Dalrymple,* Donna E. Prunkard and Donald C. Foster
Assignee	:	Pharmaceutical Proteins, Ltd., and ZymoGenetics, Inc.
Issued	:	June 17, 1997
Application	:	08/206,176
Filed	:	March 3, 1994
For	:	PRODUCTION OF FIBRINOGEN IN TRANSGENIC ANIMALS

REISSUE DECLARATION AND POWER OF ATTORNEY

We, DONNA E. PRUNKARD and DONALD C. FOSTER, two of the four named inventors of United States patent 5,639,940 ("the '940 patent"), and applicants for reissue thereof, declare that:

1. We are citizens of the United States and have residences and post office addresses as stated below under our respective names:

Donna E. Prunkard
1463 N.W. 92nd St.
Seattle, WA 98117

---

* The '940 patent incorrectly printed the middle initial of Dr. Dalrymple as "L".

Donald C. Foster
3002 NE 181st Street
Lake Forest Park, WA 98155

2. By concurrent Petition Under 37 C.F.R. § 1.324 and Motion Under 37 C.F.R. § 1.634, the four originally named inventors, Ian Garner, Michael A. Dalrymple, Donna E. Prunkard, and Donald C. Foster, have petitioned and moved to correct the inventorship for all of the claims of the '940 patent. As amended, Donna E. Prunkard and Donald C. Foster are the joint inventors of the subject matter claimed in the '940 patent.

3. We have reviewed and understand the contents of the '940 patent and this application for reissue thereof, including their claims, and believe that we are the original, first and joint inventors of the invention described and claimed in the '940 patent to the extent that a reissue application is being sought on that invention.

4. We make this declaration in support of this application for reissue of the '940 patent and acknowledge our duty to disclose to the United States Patent and Trademark Office all information known to us to be material to the patentability of the reissue application and its claims as defined in 37 C.F.R. § 1.56(a).

5. We do not know and do not believe that our invention was ever patented or described in any printed publication in any country before our invention thereof or more than one year prior to the March 3, 1994 filing date of our United States patent application 08/206,176, which issued as the '940 patent, or in public use or on sale in the United States more than one year prior to that filing date.

6. We believe that the '940 patent is "wholly or partly invalid" because of error, without deceptive intent, by reason of our having claimed more than we had a right to claim in view of the prior art. Specifically, all of the claims of the '940 patent recite methods and

transgenic animals employing "DNA" encoding, respectively, each of the Aα, Bβ and γ chains of fibrinogen. To be patentable over the prior art, we believe that these claims should be limited to genomic DNA and thereby exclude cDNA.

7. In obtaining allowance of the claims of the '940 patent, we understand that our attorney argued that the claims were patentable over the prior art based on the unexpected production of useful amounts of biologically active, fibrinogen in the milk of transgenic animals. See Amendment, May 8, 1995, pp. 9-12. We understand that at the request of the Examiner and in view of that argument, our attorney then amended the claims to recite "biocompetent fibrinogen". See Office Action, Paper No. 13, May 21, 1996, p. 4; Amendment, October 1, 1996, pp. 1-2, 6-8. It was this amendment that we understood led to allowance of the claims and grant of the '940 patent.

8. We do not believe that such amendment renders the claims of the '940 patent patentable over the prior art. We believe at the time we made our invention, in view of art published more than one year before the filing date of the application that issued as the '940 patent that it would have been obvious to the skilled worker in the recombinant fibrinogen expression and transgenic arts that biocompetent fibrinogen would be produced in the milk of transgenic animals carrying the cDNAs encoding the Aα, Bβ and γ chains of fibrinogen at about the same level on a per cell basis as had already been produced in mammalian cells transfected with those cDNAs, i.e., about 5μg/mg of cellular protein/day. Indeed, we understood that when such cDNAs were actually used to produce transgenic mice, those mice produced in their milk biocompetent fibrinogen at about that expected level.

9. We also believe that at the time we made our invention, in view of prior art published more than one year before we filed our application, that the skilled worker would

have reasonably expected that genomic DNAs encoding the Aα, Bβ and γ chains of fibrinogen could be used to produce biocompetent fibrinogen in the milk of transgenic animals in the best case at that same level and potentially at much lower levels. We believe, however, that at the time we made our invention, in view of prior art published more than one year before we filed our application, it would not have been obvious to that skilled worker that those genomic DNAs could be used to produce biocompetent fibrinogen in the milk of transgenic animals with a reasonable expectation of success at levels on a per cell basis higher than those already produced in mammalian cells transfected with cDNAs encoding the three fibrinogen claims. It was to this unexpectedly high expression level that we understood our attorney was referring when he argued to the Examiner that our invention was patentable because it unexpectedly produced useful amounts of biocompetent fibrinogen.

10. We believe that the error described in paragraphs 7-9 above arose without deceptive intent. All of the examples in our application used genomic DNA encoding the Aα, Bβ and γ chains of human fibrinogen. We understood that when our attorney made the above arguments to the Examiner and amended our claims to obtain their allowance he had in mind the genomic DNA as used in our Examples. See the '940 patent, Examples II, III, and IV. We understood that he failed to consider that the claims literally included cDNA.

11. We also believe that the '940 patent is also "wholly or partly inoperative" because of error, without deceptive intent, by reason of our having claimed less than we had a right to claim in view of the disclosure of the application that issued as the '940 patent. Specifically, none of the patent claims is directed to a set comprising a first, second, and third DNA segment encoding a secretion signal operably linked to the heterologous fibrinogen Aα, Bβ and γ chains, respectively, each of the DNA segments comprising genomic DNA encoding

the respective fibrinogen chain, and wherein each of the chains is from the same species and is operably linked to additional DNA segments required for expression in the mammary glands of a host female mammal. This set of DNA segments is useful in the methods of claims 1-20 and 23-25 of the '940 patent and in producing the non-human mammals of claims 21-22 and 26-33 of the '940 patent. This set of DNA segments is also described and enabled in the '940 patent and should have been claimed in that patent and in the application from which it issued. Without a claim to this set of DNA segments, we understand that a third party might potentially prepare the recited set of DNA segments in the United States and export that set from the United States for use outside the United States in the production of fibrinogen in the milk of transgenic animals. We also understand that without reissue such acts would not infringe the claims of the '940 patent.

12. We understand and believe that the error described in paragraph 11 arose without deceptive intent.

13. We understand and believe that these errors in the claims of the '940 patent were discovered while reviewing the '940 patent, with counsel, in connection with Garner v. Velander, Interference 104,242. We have filed this reissue application promptly after recognizing the errors.

14. As named inventors, we hereby appoint the following attorneys and agents in connection with the '940 patent and this application for reissue thereof, with full power to prosecute this application for reissue and to transact all business in the United States Patent and Trademark Office in connection therewith and with the '940 patent:

James F. Haley (Reg. No. 27,794)

Karen Mangesarian (Reg. No. p43,772)

Z. Ying Li (Reg. No. 42,800)

all of Fish & Neave, 1251 Avenue of the Americas, 49th Floor, New York, NY 10020

Send correspondence to: James F. Haley, Jr.
1251 Avenue of the Americas
New York, New York 10020-1104

Direct telephone calls to: James F. Haley
(212) 596-9000

15. We hereby declare that we understand the English language, and that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application for reissue or any Patent issued thereon.

Donna E Prunkard
DONNA E. PRUNKARD

Date: 1-13-99

DONALD C. FOSTER

Date: 1-13-99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Reissue Application	:	Not yet assigned
Serial No.	:	Not yet assigned
Filed	:	January 15, 1999
Patent	:	5,639,940
Patentee	:	Ian Garner, Michael A.. Dalrymple,* Donna E. Prunkard and Donald C. Foster
Assignee	:	Pharmaceutical Proteins, Ltd., and ZymoGenetics, Inc.
Issued	:	June 17, 1997
Application	:	08/206,176
Filed	:	March 3, 1994
For	:	PRODUCTION OF FIBRINOGEN IN TRANSGENIC ANIMALS

DECLARATION IN SUPPORT OF REISSUE APPLICATION

I, GARY E. PARKER, declare that:

1. I make this declaration in support of the accompanying Reissue Application for United States patent 5,639,940.

2. I am Principle Patent Agent at ZymoGenetics, Inc., Seattle, Washington. In March 1994, I was the Manager of the Patent Department at ZymoGenetics. I am registered to practice before the United States Patent and Trademark Office. I am not an attorney.

---

* The '940 patent incorrectly printed the middle initial of Dr. Dalrymple as "L".

3. I prepared and filed the '176 application that issued as the above-identified '940 patent.

4. I understand and believe that the '940 patent is "wholly or partly invalid" because of error, without deceptive intent. I believe that the patent claims more than the inventors had a right to claim in view of the prior art. Particularly, all of the claims of the '940 patent recite methods and transgenic animals employing "DNA" encoding, respectively, each of the Aα, Bβ and γ chains of fibrinogen. I believe that these claims should be limited to genomic DNA, and thereby exclude cDNA, to be patentable over the prior art.

5. In obtaining allowance of the claims of the '940 patent over the prior art, I argued that the claims were patentable because production of useful amounts of biologically active, fibrinogen in the milk of transgenic animals was unexpected. See Amendment, May 8, 1995, pp. 9-12. At the request of the Examiner and in view of that argument, I amended the claims to recite "biocompetent fibrinogen". See Office Action, Paper No. 13, May 21, 1996, p. 4; Amendment, October 1, 1996, pp. 1-2, 6-8. I believe that it was this amendment that led to allowance of the claims and grant of the '940 patent.

6. I do not now believe that my amendment renders the claims of the '940 patent patentable. I understand and believe that at the time the inventors made their invention in view of art published more than one year before the filing date of the application that issued as the '940 patent, it would have been obvious to the skilled worker in the recombinant fibrinogen expression and transgenic arts that biocompetent

human fibrinogen would be produced in the milk of transgenic animals carrying the cDNAs encoding the Aα, Bβ and γ chains of human fibrinogen at about the same level on a per cell basis as had already been produced in mammalian cells transfected with those cDNAs, i.e., about 2μg/2x10^{6}cells/day.* In fact, when cDNAs encoding the three chains of fibrinogen were used to produce transgenic mice, those mice produced biocompetent fibrinogen in their milk at about the expected level.

7. I also understand and believe that at the time of invention, in view of prior art published more than one year before the application was filed, that it would not have been obvious to that skilled worker that genomic DNAs encoding the Aα, Bβ and γ chains of fibrinogen could be successfully used to produce biocompetent fibrinogen in the milk of transgenic animals at levels on a per cell basis higher than those already produced in mammalian cells using the corresponding cDNAs. It was to this unexpectedly higher production of biocompetent fibrinogen which I referred when I argued that the Garner claims were patentable. *See, supra*, ¶ 5.

8. I believe that the error described in paragraphs 4-7 above arose without deceptive intent. Although I do not recall the specific details of the prosecution of the application that issued as the '940 patent, I believe that during prosecution I did not consider that the claims covered low level expression of cDNA. All of the examples in the application used genomic DNA encoding the Aα, Bβ and γ chains of human fibrinogen. See the '940 patent, Examples II, III, and IV. And, it was only genomic DNA that the inventors had used to produce useful amounts of biocompetent fibrinogen in the milk of

---

* During prosecution of the application that issued as the Garner '940 patent, the Examiner cited Roy et al. for its report of the production of 2μg of fibrinogen per 2x10^{6}cells/day in COS cells.

transgenic animals. It was this work that was the basis of my patentability arguments. As best I can recollect, I failed to consider or realize that the pending claims literally included cDNA.

9. I also understand and believe that the '940 patent is also "wholly or partly inoperative" because of error, without deceptive intent. I believe that the patent claims less than the inventors had a right to claim in view of the disclosure of the application that issued as the '940 patent. None of the patent claims is directed to a set comprising a first, second, and third DNA segment encoding a secretion signal operably linked to the heterologous fibrinogen Aα, Bβ and γ chains, respectively, each of the DNA segments comprising genomic DNA encoding the respective fibrinogen chain, and wherein each of the chains is from the same species and is operably linked to additional DNA segments required for expression in the mammary glands of a host female mammal. This set of DNA segments is useful in the methods of claims 1-20 and 23-25 of the '940 patent and in producing the non-human mammals of claims 21-22 and 26-33 of the '940 patent. I also believe that this set of DNA segments is described and enabled in the '940 patent. Finally, I believe that the set of DNA segments should have been claimed in the '940 patent and in the application from which it issued. Without a claim to this set of DNA segments, I understand and believe that a third party might potentially prepare the recited set of DNA segments in the United States and export that set from the United States for use outside the United States in the production of fibrinogen in the milk of transgenic animals. I also understand and believe that without reissue such acts would not infringe the claims of the '940 patent.

10. The error described in paragraph 11 arose without deceptive intent. Today, I do not recall the specific details of the prosecution of the patent application that issued as the '940 patent. Nonetheless, to the best of my recollection, I believe that I did not claim the set of DNA segments now claimed in reissue claim 34, because I was focusing on the end product -- fibrinogen -- and the methods and animals used to make it. I did not, as I recall, consider claiming the various intermediates -- including this set of DNA segments -- used in producing those animals or the claimed method.

11. I discovered these errors (paragraphs 4-7 and 8-10) in the claims of the '940 patent while reviewing the '940 patent, with counsel, in connection with Garner v. Velander, Interference 104,242.

12. I hereby declare that I understand the English language, and that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application for reissue or any Patent issued thereon.

Gary E. Parker

GARY E. PARKER

Date: Jan. 13, 1999